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ABSTRACT  Genomic  imprinting  directs  the  allele‐specific  expression  of  a  subset  of  loci according  to  their  parental  origin.  Monoallelic  expression  of  these  genes  is regulated  by  imprinting  control  regions  (ICRs)  and  is  established  in  the embryonic germ line through differential DNA methylation.  Differentiated  cells  can  be  reprogrammed  to  pluripotency  by  several  strategies including  the  ectopic  expression  of  specific  ‘inducers’  and  by  transfer  of  nuclei into enucleated eggs. Cellular fusion of somatic cells with a pluripotent stem cell partner can also lead to dominant pluripotent reprogramming. Although ES cells (derived from the  inner cell mass) and embryonic germ cells (EG, derived  from primordial germ cells) can both reprogram, EG cells are unique  in being able  to erase  genomic  imprints  from  the  somatic  partner.  In  order  to  characterize  the earliest  events  in  successful  reprogramming,  as  well  as  EG‐specific  DNA demethylation, I generated experimental heterokaryons between B‐lymphocytes and mouse stem cell  lines.  I  showed that ES cells  that  lack Polycomb Repressor Complex  2  (PRC2)  failed  to  reprogram  B  cells  and were  unable  to  induce  two early  events  that  characterise  successful  B  cell  reprogramming;  a  global redistribution of HP1α and an increased serine 10 phosphorylation. In the second part of my study I confirmed that EG cells were able to induce DNA demethylation at  several  ICR  in  B  cells  following  fusion.  I  present  evidence  that  this reprogramming  of  the  somatic  genome  requires  Tet1  and  Tet2  and  is accomplished  through  a  two‐step  process  involving  both  DNA  synthesis  and conversion of 5methylcytosine into 5hydroxymethylcytosine. 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CHAPTER 1. INTRODUCTION  Higher eukaryotic organisms are characterized by an orderly multicellular structure that from the totipotent zygotic cell allows the coordinate development of an array of different cell types in the adult. In mammals for example there are more  than  200  different  types  of  cell.  Each  is  characterized  by  specific morphology and function, and these can vary from hormone secretion to defense from pathogens,  creation  of neuronal  network  and  sexual  reproduction  (Figure 1.1).  
1.1. Cellular identity 
 How  each  cellular  identity  is  established  during  development  and  how these are stably maintained throughout the life of an organism is a central issue in  developmental  biology.  A  first  attempt  to  explain  this  cellular  specialization process  argued  that  during  embryonic  development  heritable  elements  (now known  as  genes)  were  selectively  lost  according  to  the  cell  type  generated (Weismann, 1892). This mechanism suggested that during specialization of lung cells,  all  genes  that were  not  required  for  the  lung  functions  (such  as  neuronal genes)  would  be  lost.  Later,  this  hypothesis  was  challenged  and  proved  to  be wrong by experiments in amphibia in which an adult specialized cell of Xenopus 
laevis  was  shown  to  give  rise  to  a  whole  fertile  frog  using  nuclear  transfer (Gurdon,  1962).  This  remarkable  first  observation  was  later  confirmed  also  in mammals  with  the  successful  cloning  of  a  sheep  named  Dolly  (Wilmut  et  al., 1997) and also in mice (Wakayama et al., 1998). Thus, these experiments proved that  specialization  was  reversible  and,  more  importantly,  demonstrated  the nuclear  equivalence  (equal  genetic  information)  of  a  whole  range  of  different adult cell types and the original totipotent zygotic cell.   It  is  now  widely  accepted  that  cellular  identity  arises  from  the  specific expression of different fractions of genes encoded by the same genome. But how activation of  a  specific  subset of  genes  is  established during development of  an 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organism is not fully understood. Commitment towards specific lineages is driven and  perpetuated  by  coordinate  combinations  of  intrinsic  and  extrinsic  signals that, acting at the gene regulation level, establish lineage‐specific transcriptional circuits, which in turn determine the cellular identity.   
 
Figure  1.1.  Hierarchical  model  for  the  generation  of  specialized  cell  types  from  a 
pluripotent  source.  Schematic  representation  of  the  establishment  of  different  type  of specialized  cells.  In the course of differentiation,  less specialized  cells (white nucleus) gradually lose developmental potential  generating an array  of different  types of  differentiated  cells  (grey nuclei), which will account for various specialized functions in the adult organism.     
Lineage induction; the role of intrinsic and extrinsic factors  Lineage‐determining  transcription  factors  control  specialized  gene regulatory  networks  inducing  expression  of  selected  subsets  of  genes  and repressing  those  associated  with  alternative  identities.  The  very  first  event  of lineage commitment in mammalian embryos is for example characterized by the mutually exclusive expression of Oct4 and Cdx2  that  segregates  embryonic and extra‐embryonic tissues.   Therefore, later in the blastocyst cells belonging to the inner  cell  mass  (ICM)  can  be  distinguished  from  those  generating  the trophectoderm because of their expression of Oct4 or Cdx2 respectively (Niwa et 
al.,  2005).  Importantly,  the  central  gene  regulatory  role  for  these  transcription factors was proved by ectopic expression of Cdx2 in ES cells (derived from ICM) that  induces  the  formation  of  trophectoderm  cells  by  inhibiting  Oct4  through direct protein interaction (Niwa et al., 2005). Later in ontogeny more examples of transcriptional  “master  regulators’  capable  of  driving  cells  towards  specific lineage  are  evident.  These  include  MyoD,  whose  expression  is  sufficient  to 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activate muscle  expression  program  in  fibroblasts  (Davis  et  al.,  1987),  and  the transcription  factor  C/EBPα,  which  can  convert  B  and  T  cell  precursors  into functional macrophages  (Xie  et  al.,  2004).  Importantly,  these  regulators  act  not only  in dictating  the differentiation  into a  specific  cellular  fate but also actively maintain  the  committed  status  repressing  genes  associated  with  alternative lineage  fates.  An  example  of  this  is  the  transcriptional  regulator  Pax5  that  not only    induces B‐lymphocyte gene expression but also  inhibits  the expression of genes  associated  with  alternative  (non‐B  cells)  fates.  Pax5  ablation  in  B‐cell precursors  results  in  de‐differentiation  and  the  acquisition  of  multilineage potential,  so  that  expression  of  genes  associated  with  different  hematopoietic lineages  is  now  permitted  (Nutt  et  al.,  1999;  Busslinger  et  al.,  2000).  Extrinsic signals  are  also  important  in  conferring  specific  cellular  identity.  Several  key signaling  ligands are known  to  influence gene  regulatory networks  that  sustain the  expression  of  specific  master  regulators  or  block  pathways  that  promote alternative lineages. An example of the extrinsic contribution on cellular identity perpetuation is displayed in the choice of embryonic versus extra‐embryonic fate. Here the signaling molecules LIF and BMP are required for self‐renewal capacity of ES cells (derived from ICM, see section 1.2.3), which deflect commitment cues by FGF receptor and ERK pathway, while FGF4‐mediated signaling is needed for maintaining Trophoblast  Stem  (TS)  cells  (Rossant,  2001).  Another well‐studied example  of  extrinsic  signals  that  regulate  cellular  identity  during  embryonic development  is  the  specification  of  muscle  progenitors.  Embryological  and genetic  experiments  have  shown  that  Shh  and Wnt  pathways  induce Myf5  and MyoD  while  BMP  and  Notch  signaling  repress  the  expression  of  these  master regulators. Thus opposing signaling pathways constrain the expression of lineage and stage‐specific factors within the muscle lineage (Pownall et al., 2002)  
Cellular “memory”  Apart  from  few  examples  in  which  expression  of  a  single  transcription factor or signaling molecules can dictate cell fate, most differentiated mammalian cells remain committed to a single lineage and ‘plasticity’ is limited. For example while MyoD was shown to be sufficient  to generate muscle cells  from fibroblast 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(Davis  et  al.,  1987),  its  ectopic  expression  in  other  cell  types,  that  are  more distantly related to muscle, fails to instruct conversion into muscle tissues (Graf, 2011).  Also,  although  ectopic  expression  of  C/EBPα  can  convert  B  cells  into functional  macrophages  (Xie  et  al.,  2004),  but  when  the  same  experiment  is performed in pancreatic cells the outcome is the induction of hepatocyte cell fate (Graf,  2011).  Likewise,  LIF  signaling,  which  contributes  to  the  self‐renewal capacity  of  ES  cells  (Chambers  and  Smith,  2004),  when  expressed  later  in development  induces macrophage maturation and enhances  sensory and motor neuron survival (Metcalf, 2003).  Since the outcome of intrinsic or extrinsic signals varies depending on the receiving  cell  type,  it  is  proposed  that  identical  developmental  cues  encounter different  nuclear  environments  so  that  the  readout  of  signals  is  context dependent.   Thus cells may accumulate a "developmental history" of  the signals they have received over time, a concept often referred to as “epigenetic memory”.   
The epigenetic environment  Allele‐specific  differences  in  gene  expression  (such  as  monoallelic expression  of  imprinted  genes  and  X‐linked  genes  in  females)  have  provided strong evidence  that  in addition  to DNA binding  factors,  cis‐acting mechanisms can regulate gene expression. The term “epigenetic” refers to heritable traits that do  not  involve  changes  in  the  underlying  DNA  sequence  (Waddington,  1942). Epigenetic  control  of  gene  expression  is  achieved  by  a  variety  of  different molecular mechanisms, many  of which  have  been  revealed  during  the  last  two decades. These include gene regulation by small interfering RNA, modifications of chromatin  (histones  and  nucleosomes)  structures,  methylation  of  DNA,  and higher order genome organization (Figure 1.2). The interplay of these regulatory agents  with  intrinsic  cues  and  extrinsic  signals  direct  the  establishment  and maintenance  of  specific  gene  expression  programs  through  mitosis  and differentiation and conversely in cellular reprogramming. 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1.1.1 Chromatin structure, nuclear organization and gene expression  The  large  eukaryotic  genome,  containing  a  high  proportion  of  non‐transcribed sequences, is compartmentalized within the nucleus, framed by lamin and enclosed  in a nuclear membrane that allows exchanging of macromolecules with the cytoplasm through nuclear pores.  Internal nuclear components are not equally distributed but they appear compartmentalized in nuclear bodies distinct in  their  composition,  morphology  and  abundance.  These  include  transcription factories, splicing speckles and nucleoli (Branco and Pombo, 2007). The nucleolus is  the  site of ribosomal RNA transcription and contains the machinery essential for the transcription of 45S rRNA genes (Martin and Pombo, 2003) (Figure 1.2 A). The presence of these compartments in the nucleus is believed to affect genome functions  (such  as  replication,  transcription  and  repair)  organizing  local accumulation of nuclear factors.  In  the nucleus, genomic DNA is complexed  into a macromolecule  formed with  chromosomal  proteins  and  known  as  chromatin  (Figure  1.2 B).  The  basic repeating unit of chromatin is the nucleosome which is composed by a compact octameric  histone  complex  consisting  of  two  copies  of  each  of  the  four  core histones H2A, H2B, H3 and H4 (plus histone variants that will not be discussed in this thesis) wrapped by 146 basepairs (bp) of DNA (Luger et al., 1997). While the length of DNA engaged in nucleosomes is always the same, the spacing between nucleosomes varies from a minimum of about 80 bp. In vitro studies indicate that nucleosomes are inhibitory for transcription initiation (Knezetic and Luse, 1986). Recent genome‐wide nucleosome mapping of human T lymphocytes (Schones et 
al., 2008) have confirmed that the positioning of nucleosomes with respect to the DNA template plays an important role in the regulation of gene expression (Li et 
al.,  2007a;  Henikoff,  2008).  Specific  chromatin  remodelling  proteins  that dynamically regulate nucleosome positioning and/or nucleosome structure have been  identified.  Many  of  these  proteins  are  ATPases  that  often  function  as subunits of  larger  complexes,  including  the SWI/SNF,  ISWI and CHD complexes (Tsukiyama, 2002; Saha et al., 2006). Together with additional proteins, including linker  histone  H1,  chromatin  is  wrapped  around  DNA  and  then  condensed  by several  levels  of  higher‐order  folding  (Maresca  and Heald,  2006).  Although  the 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molecular details of this structure are still not precisely known, it is thought that the  10nm  nucleosomal  structure  is  folded  into  a  30nm  fiber  and  then  further packed into 130 nm chromonema fiber within the nucleus (Misteli, 2007).  The result of this organization was recognised in early microscopy studies where  interphase  chromatin  was  described  in  two  distinguishable  forms: heterochromatin,  in which  chromatin was  highly  condensed  appearing  densely stained with  specific  dyes  and  euchromatin was  less  intensely  labeled  and was more accessible to nuclease digestion (Craig, 2005) (Heitz, 1928) (Figure 1.2 A).  In  the  same  period,  pioneering  experiments  on  Drosophila  mutants obtained  from X‐ray  irradiation described mosaic expression of  the white  locus (which  generates  a  red  eye  phenotype)  when  it  was  translocated  close  to centromeric  heterochromatin  regions  (Muller  and  Altenburg,  1930).  This phenomenon of variable  silencing was named position effect variegation  (PEV), and  was  later  reported  to  occur  in  other  organisms  (Dillon  and  Festenstein, 2002).  It  provided  the  first  indication  that  chromatin  organization  might  be critically important for gene expression. Now, two types of heterochromatin can be  distinguished.  Constitutive  heterochromatin  is  generally  silenced  in  all  cell types  and  includes  major  and  minor  satellite  DNA  repeats  clustered  around mouse centromeres, other repetitive DNA elements and transposons. Facultative heterochromatin is developmentally regulated and is found in different regions in specific cell‐type and contexts. Initially  it  was  proposed  that  chromatin  structures  operate  by  making domains more or less physically accessible to regulatory elements. According to this  argument  expressed  genes  should  mostly  localize  within  euchromatin regions  while  silenced  genes  should  be  confined  to  heterochromatin.  This simplistic view is not supported by genome‐wide expression mapping of DNase and  micrococcal  nuclease  digestions  (Sabo  et  al.,  2004;  Weil  et  al.,  2004)  and analysis of biochemically separated condensed and decondensed regions (Gilbert 
et al., 2004). In fact these studies report a segregation between gene rich versus gene poor regions while no correlation between chromatin density/accessibility and gene activity was found.   Using Fluorescence In Situ Hybridization (FISH) technology it was shown that  some  silent  genes  in  lymphocytes  preferentially  localize  at  the  nuclear 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periphery (Kosak et al., 2002) or relocate to centromeric domains (Brown et al., 1997). On the other hand, genome‐wide mapping of lamina‐interacting domains has shown that many genes tend to move away from the nuclear membrane upon activation  (Peric‐Hupkes  et  al.,  2010).  This  suggests  that  although  spatial contributions  to  gene  regulation  are  more  complex  than  previously  thought, similar domains may be co‐localized in the nucleus.  Recently,  the  establishment  of  Chromosome  Conformation  Capture  (3C) technology  and  of  its  genome‐wide  derivates  (4C  and  HiC)  has  provided  a powerful method to  identify new interactions between different domains of  the genome. Using these approaches it was shown that β­globin  locus interacts with active  regions  of  the  genome  in  fetal  liver  (where  it  is  active) while  it  clusters with inactive domains in the brain (where it is inactive). Rad23a, which is active in  both  cell  types,  interacts  with  active  regions  in  both  tissues  (Simonis  et  al., 2006). Another example is given by the analysis of olfactory receptor (OR) gene expression in olfactory neurons of the nasal epithelium. Each cell expresses only one of the ~1300 OR genes present in the genome. Interaction of the enhancer H element with  one of  these OR  genes  corresponds  to  its  specific  expression  in  a given cell (Lomvardas et al., 2006). Thus, with these approaches it was possible to define  architectural  organization  and  ‘looping’  of  the  genome  at  the  local  level (cis‐interacting  regions  in  a  loop)  as  well  as  long‐range  inter‐chromosomal association  between  different  genomic  domains,  demonstrating  an  increased complexity of the structural gene‐regulatory function of chromatin. 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Figure 1.2. Epigenetic levels of gene regulation. Schematic representation of different levels of genome organisation.  (A) The  genome  is  contained  in  the nucleus, packed  into  several  levels of condensed,  higher‐order  chromatin  domains  and  organised  in  functional  macro‐nuclear organelles  (such as nucleoli,  here depicted  in pink) and compartments. Broadly  speaking,  these compartments  can  be  divided  into  heterochromatic  (dark  grey)  and  euchromatic  (light  grey) regions. (B‐C) Inside these regions, DNA is wrapped around histones to form a “beads on a string” structure that  is folded into higher order chromatin domains, characterized by different levels of compaction (compare B and C). Specific amino acids of histone tails (black wavy lines) are targets for  a  number  of  covalent  modifications,  including  acetylation  (ac),  methylation  (me), phosphorylation  (ph).  These  histone  modification  represent  then  docking  sites  for  several chromatin  interacting proteins  including HP1  (in yellow). Histone modifications are depicted  in green or red according to their activator or repressor functions respectively.  (D) The DNA double helix  carries  the  genetic  information  (contained  in  the  nucleotides  sequence)  used  for development  and  functioning  of  all  known  living  organisms.  Beyond  the  sequence,  DNA methylation  (black  circle  above  and  depicted  in  red  below)  at  the  carbon  5  of  cytosines  (C) provides the most direct epigenetic mechanism of gene regulation (see section 1.1.3). 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1.1.1a Histone modifications  Histones are small, highly conserved proteins characterized by a globular stable  domain  and  an  unfolded  NH2‐terminus  tail  that  protrudes  from  the nucleosome  and  where  modifications  take  place.  During  the  last  few  decades several  enzymes have been discovered  that  can modify  residues within histone tails.  These  factors  induce  a  range  of  modification  to  histone  tails  including acetylation  (of  lysine  residues),  methylation  (lysine  and  arginine), phosphorylation  (serine  and  threonine),  ubiquitylation  (lysine),  sumoylation (lysine)  and ADP‐ribosylation  (Peterson  and  Laniel,  2004;  Simonis  et  al.,  2006; Bhaumik et al., 2007)(Figure 1.2 B and C). Different modifications  influence the biological  functions  of  the  underlying  DNA  by  altering  chromatin  structure, recruiting or blocking the binding of different kind of effectors, or by unwrapping the underlying DNA.  
 
Histone acetylation  Acetylation  levels  at  target  loci  are  affected  by  the  balance  between histone acetyltransferase (HAT) and histone deacetylase (HDAC) activity (Wade 






Histone methylation  Different kinds of histone methyltransferases, containing a conserved SET domain,  have  been  found  to  catalyze  mono‐,  di‐  or  tri‐methylation  of  specific lysine or arginine residues of the tails of Histones H3 and H4. The correlation of these  modifications  with  gene  expression  activity  is  less  straightforward  than histone  acetylation  as  the  outcome  depends  on  the  position  of  the  modified residue and the extent of the modification (Kouzarides, 2007). Thus, methylation of  histone  H3  at  lysine  (K)  4,  36  and  79  are  found  predominantly  at transcriptionally active domains while H3K9me3 is associated with centromeric constitutive  heterochromatic  foci  and  H3K27me3  is  normally  associated  with facultative  heterochromatin  region  (Martin  and  Zhang,  2005;  Peters  and Schübeler, 2005) or bivalent domains (see section 1.2.3). In contrast to what was initially  thought,  histone  methylation  is  a  reversible  process.  Thus,  several families  of  histone  demethylases  have  been  identified.  These  contain  a  highly conserved  JmjC  motif  that  catalyze  demethylation  of  histone  tail  amino  acids through an iron dependent oxidative reaction (Klose and Zhang, 2007).   Apart  from  the  effect  that  single  histone  modifications  have  on  gene regulation,  it  is  important  to  comprehensively  consider  the  function  that  these modifications have when integrated (resulting in thousands of potential different combination)  and  the  synergy  between  them. Broadly  speaking,  we  know  now that combination of high level of acetylation together with methylation at H3K4, H3K36  and  H3K79  characterized  an  euchromatic  domain,  which  is  actively transcribed, while  low  level of  acetylation  combined with methylation at H3K9, H3K27  and  H4K20  is  associated  with  heterochromatic  transcriptionally repressed  loci  (Portela  and  Esteller,  2010).  Also,  it  was  shown  that  H3S10 phosphorylation  inhibits  H3K9 methylation  but  is  synergistically  coupled  with H3K9 or H3K14 acetylation (Rea et al., 2000), providing an example of cross‐talk between  different  epigenetic  pathways.  Together  with  others,  these  examples support  the hypothesis  that distinct histone modifications act sequentially or  in combination to  form an “histone code”  that  is  “read” by other proteins to bring about  distinct  downstream  biological  functions  (Jenuwein  and  Allis,  2001; Spotswood and Turner, 2002). 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1.1.1b Histone modification ‘readers’  Currently  it  is  believed  that  the  way  histone  modifications  affect  gene expression  is  by  regulating  the  accessibility  of  various  effector  proteins  to  the underlying genomic sequence via direct or indirect means. This can be achieved by  regulating  different  grades  of  chromatin  compaction  (physically  regulating accessibility  through histone acetylation) or by recruiting additional chromatin‐associated protein, or chromatin “readers”.  Covalent modifications  of  the  histone  tail  can  create  an  array  of  binding sites  for a variety of  regulatory proteins  that, by  themselves, or  combined with additional effector complexes, regulate chromatin structure and gene expression (Daniel et al., 2005). Several of these “readers” have been described to specifically recognise  and  interact with methylated  lysines  by  different  specific  chromatin‐binding  domains.  These  include:  chromo  domain,  tudor  domain  and  WD40‐repeat domain proteins (Martin and Zhang, 2005). Generally, those that associate with  methylated  H3K4  are  normally  involved  in  transcriptional  activity  (Pray‐Grant  et  al.,  2005; Wysocka  et  al.,  2006),  whereas  those  that  bind  methylated H3K9 or H3K27 have been implicated in transcriptional repression (Fischle et al., 2003; Thiagalingam et al., 2003) Heterochromatin  Protein  1  (HP1)  was  identified  in  a  genetic  study  for factors that suppress PEV, and was the first characterized chromatin interacting protein  (Festenstein  et  al.,  1999).  Experiments  performed  in  vitro  and  in  vivo have shown that HP1 protein binds to chromatin through its chromodomain that displays high affinity  for  the H3K9me3 docking  site  catalyzed by Suv39 histone methyltransferase  (Lachner et al., 2001). Once bound to  its chromatin site, HP1 can  recruit  additional  factors  involved  in  heterochromatin  formation.  These include  Suv39h  itself,  suggesting  a  possible  mechanism  of  heterochromatin spreading, whereby HP1  binding  to H3K9m3 recruits  Suv39h, which methylate adjacent  histones  and  so  on  (Hiragami  and  Festenstein,  2005).  Interestingly,  it was  shown  that  HP1  (which  exist  in  three  isoforms  in  mammals)  is  displaced from  its  chromatin‐docking  site  during  the mitosis  phase  of  the  cell  cycle.  This displacement  occurs  even  though  H3K9me3  levels  remain  unchanged. Phosphorylation of the nearby Serine 10 residue on the histone tails (H3S10ph) 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from mitotic  kinase Aurora B was  shown  to  be  sufficient  to  evict HP1  from  its binding site (Fischle et al., 2005; Hirota et al., 2005). After mitosis, the daughter cells lose H3S10ph allowing HP1 to return to its heterochromatin docking sites in interphase. Covalent histone modifications provide an attractive “annotation” system for  mitotically  inheritable  information  that  can  be  “read”  by  various  effector proteins.  In  the  course  of  cell  division  the  genome  is  faithfully  duplicated  and divided  between  two  daughter  cells.  Therefore,  in  order  to  maintain  cellular identity,  the  cell must  replicate  its  DNA  sequence  together with  the  epigenetic information  coded  within  its  chromatin  structure.  The  mechanism  for propagating  epigenetic  information  through  cell  proliferation  has  been  called “mitotic memory” and this is the subject of investigation by many laboratories for many years (Patterton and Wolffe, 1996) (Fisher and Brockdorff 2012). 
1.1.2 Thritorax and Polycomb protein groups  
 Trithorax  (TrxG)  and  Polycomb  (PcG)  group  proteins  were  originally identified as regulators of homeotic (Hox) genes in Drosophila mutants that had altered body segmentation (Lewis, 1978). Transcription of Hox genes  is  initially achieved  by  transcription  factors  and  subsequently maintained  by  PcG  or TrxG proteins.  These  proteins  are  part  of  a widely  conserved  “cell memory”  system employed  in  the  homeostasis  of  cell  identity  by  dynamically  restricting transcription patterns  from  the  first  embryonic  stage,  throughout development, until adulthood (Ringrose and Paro, 2004). We know that, in addition to the Hox genes,  TrxG  and  PcG  proteins  regulate  many  other  genes  including developmental‐regulated transcription factors as well as signalling proteins, cell cycle  regulators  and  stress  responsive  genes  (Boyer  et  al.,  2006b; Schuettengruber  and  Cavalli,  2009).  TrxG  proteins  were  described  to  facilitate gene  expression  while  PcG  proteins  are  involved  in  gene  repression counteracting  activatory  TrxG  functions  (Orlando  and  Paro,  1995).  Thus,  both regulatory  groups  encode  components  of multiprotein  complexes  that  regulate chromatin structure in opposite ways. 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Polycomb group proteins  Mammalian orthologous of polycomb proteins form two major repressive complexes, Polycomb repressive complex 1 and 2 (PRC1 and PRC2). Core PRC2 complex  is  composed  of  four  factors;  EZH1/2,  SUZ12,  EEd  and  RBBP7/4,  plus other  associated  polypeptides  such  as  AEBP2,  PCLS  and  JARID2.  Histone methyltransferase activity lies with Ezh1 and Ezh2, and Prc2‐Ezh1 display lower methyltransferase  activity  than  PRC2‐EZH2  (Margueron  et  al.,  2008).  PRC1 comprises  RING1A  and  RING1B  as  two  common  components,  associated  with different combinations of other factors including BMI1, MEL18, NSPC1 plus CBX proteins.  PRC1  and  PRC2  complexes  are  generally  associated  with developmentally regulated gene repression. Their key role has been reported in several  developmental  regulation  functions  such  as  X‐chromosome  inactivation (which  will  not  be  discussed  here)  and  together  with  thritorax  activity  in  the maintenance  of  bivalency  at  developmentally‐associated  gene  loci  in  ES  cells (which will be discussed later in section 1.2.3). The repressive  function of PcG  is believed to depend on  its regulation of the  chromatin  landscape  through  histone  modifications.  Thus,  PRC2  catalizes H3K27  methylation  through  its  enzymatic  subunit  EZH1  and  EZH2,  and  PRC1 ubiquitinates  K119  on  the  histone  H2A  (Schuettengruber  and  Cavalli,  2009). Genome‐wide  mapping  analysis  of  PRC2  binding  and  H3K27me3  marks  have identified two different types of chromatin patterns: same large domains of more than 100 kb and smaller domains  covering a  few kb. H3K27me3 marks appear enriched  around  the  transcription  start  site  at  gene  promoters  (Boyer  et  al., 2006b). PRC1 complex has been implicated in gene repression in a manner that is independent of RING1A/B mediated H2A ubiquitination by physical compaction of chromatin structure (Eskeland et al., 2010). Histone  modifications  can  regulate  biological  functions  (such  as  gene expression)  by  either  modulating  chromatin  structure  (affecting  DNA‐histone interaction)  or  recruiting  additional  regulatory  factors  (see  section  1.1.1). H3K27me3  has  been  associated  with  the  second  of  these  mechanisms. Interestingly,  PRC1 was  shown  to  be  able  to  bind  H3K27me3  sites  through  its chromodomain‐containing  CBX  subunit,  suggesting  that  the  two  polycomb 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groups,  PRC2  and  PRC1  function  sequentially.  However,  this  is  not  always  the case  as  several  studies  have  shown  that  PRC1  can  bind  to  chromatin independently from H3K27me3 (Schoeftner et al., 2006; Ku et al., 2008; Tavares 
et  al.,  2012).  Alternatively,  H3K27  methylation  might  also  indirectly  regulate transcription by sterically inhibiting the binding of activator factors to chromatin. Another  mechanism  by  which  PRC2  might  repress  gene  expression  is  by maintaining RNA Pol II in a poised state state. In fact, it was shown that in several H3K27me3‐enriched  promoters,  RNA  Pol  II  is  present  but  phosphorylated  at Serine  5  of  its  C‐terminal  domain  (indicating  a  poised  state)  rather  than  being phosphorylated  at  the  Serine  2  residue, which  indicates  an  active  state  instead (Stock et al., 2007). The  molecular  details  of  how  mammalian  PcGs  are  recruited  to  their targets  are  still  unclear.  Although  most  of  PRC2  targets  are  CpG  islands,  the underlying  DNA  sequence  does  not  contain  a  clear  consensus  sequence  (Ku 2008).  Genetic  approaches  have  identified  DNA  binding  proteins  (such  as  YY1 and RYBP) that appear to be required for PRC1 and PRC2 recruitment (Wilkinson 
et  al.,  2006;  Woo  et  al.,  2010).  However,  these  results  were  not  confirmed  in genome‐wide  analyses  in  which  the  overlap  between  these  trans‐acting  co‐factors and PRC2  targets was only partial  (Margueron and Reinberg, 2011). On the  other  hand,  it  was  proposed  that  long  ncRNA  might  be  important  for  the recruitment and  function of PRC2.  It was proposed  that Xist ncRNA can  recruit PRC2  (in  cis)  leading  to  heterochromatization  (Zhao  et  al.,  2008).  Similarly, KCNQ1OT1  ncRNA  is  reported  to  facilitate  PRC2  binding  and  spreading throughout to maintain imprinted expression (Pandey et al., 2008).  
 
1.1.3 DNA methylation and gene silencing  In mammals, DNA is modified by the addition of a methyl group to the 5’ position of the cytosine‐pyramidine ring (5mC) in symmetrical CpG dinucleotide sequences  (Figure  1.2  D).  DNA  methylation  is  catalyzed  by  a  family  of  DNA methyl‐transferases, DNMTs. The first of these enzymes to be characterised was DNMT1  (Bestor  et  al.,  1988;  Li  et  al.,  1992),  which  is  responsible  for  the maintenance of DNA methylation marks throughout the cell cycle in the daughter 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cells.  DNMT1,  together  with  its  tethering  factor  UHRF1  (Arita  et  al.,  2008) (Avvakumov  et  al.,  2008;  Hashimoto  et  al.,  2008)  preferentially  bind hemimetylated CpG site (Leonhardt et al., 1992), such as those generated by the replication of methylated DNA. The N‐terminal region of DNMT1 contains several nuclear  localization  signal  sites  that  may  be  important  for  regulating  nucleus‐cytoplasm shuttling  (Cardoso and Leonhardt, 1999;  Inano  et al.,  2000). DNMT1 associates with  replication  foci  in  the  S‐phase  of  the  cell  cycle  and methylates newly  synthesized  cytosine  paired  with  methylated  CpG  in  the  template  DNA strand. In mice, disruption of DNMT1 function (phenocopied by UHRF1 ablation) results in embryonic lethality and a reduction in global DNA methylation levels to approximately 5% of that found in the wild‐type (Klose and Bird, 2006). DNMT3A and DNMT3B are de novo methyltransferases expressed early in development  that  preferentially  target  unmethylated DNA (Okano  et  al.,  1999). Although neither show a preference for hemimethylated CpG substrates in vitro, DNMT3A  and  3B  contribute  to  the  maintenance  of  DNA  methylation  patterns, possibly by methylation of CpG sites overlooked by DNMT1 (Liang  et al.,  2002; Chen et al., 2003). While inactivation of both genes results in a complete failure to establish  genome‐wide  methylation,  DNMT3A  and  DNMT3B  display  different functions during development, as evidenced by knock‐out mice showing different defects at different developmental stages (Okano et al., 1999). The expression of these  two  de  novo  DNA  methyltransferases  is  developmentally  regulated (Watanabe et al., 2002; Watanabe et al., 2006). DNMT3b is specifically expressed in  undifferentiated  cells  (such  as  the  inner  cell  mass,  epiblast  and  embryonic ectoderm  cells)  and  is  downregulated  upon  ES  differentiation,  while  Dnmt3a appears almost ubiquitously expressed (Watanabe  et al.,  2002). To establish de 
novo  DNA  methylation  DNMT3A  and  B  require  DNMT3L,  which  is  similar  in sequence with other DNMTs but lacks a catalytic domain (Bourc'his et al., 2001). Despite being catalytically inactive, DNMT3L regulates DNMT3A and B activity by forming  tetrameric  complexes  that  are  believed  to  direct  localization  of  the catalytically active isoforms to target sequences (Suetake et al., 2004).  DNA methylation interferes with activation of transcription by at least two independent mechanisms (Bird and Wolffe, 1999). 1) Methylated CpG sequences can directly prevent the binding of transcription activators to their DNA targets. 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2) Methylated CpG sites can recruit repressive complexes (for instance containing HDACs), which have been shown to bind methylated DNA regions through their Methyl CpG‐Binding Domain (MBD), and therefore  indirectly silencing the  locus (Bird,  2002).  Consistent  with  the  repressive  function  of  methylated  CpGs, genome‐wide analyses have revealed a strong inverse correlation between DNA methylation  and H3K4me,  suggesting  a  relationship  between  the  ‘histone  code’ and methylation of  CpG  sites.  Direct  interaction  between DNA methylation  and chromatin  was  confirmed  in  studies  where  DNMT3L  (together  with  DNMT3A) was  shown  to  interact with histone H3  tail  (via  its  PHD‐like domain) when  the residue Lysine 4  is unmethylated (Suetake et al., 2004). Further evidence of the interconnection  between  DNA  and  histone  methylations  has  been  reported  by DNA methylation analysis on Suv39h1 and Suv39h2 double knockout ES cells. In this study, it is shown that the absence of the enzymes responsible for H3K9me3 abrogates  recruitment  of  DNMT3b  at  pericentromeric  regions  and  results  in  a decreased DNA methylation level of these loci (Lehnertz et al., 2003). Also, it was shown  that  UHRF1  binds  to  histone  H3  tails  on  trimethylated  lysine  9  via  its Tudor domain  (Rottach  et al.,  2010). Thus,  these observations  support  the  idea that DNA methylation represents a heterochromatic mark that might play a role in  maintaining  and  propagating  the  locked  heterochromatic  state  throughout mitosis.  Genetic studies have shown the biological relevance of DNA methylation in mammalian embryonic development as mice depleted of DNMTs activity die early after  embryonic  implatation  (Li  et  al.,  1992).  Interestingly,  low  levels  of  DNA methylation  (due  to  DNMTs  depletion)  result  in  incomplete  X‐chromosome inactivation  in  female  cells,  defects  in  allele‐specific  expression  of  imprinted genes,  elevated  transcription  transposon  elements  and  overall  chromosomal instability (Walsh and Bestor, 1999; Chen et al., 2003). In mammalian cells ~70 to 80%  of  all  CpG  are  methylated  with  the  exception  of  CpG  island,  which  are normally  present  at  regulatory  elements  of  housekeeping  genes  (Bird,  2002). DNA  methylation  was  revealed  at  repetitive  sequence  where  it  is  believed  to maintain  transposon  elements  stably  repressed  in  order  to  either  protect genomic DNA from unconstrained transposition (Yoder et al., 1997) or  to avoid excessive expression of irrelevant transcripts (Fazzari and Greally, 2004; Suzuki 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and  Bird,  2008).  Besides  the  majority  of  CpG  islands  that  are  ubiquitously unmethylated, Differentially Methylated Regions (DMRs) have been described in mammal  genomic  DNA  sequences.  These  broadly  include  Imprinted  Control Region  (ICR,  detailed  in  following  section),  regulatory  elements  (such  as promoters and enhancer) of differentially expressed genes (tDMR, see following section)  and  X‐linked  sequences  (xDMR)  in  female  cells  (that  will  not  be discussed here). Overall,  DNA  methylation  fulfills  the  most  stringent  epigenetic  criteria (Bartolomei and Ferguson‐Smith, 2011) as it directly (or indirectly) controls gene expression,  is  faithfully  maintained  throughout  cell  division  (with  a  known mechanism) and  is  inherited by  the progeny  from parental  gametocytes, which carry DNA methylation patterns  that  are erased and  re‐established  in  the germ line at each generation (this is discussed in more detail below, see section 1.2.1). 
 
1.1.4 DMRs and Genomic imprinting  
 Apart  from  its  function  in  maintaining  chromosomal  stability,  DNA methylation  is  important  to silence differentially expressed genes. Among those there  are  developmentally  regulated  genes  that  are  stably  silenced  via methylation of DMR in their regulatory elements. Thus, these elements display a different DNA methylation profile (tissues specific DMR, tDMR) (Doi et al., 2009) in  different  tissues  (or  cellular  identities)  according  to  their  different  gene expression profile.   Another example of DMRs are  those  regions  in  the genome that  within  the  same  cells  display  differentially  allelic  methylation  ensuring monoallelic  gene  expression.  These  include  X‐linked  regions  (xDMR)  in  female cells and several imprinted control regions (ICRs) at genetic imprinted domains. 
 
Oct4 promoter as tDMR prototype 
 A well characterised example of a  locus regulated by DNA methylation  is the  ES‐specific  transcription  factor Oct4, which  becomes  stably  repressed  upon cell differentiation. A  tissue  specific DMR  is present  at  the promoter and at  the TSS  of  Oct4  gene  locus  in  both  mouse  and  human.  Human  and  murine  Oct4 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promoters  are  unmethylated  in  undifferentiated  cells  while  they  become progressively methylated in differentiating cells (Hattori et al., 2004; Deb‐Rinker 
et  al.,  2005).  Inactivation  of  Oct4  involves  recruitment  of  transcriptional repressors and alterations in chromatin structure at its promoter region  (Hattori 
et  al.,  2004;  Deb‐Rinker  et  al.,  2005)  (Gu  et  al.,  2006).  Dnmt3a  and  Dnmt3b function synergistically to methylate the promoter region of the Oct4 gene (Li et 
al., 2007b), which recruits the methyl‐CpG binding proteins MBD2 and MBD3 (Gu 
et al., 2006) to stably inactivate Oct4 in differentiated tissues (Tsuji‐Takayama et 
al.,  2004).  DNA  methylation  at  Oct4  promoter  occurs  after  transcriptional silencing (Feldman et al., 2006) and it is therefore believed to stabilize repression rather  than  initiate  silencing.  For  this  reason,  loss  of  methylation  at  the  Oct4 promoter may  be  required  to  destabilize  repression  prior  to Oct4  re‐activation induced by reprogramming (section 1.3).  
Imprinted genes and ICRs 
 Imprinted genes are monoallelically expressed according to their  parental origin.  They  are  present  in  metatherian  and  eutherian  mammals  and  due  to convergent evolution  in  flowering plants  (Edwards and Ferguson‐Smith, 2007). The parent of origin effect was initially noticed in uniparental embryos in which parthenogenic  (maternal  uniparental)  and  androgenic  (paternal  uniparental) embryos  exhibited  alternative  developmental  abnormalities  (McGrath  J  and  D., 1983;  Surani  MA  and  SC.,  1983).  Investigators  reasoned  that  both  parental contributions  were  required  for  mammalian  development  and  suggested  that ‘imprinting  of  the  genome’  occurred  in  gametocytes  (Surani  MA  et  al.,  1984). Later,  genetic  approaches  allowed  the  identification  of  the  first  imprinted  loci (Barlow  et  al.,  1991;  Bartolomei  et  al.,  1991;  DeChiara  et  al.,  1991;  Ferguson‐Smith et al., 1991), which now encompass approximately 100 genes. The majority of  these  genes  has  been  annotated  in  1  Mb  clusters  throughout  mammalian genomes,  with  the  exception  of  several  identified  singletons  (Edwards  and Ferguson‐Smith, 2007). Over the years, phenotypic analysis of mice and humans with defective  imprinted gene expression have  shown  that  imprinted genes are important  for  the  development  of  specific  lineages,  prenatal  growth  control, 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normal brain function and postnatal energy homeostasis (Ferguson‐Smith, 2011). In  particular,  in  humans,  numerous genetic  diseases  have  been  associated with imprinting  defects,  including  Beckwith–Wiedemann,  Silver–Russell,  Angelman and Prader–Willi syndromes (which will not be discussed here). Allelic‐specific  gene  expression  is  directed  by  parental‐associated monoallelic  DNA  methylation  established  during  gametogenesis  at  specific genomic DMR (more detailed in section 1.2.1). Targeted deletion experiments of a subset  of  maternally  or  paternally  methylated  DMRs  have  provided  definitive evidence  of  their  central  role  in  controlling  the  expression  of  imprinted  genes, therefore  termed  Imprinting  Control  Regions,  ICR  (John  and  Lefebvre,  2011). ICRs are cis‐acting sequences that regulate expression of clusterized or individual imprinted genes. Differential methylation at ICRs controls monoallelic expression through different mechanisms reviewed  in (Koerner and Barlow, 2010).   A well characterised  example  is  the H19/Igf2  locus,  in which  the  paternally  expressed 
Igf2  is  90kb  upstream of  the maternally  expressed  ncRNA H19.  The  two  genes share  an  enhancer  that  is  located  downstream  of H19,  while  their  ICR  resides upstream  of  H19  TSS  (in  between  the  two  genes).  It  was  shown  that  the methylation‐sensitive  insulator  protein  CTCF  binds  exclusively  to  the maternal unmethylated ICR. Here, CTCF binding blocks the enhancer from interacting with the  Igf2  promoter  allowing  expression  of  H19  gene  only.  On  the  paternal chromosome,  methylation  of  the  ICR  blocks  CTCF  binding  and  allows  the enhancer to drive Igf2 expression (Hark et al., 2000) (Murrell et al., 2004). Although  it  is  arguable  whether  DNA  methylation  actually  controls  the expression  of  developmentally  regulated  genes  through  their  tDMR  or  rather, that it is important for the maintenance of a repressed state, DNA methylation at ICRs  represents  one  of  a  few  directed  examples  of  epigenetic  mechanisms controlling gene expression.    
1.1.5 Reversing gene silencing and DNA de­methylation 
 Whether  DNA  methylation  directly  represses  gene  expression  or reinforces  silencing,  it  is  an  extremely  stable mark,  originally  considered  to  be 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irreversible (Bird, 2002). Loss of DNA methylation has been observed in several processes;  globally,  during  embryonic  development  in  the  parental  pronuclei following fertilization as well as in gametogenesis (detailed in section 1.2.1) and locally, in neurons (Ma et al., 2009) and T‐cells following stimulation (Bruniquel and  Schwartz,  2003).  DNA  demethylation  also  occurs  during  somatic reprogramming  (more detailed  in  section 1.3). Loss of DNA methylation  can be achieved  passively  (by  failing  to  methylate  newly  synthesized  DNA)  at  DNA replication, or actively (by a replication independent process) (Bird, 2002).   
 
 
Figure  1.3.  Passive  DNA  demethylation.  Schematic  representation  of  DNA  replication dependent  loss  of  5mC marks.  Following  replication,  in  the  absence  of  DNMT1  activity,  newly synthesized DNA strands  remain unmethylated  resulting  in a  progressive  loss of 5mC residues, which  are  diluted  at  each  cell  division.  Methylated  cytosines  are  represented  with  black  dots while unmethylated cytosines are depicted as white dots.    Lack  of  DNMT1  activity  in  replicating  cells  results  in  serial  dilution  of methylated  DNA  and  a  passive  eviction  of  5mC  from  the  genome  (Figure  1.3). Following  fertilization,  the oocyte DNMT1  isoform DNMT1o,  that  lacks  the  first 118 residues of the N‐terminal domain (Mertineit et al., 1998) is retained in the cytoplasm for the first three cleavage divisions, resulting in loss of methylation by a passive mechanism (Cardoso and Leonhardt, 1999; Mayer et al., 2000; Ratnam 
et al., 2002; Grohmann et al., 2005). From fertilization to the 8‐cell stage, when 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DNMT1o  enters  the  nucleus,  the  maternal  genome  undergoes  global  DNA demethylation with the exception of imprinted loci that are probably maintained methylated  by  the  activity  of  other  DNMTs  (more  detailed  in  section  1.2.1). DNMT1  activity  can  also  be  inhibited  pharmacologically  by  treatment  with  5‐azacytidine,  a  chemical  analogue  of  cytosine  in which  the 5’  carbon  is  replaced with  a  nitrogen  that  cannot  be  methylated.  Therefore,  5‐azacytidine  is incorporated  in  the  DNA  during  replication  inducing  progressive  loss  of methylation with cell divisions (Christman, 2002). Consistent with a role of DNA methylation  in maintaining  cellular  identity,  several  studies have  shown  that 5‐azacytidine treatment of somatic cells results in increased plasticity so that trans‐differentiation,  reprogramming  and  differentiation  are  enhanced.  (Mikkelsen  et 
al., 2008; Lal et al., 2009). This issue will be discussed in more detailed in section 1.3.  Several studies have shown that the paternal pronucleus and the germ line precursors  (primordial  germ  cells,  PGCs)  undergo  a  wave  of  global  DNA demethylation that does not require cell division (Oswald et al., 2000; Hajkova et 




Figure 1.4. Putative active DNA demethylation mechanisms. Schematic representation of  the processes that have been proposed to lead to loss of 5mC marks in a DNA replication independent manner.  (A)  Direct  removal  of  the  methyl  group,  released  as  methanol.  (B)  Excision  of  5mC residues by specific glycosylases. Unmethylated cytosine residues will be then re‐incorporated by BER mechanism. (C) Deamination of methylated cytosine would convert it into a thymidine (T, in red). The generated mismatch would then be resolved by known BER factors that will substitute T residues with unmethylated cytosine.    In  plants  5mC  residues  can  be  directly  removed  by  5mC‐specific glycosylases. For example, it was shown that Arabidopsis thaliana express at least four of  these glycosylases  that  are  able  to directly  remove  the methylated base and cleave the abasic site leaving a nick, which can be restored by base excision repair (BER) mechanism (Zhu, 2009). Although BER pathway is mostly conserved in  mammals,  where  it  has  been  well  characterized  for  mismatch  repair  and chemically  modified  base  substitutions,  the  mammalian  orthologous  of  the botanic 5mC‐glycosylases has never been identified (Ooi and Bestor, 2008). Two  studies  have,  however,  provided  evidence  to  support  a  role  of  BER components  in  active DNA demethylation  processes  in mammals.  In  the  zygote single‐strand  break  binding  proteins  PARP1  and  XRCC1  have  been  observed accumulating  in  the paternal pronucleus  (that undergoes active demethylation) but  not  in  the  maternal  one  (Hajkova  et  al.,  2010)  (Wossidlo  et  al.,  2010). 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Importantly one  of  the  studies  confirmed  the  key  role  of  BER pathway  in DNA demethylation  showing  that  the  inhibition  of  PERP  resulted  in  a  significantly higher DNA methylation level in the paternal genome (Hajkova et al., 2010). The same  study  also  showed  that  concomitantly  with  the  wave  of  active  DNA demethylation  occurring  in  PGCs  (see  section1.2.1)  the  expression  of  BER components was induced (Hajkova et al., 2010). If the BER pathway is involved in the process of active DNA demethylation the question arises of how does it sense methylated CpG? One possibility is that glycosylases such as MBD4 and TDG might recognize and remove 5mC albeit with an activity dramatically  lower  than  towards T:G mismatch   (Zhu, 2009)  (Figure 1.4 B). Anyhow, MBD4 does not seem to be required for global demethylation of the  zygotic paternal pronucleus or  for normal development,  as MBD4‐null mice are  viable  and  fertile  (Santos  et  al.,  2002).  However  local  MBD4  DNA demethylation  activity  was  reported  in  response  to  parathyroid  hormone stimulus. Interestingly, in this study the investigators show that upon stimulation posttranslational  phosphorylation  of  MBD4  enhances  its  glycosylase  activity towards 5mC residues (Kim et al., 2009) Alternatively,  a  preceding  step  of  5mC  deamination,  generating  a  G:T mismatch, might  trigger MBD4  and TDG  glycosylase  activity  followed  by  other BER  components  (Figure  1.4  C).  Mammalian  cytosine  deaminases  activity  has been  characterized  in  several  biological  processes.  For  example,  the  family  of APOBEC  protein  is  involved  in  several  pre‐mRNA  editing,  in  which  cytosine residues  are  deaminated  in  uracil  (Scott,  1995).    AID  was  described  being essential for somatic hypermutation, which increases antibody diversity upon B‐cell  stimulation  (Muramatsu  et  al.,  2000). More  recently,  a  study  conducted  in zebrafish  embryos  have  provided  evidence  supporting  the  idea  that  the  active DNA demethylation process involves the deaminase activity of AID, which creates a G:T mismatch intermediate resolved by MBD4 glycosylase. These investigators observed  that  the  DNA  damage  response  protein  GADD45  enhanced  the  DNA demethylation activity of the two enzymes regulating targeting to 5mC sites (Rai 
et al.,  2008). This  result  is  in agreement with other  reports  in which GADD45α and  GADD45β  isoforms  have  been  shown  to  be  involved  in  global  and  locus‐specific DNA demethylation, respectively (Barreto et al., 2007) (Ma et al., 2009), 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but contrasts with another report that excluded GADD45α involvement (Jin et al., 2008)  because  no  increase  in  global  or  local  methylation  was  observed  in GADD45α‐null mice (Engel et al., 2009). Recently,  two  additional  studies  have  supported  the  hypothesis  of  AID‐dependent deamination as the intermediate step for active DNA demethylation in mammals. One of them reported a genome‐wide DNA methylation analysis of Aid‐/‐ mice  in which  the  lack  of  deaminase  expression  results  in  a  higher  level  of methylated DNA in PGCs (Popp et al., 2010). The other, using reprogramming in heterokaryons  (see  section  1.3.3)  formed  by  fusion  of  human  fibroblast  and mouse  ES  cells,  claimed  that  AID  is  required  for  the  active  demethylation  of human OTC4 and NANOG promoters (Bhutani et al., 2010). However, as AID is not expressed  in ES cells or  fibroblasts (Foshay et al., 2012) (personal observation) and AID‐null mice are viable and  fertile  (Muramatsu  et al.,  2000),  these  finding have been called into question. Other  factors  have  also  been  proposed  as  being  involved  in  active  DNA demethylation. For  instance, a recent  screening of candidate genes, ablated (via siRNA)  in  a  live‐cell  imaging  assay,  has  revealed  that  Elongation  Complex Proteins  (Elp1,  Elp3  and  Elp4)  are  required  for  demethylation  of  the  paternal genome  in  the  zygote  (Okada  et al.,  2010). Two concomitant  reports  claim  that DNMT3A and DNMT3B, well characterized for de novo methyltransferase activity (see  section 1.1.3),  could also be  required  for active DNA demethylation. These studies  report  that  in  human breast  cancer  cells  both  enzymes  are  involved  in cyclical processes of methylation and demethylation at estrogen receptor target genes,  facilitating rapid transcriptional activation and silencing (Kangaspeska et 
al., 2008; Métivier et al., 2008). One of the studies suggests that besides classical methyltransferase  activity,  DNMT3A  and  DNMT3B  also  display  deaminase potential  that  yielding  G:T  mismatches  may  trigger  BER  mechanism  which  in turns results in loss of DNA methylation (Métivier et al., 2008) 
Oxidative modification of 5mC by Tet­mediated hydroxylation 
 Alternative  mechanisms  for  DNA  demethylation  arose  from  the  recent discovery  that  methylated  cytosine  can  be  converted  into  5‐hydroxymethylcytosine (5hmC) (Figure 1.5).  Although 5hmC traces were initially 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detected  in mammalian tissues more than 40 years ago (Penn NW et al., 1972), only  recently  has  this  data  been  confirmed  (Kriaucionis  and Heintz,  2009). We know now that 5hmC is variably present at low frequency in several mammalian tissues. Thus, in mouse Purkinje neurons 0.6 % (the highest observed) of all the cytosine residues are hydroxymethylated (Kriaucionis and Heintz, 2009) and the amount of cytosine carrying a 5‐hydroxymethyl modification in mouse ES cells is even  lower    (less  than  0.1%)  (Tahiliani  et  al.,  2009).  Since  hydroxymethylated cytosine could not be detected in DNMT triple knockout ES cells, it was suggested that 5hmC is produced by an oxidative reaction on preexisting 5mC sites, (Ficz et 
al., 2011; Szulwach et al., 2011; Williams et al., 2011b). 5hmC is undetecteble by classical bisufite  sequencing analysis  as  it behaves as 5mC,  albeit with a  slower DNA polymerase kinetics than unmodified and methylated cytosine (Huang et al., 2010).  The  two  can  be  distinguished  by  antibody‐based  staining  or  by glycosyltransferase  treatment  (that  glycosilate  of  5hmC,  but  not 5mC)  followed by  restriction  enzyme  digestion;  as  5hmC  is  selectively  protected  (Ficz  et  al., 2011).  An oxidative reaction similar to the one that generates 5hmC, is catalyzed by  JBP1  and  JBP2  on  thymidine  residues  during  the  biosynthesis  of  base  J  in trypanosome  (Cliffe  et  al.,  2009).  Attempts  to  determine  the  mammalian orthologous  of  JBP  proteins  has  led  to  the  identification  of  the  ten‐eleven translocation (TET) protein family (Tahiliani et al., 2009), initially characterized in patients with acute myeloid leukemia in which histone methyltransferase MLL is  a  fusion  partner  (Lorsbach  et  al.,  2003).  The  three  members  of  this  family (namely  TET1,  2  and  3)  are  all  able  to  convert  5mC  into  5hmC  through  a  α‐ketoglutarate  dependent  oxidative  reaction  (Tahiliani  et  al.,  2009)  (Ito  et  al., 2010).  It was also shown that, besides the catalytic domain containing the  iron‐binding site, TET proteins (with the exception of TET2) contain a binuclear Zn‐chelating  CXXC  domain  that  might  allow  their  direct  binding  to  chromatin (Tahiliani et al., 2009). 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Figure 1.5. Methylated cytosine hydroxylation. Schematic representation of the three forms of genomic  cytosine  nucleotide‐base.  The  oxidation  of  5mC  mediated  by  Tet  proteins  generate 5hdroxymethylcytosine  residues  (5hmC,  hydroxyl  group  is  highlighted  in  red).  Unmethylated cytosines (C) are represented below as white circle, methylated cytosines (5mC) as black dot and hydroxymethylcytosines (5hmC) as back circle with a red dot.     TET  family  members  are  developmentally  regulated.  Gene  expression analysis has revealed that TET3 is expressed in the zygote while TET1 and TET2 begin to be expressed at 2‐cell stage as TET3 is silenced (Wossidlo et al., 2011). In cultured ES cells TET1 and TET2 are highly expressed whereas TET3  levels are low (Koh et al., 2011; Wossidlo et al., 2011). Upon differentiation TET1 and TET2 (whose  expression  is  directly  induced  by Oct4)  are  downregulated while  TET3 levels  increase  (Koh  et al.,  2011).  In PGCs TET1 and TET2 expression has been reported (Hajkova et al., 2010).  Currently,  the  biological  consequences  of  genomic  5hmC  sites  remain unclear. One possibility is that hydroxymethylated cytosine might function as an epigenetic modifier by altering chromatin structure or affecting the recruitment of DNA binding factors. Two reports have shown that several methyl‐CpG binding (MBD)  proteins  are  unable  to  recognise  5hmC  residues  (Valinluck  et  al.,  2004) (Jin et al., 2010), while an  in vitro study has shown that MBD3 binds 5hmC and unmodified cytosine, but not 5mC residues (Yildirim et al., 2011). Genome‐wide analyses of 5hmC sites  in mouse ES  cells  reveal  a  significant overlap with 5mC residues.  Exceptions  are  heterochromatic  repetitive  sequences  (in  which  high levels of 5mC are found but hydroxylation is rare) and promoters and TSS (where 5hmC enriched and methylation is mostly excluded) (Ficz et al., 2011; Williams et 
al., 2011b). TET1‐depletion in ES cells results in a significant reduction of 5hmC levels and a slight increase in global DNA methylation (Dawlaty et al., 2011; Ficz 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et al.,  2011; Williams  et al.,  2011b; Wu  et al.,  2011). However  in TET1‐ablation experiments  performed  in  two  independent  reports,  only  10%  of  TET1‐target genes  are  actually  mis‐expressed  (Williams  et  al.,  2011b;  Wu  et  al.,  2011). Moreover, both studies showed that lack of TET1 expression resulted in an equal number  of  downregulated  and  upregulated  genes,  leading  one  of  the  papers  to claim  a  dual  role  (as  activator  and  repressor)  for  TET1  in  controlling transcription in ES cells. Consistent with a repressive function, a large fraction of 5hmC  sites  overlap  with  PRC2  target  genes  and  many  of  these  targets  are upregulated  in TET1‐depleted and Eed‐deficient ES  cells  (Wu  et al.,  2011).  It  is also  possible  that  TET1  induces  gene  silencing  independently  of  its  enzymatic activity, as it has been shown to interact with the Sin3 co‐repressor complex and silence target genes in DNMT triple knockout ES cells (Williams et al., 2011b).   
 
Figure 1.6. Passive DNA demethylation following hydroxylation. Schematic representation of replication  dependent  loss  of  5hmC  residues.  Albeit  in  presence  of  catalytically  active  DNMT1, newly synthesized DNA strands from hydroxylmethylated template are left unmodified because of the  inability  of  DNMT1  to  bind  and  perpetuate  5hmC  residues.  Thus,  following  hydroxylation modified cytosines are progressively diluted through cell divisions.      It  has  been  suggested  that  5hmC might  be  an  intermediate  in  the  DNA demethylation  process.  Several  studies  have  shown  that  after  fertilization, methylated  cytosines  are  converted by TET3  into 5hmC  in paternal pronucleus only  (Wossidlo  et al.,  2010; Gu  et al.,  2011;  Inoue and Zhang, 2011;  Iqbal  et al., 2011).  These  reports  suggest  that  global  DNA  demethylation  of  the  paternal genome might instead reflect a genome‐wide hydroxylation (Münzel et al., 2011). 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Interestingly,  in  one  study  5hmC was  eliminated  from  the  paternal  genome  by passive dilution at DNA replication, together with the dilution of 5mC residues in the maternal genome (Inoue and Zhang, 2011) (Figure 1.6). This observation was consistent with  a  recent  study  in which DNMT1  activity was  reduced  on hemi‐hydroxymethylated CpG substrates (Hashimoto et al., 2012).  
 
Figure  1.7.  Putative  active  DNA  demethylation  mechanisms  involving  Tet­mediated 
hydroxylation.  Schematic  representation  of  the  proposed  processes  leading  to  loss  of  5hmC marks in a DNA replication independent manner. (A) Direct removal of the hydroxymethyl group by an unknown factor (???) that would release  formaldehyde. (B) Excision of 5hmC residues by putative  specific  glycosylases,  which  are  currently  unknown  (???).  (C)  Deamination  of  5hmC residues  would  convert  them  into  hydroxymethyl‐uracil  (U,  in  blue).  SMAG1  glycosylase  that recognizes  and  excides  hmU  residues  could  then  resolve  the  generated  mismatch.  The  abasic residues  left  could  be  repaired  by  BER  factors  that  ultimately  will  incorporate  unmodified cytosines. (D) 5hmC residues can be further oxidized by Tet1 protein generating 5‐formylcytosin (5fC) and again 5‐carboxylcytosine (5CaC) residues, which then can be either decarboxylated or recognized and excised by TDG glycosylase. Oxidation products are highlighted in red.  5hmC might also represent an  intermediate  in active DNA demethylation (Figure  1.7).  It  has  been  proposed  that  hydroxymethylated  cytosines  could  be removed directly by a putative 5hmC‐specific DNA glycosylase (Figure 1.7 B) or, 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indirectly,  by  an  additional  deamination  step  generating  5hmU  (Figure  1.7  C), which could trigger BER initiation through the specific glycosylase SMUG1 (Guo 
et al., 2011). Moreover, it has been proposed that the hydroxymethylated group could  be  removed  as  formaldehyde  leaving  an  unmethylated  cytosine (Liutkeviciute  et  al.,  2009)  (Figure  1.7  A).  An  additional  mechanism  for  active DNA demethylation proposed that TET proteins can further oxidize 5hmC site by generating 5‐formylcytosin (5fC) and 5‐carboxylcytosine (5CaC), which then can be  either  decarboxylated  (Ito  et  al.,  2011)  or  recognized  and  excised  by  TDG glycosylase (Cortellino et al., 2011; He et al., 2011; Maiti and Drohat, 2011; Zhang 
et al., 2012) (Figure 1.7 D). Consistent with the later hypothesis, ES cells start to accumulate 5CaC upon TDG depletion (He et al., 2011).  Although  one  report  has  argued  that  TET1  expression  is  needed  for  ES cells self‐renewal capacity, maintaining NANOG promoter hypomethylated (Ito et 
al., 2010), other studies could not confirm this result (Koh et al., 2011; Williams et 
al.,  2011b)  (Ficz  et  al.,  2011; Xu  et al.,  2011).  Furthermore, TET1‐null mice are viable and fertile (Dawlaty et al., 2011) and TET2‐deficient mice are also viable, but may develop spontaneous myeloid  leukemia  in  the adult (Li et al., 2011).  It has also been postulated that in ES cells 5hmC is generated by TET1 at normally unmethylated regulatory regions as a defense mechanism to counteract aberrant 
de novo methylation (Cortázar et al., 2011; Williams et al., 2011a). 
1.2 Pluripotency 
Pluripotency is the epigenetic condition in which a cell is able to generate (or develop into) any cell type of an adult organism (Chambers and Smith, 2004). During  embryonic  development  pluripotent  cells  are  present  within  the  inner cells mass (ICM) of the blastocyst. Pluripotency can be indeﬁnitely perpetuated in 
vitro  by  deriving  Embryonic  Stem  (ES)  cells  from  the  ICM  or  Embryonic  Germ (EG) cells from primordial germ cells (PGCs)(Surani, 2001).  
1.2.1 Mouse life cycle 
 Mammalian development begins with the totipotent zygote (Figure 1.8), in which  two parental haploid  (1n) genomes unite upon  fertilization. At  this  stage 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the two parental pronuclei are epigenetically asymmetric as the paternal genome is fully methylated and rich in protamines (Balhorn, 2007). One of the first steps in  embryonic  development  is  the  conversion  of  the  paternal  genome  from  a transcriptional  quiescence  to  an  active  state.  This  is  achieved  by  a  number  of maternally  inherited  factors  including  transcription  factors  (such  as  OCT4  and SOX2),  histone  modifiers  and  chromatin  remodellers  (Zernicka‐Goetz,  2005; Surani et al., 2007) that  initiate  the reprogramming of  the paternal genes. Even before  the  first  cell  division  protamines  are  replaced  with  histones  (Torres‐Padilla  et  al.,  2006)  and  the  paternal  genome  undergoes  rapid  genome‐wide TET3‐mediated DNA hydroxylation (Mayer et al., 2000; Oswald et al., 2000; Inoue and  Zhang,  2011).  Following  the  first  cleavage  division  zygotic  DNA  becomes transcriptionally  active  and  the  parental  genomes  become  more  similar.  An exception is the DNA methylation status, as paternal DNA still contains high levels of  5hmC  than  the maternal  genome.  This  difference  persists  for  two  additional cleavage divisions during which DNA modifications present at both maternal and paternal  genomes  passively  decline  (Inoue  and  Zhang,  2011).  Importantly,  the wave  of  active  demethylation  (or  hydroxylation)  occurring  in  the  paternal pronucleus,  does  not  involve  the  maternal  genome  or  paternally  methylated imprinted loci.  This could be explained by the initial asymmetry between the two pronuclei  that might direct DNA hydroxylation.  It  is  also possible  that  the non‐histone factor Stella (PGC7) might function to protect DNA against demethylation or  hydroxylation.  Consistent  with  this,  in  Stella‐deficient  oocytes  the  maternal genome appears strongly demethylated (Nakamura et al., 2007). Both hypotheses might  apply,  as  a  recent  investigation  has  shown  that  Stella  blocks  TET3‐mediated hydroxylation  interacting with H3K9me2 sites, which are abundant  in the maternal pronucleus and present at  specific paternal  loci  (such as H19 and 
Rasgrf1  imprinted  genes)  (Nakamura  et  al.,  2012).  Likewise,  the  passive  DNA demethylation  that  the  maternal  genome  undergoes  during  the  first  cleavage divisions does not include maternally methylated imprinted genes because of the compensatory  function  of  other  DNMTs  as  discussed  in  section  1.1.5. Furthermore,  it  appears  that  maintenance  of  DNA  methylation  at  maternal imprinted  loci might  depend  on  the  activity  of  trans‐active  factors  such  as  the KRAB  zinc  finger  protein  ZFP57.  Lack  of  both  maternal  and  zygotic  ZFP57  is 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lethal and results in complete loss of methylation at numerous imprinted loci (Li 
et  al.,  2008).    Therefore,  by  the  8‐cell  stage,  both  parental  genomes  are epigenetically similar with the exception of imprinted loci that retain differential methylation from gametes onwards (Reik and Dean, 2001). 
 
Figure  1.8 Establishment  and maintenance of  pluripotency  in vivo  and  in vitro.  Schematic representation  of  the  mouse  life  circle  and  the  derivation  of  pluripotent  cells  in  culture.  The totipotent  zygote  containing  maternally  inherited  epigenetic  and  transcription  factors  is established  upon  fertilization.  Following  a  ‘reprogramming’  process  that  includes  a  wave  of genome‐wide DNA demethylation of both parental genomes without involving imprinted loci, the zygote develops into the blastomere, where the pluripotent cells are established in the inner cell mass  (ICM,  in  red  at  E3.5).  In  the  postimplantation  embryo,  a  portion  of  the  differentiating pluripotent epiblast cells (in  red at E6) undergoes germ cell  lineage speciﬁcation repressing the somatic developmental program in place during gastrulation and becoming primordial germ cells (PGCs). Early PGCs  (in  red,  at E7.5) undergo a  second embryonic  ‘reprogramming’  process  that involved  a  wave  of  genome‐wide  DNA  demethylation  including  imprinted  loci.  Following imprinting  erasure,  PGCs  also  exhibit  epigenetic  and  transcriptional  states  that  are  associated with  pluripotency  (in  red  at  E12.5).  From  hypomethylated  PGCs  genomic  imprinting  is  re‐established  in  the  mature  gametes,  which  gain  the  ability  to  re‐generate  totiptency  in  the following offspring upon fertilization. In red are highlighted the two waves of embryonic genome‐wide  DNA  demethylation  that  include  or  not  imprinted  loci.  Embryonic  Stem  (ES)  cells  and Embryonic  Germ  (EG)  cells  are  derived  by  ICM  and  PGCs,  respectively.  Albeit  similar  in  most respects, ES  cells display monoallelic  DNA methylation  at  imprinted domains, while EG  cell  are hypomethylated at these loci. Although some bias might be introduced at the fertilization stage, cells of the early blastomeres are essentially identical and totipotent until the 8‐cell stage (Zernicka‐Goetz,  2005).  Here  the  blastomere  becomes  polarized  signaling  the beginning  of  cell  diversification.  Thus,  transiting  to morula  (the  16‐cell  stage), cells  can  divide  either  symmetrically,  generating  two polar  cells  located  on  the outside of the morula, or asymmetrically, generating an apolar cell residing inside and  a  polar  one  that  gathers  with  other  polarized  cells  on  the  surface  of  the 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morula.  In  this  transition  to  the  16‐cell  stage,  one  of  the  first  steps  in differentiation  is  initiated  generating  outside  polarized  cells,  that  will  develop into  the  extra‐embryonic  trophectoderm  and  inside  non‐polarized  cells  that become the ICM (Zernicka‐Goetz, 2005; Yamanaka et al., 2006)(Figure 1.8). In the lineage commitment process several transcription factors are involved including Oct4 and Cdx2 (expressed in the polar outside cells) (Niwa et al., 2005). The ICM is further separated into the inner primitive ectoderm (pEct, the pluripotent cells of the blastocyst) and the outer primitive endoderm (pEnd). Development of the pEct or pEnd is dictated by a mutually exclusive expression of NANOG and GATA6 respectively (Chambers et al., 2003(Chazaud, 2006 #84).  Following  implantation, epiblast  cells  are  formed  from pEct  (Figure 1.8). Despite  retaining  pluripotency  features,  newly  generated  epiblast  cells  rapidly lose  the  expression  of  transcription  factors  such  as  NANOG  (Chambers  et  al., 2003)  and  acquire  ability  to  respond  to  signals  from  surrounding  extra‐embryonic tissues (Hayashi and Surani, 2009). At this stage female cells begin to randomly inactivate one of their two X‐chromosomes (Xi) (Surani et al., 2007). Precursors  of  the  germ  line  (known  as  Primordial  Germ  cells,  PGCs)  are specified from a subset of proximal epiblast cells, which would otherwise initiate somatic differentiation  (Figure 1.8).  It has been  shown  that nascent PGCs block the ongoing somatic differentiation and induce the germ cell program, activating the  transcriptional  regulators  Blimp1  and  Prdm14  in  response  to  localized signals  (Ohinata  et  al.,  2005;  Ohinata  et  al.,  2009).  In mice  this  occurs  around embryonic day 6 (E6) and eventually at around E10.5 and E12.5 the nascent PGCs migrate  into  the  developing  gonads where male  germ  cells will  go  into mitotic arrest  and  female germ cells  into meiotic  arrest  around E13.5.  In  the  course of this  specification  process  PGCs  undergo  a  biphasic  epigenetic  reprogramming 
process  that  ultimately  leads  to  global  DNA  hypomethylation  including  the erasure of genomic  imprinting. Chromatin reorganization in migrating PGCs has been  reported  at  around  E8  including  loss  of  H3K9me2  as  well  as  a  global increase  of H3K27me3.  This  process  establishes  a  chromatin  environment  that resembles the one of pluripotent ES cells (see  section1.2.3), which  is associated with  the  re‐expression  of  pluripotency  genes  (such  as  NANOG  and  SOX2) (Hajkova  et  al.,  2008;  Surani  and  Hajkova,  2010).  Consistent  with  epigenetic 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As discussed in section 1.2.1 pluripotency is a property of cells located in the  ICM.  However  these  cells  persist  only  transiently  in  vivo,  as  they  tend  to undergo differentiation becoming progressively restricted in their developmental potential. Pluripotent cells from the ICM (aka pEct) can be explanted and cultured 
in  vitro  as  Embryonic  Stem  (ES)  cells  essentially  indefinitely,  albeit  in  the presence of appropriate conditions (discussed in more details in section 1.2.3). 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Functional  studies  have  identified  a  group  of  transcription  factors required  for sustaining pluripotency  in mouse and human ES cells (reviewed  in (Ng,  2011  #1373).  It  is  believed  that  these  factors  are  part  of  a  larger pluripotency  circuit  that  is  essential  for  maintaining  an  undifferentiated  state while  being  primed  to  respond  to  appropriate  signals  (Silva  and  Smith,  2008). Among these, the transcription factors Oct4 and Nanog are thought to constitute the  core  of  this  network,  together  with  Sox2  (Boyer  et  al.,  2005;  Boyer  et  al., 2006a). Interestingly, both Oct4 and Nanog are expressed in pluripotent cells of the ICM and reprogrammed PGCs (see section 1.2.1) in the embryo, as well as in their culture counterparts, ES and EG cells respectively (see section 1.2.3). Sox2 is instead  more  broadly  expressed  as  it  has  been  detected  also  in  several differentiated tissues as well as in extra‐embryonic ectoderm.  Mouse  ES  cells  conditionally  depleted  for  Oct4  differentiate  into trophectoderm, consistent with what is observed at the morula stage  (Niwa et al., 2005). Additionally it was shown that less than a twofold increase of Oct4 protein levels  induces  differentiation  into  pEnd  and  mesodermal  tissues  (Niwa  et  al., 2000). Lack of Sox2 expression in mouse ES cells has been shown to phenocopy trophectoderm  conversion  seen  after OCT4 depletion.  Since Oct4  up‐regulation has  been  shown  to  rescue  Sox2  deficiency  (Masui  et  al.,  2007),  it  has  been proposed that the main role of Sox2 in the pluripotency network is in fine‐tuning Oct4 expression  in order to maintain undifferentiated condition (Chambers and Tomlinson, 2009). It is not clear whether or not upregulation of Sox2 in wild type mouse ES cells triggers differentiation per se, but it has been consistently shown to create a bias  towards neuronal differentiation (Zhao et al., 2004; Kopp et al., 2008). Embryonic Nanog ablation results in lethality, blocking pEct formation in favor  of  non‐pluripotent  pEnd  (Mitsui  et  al.,  2003).  However,  Nanog  can  be depleted  in  cultured  ES  cells,  maintaining  them  self‐renewing  and undifferentiated (Chambers et al., 2007). In cultured pluripotent ES cells, Nanog protein  displays  fluctuating  expression  between  Nanog  high  and  Nanog low/negative, resulting in a bimodal profile at the population level (Chambers et 
al.,  2007).  It  has  been  therefore  postulated  that  there  are  two  dynamically interchangeable  stages  of  pluripotency:  ground  state  (Nanog  high)  and  primed 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(Nanog  low/negative).  Studies  employing  Nanog‐GFP  knock‐in  mouse  ES  cells have  further  analysed  the  functional meaning of  this  bimodality  demonstrating that  differentiation  can  be  initiated  only  following  Nanog  silencing  (Silva  and Smith, 2008; Ying et al., 2008).  Genome‐wide  mapping  analyses  of  Oct4,  Nanog  and  Sox2  chromatin occupancy in human and mouse ES cells have identified several target genes co‐bound  by  all  three  transcription  factors.  These  targets  comprise  both transcriptionally  active  and  inactive  transcription  factors  (Boyer  et  al.,  2005) (Loh et al., 2006). Active genes include Oct4, Nanog and Sox2 themselves as well as other pluripotency‐associated  factors, while, among silenced genes,  there are transcription  regulators  involved  in  cellular  specification,  suggesting  that  the core pluripotency factors may act as either activators or repressors. Currently the molecular details of these opposite effects are yet to be fully understood. Studies have identified additional factors such as Klf4 and c‐Myc, which have been shown to contribute to the successful maintenance of pluripotency  (Jaenisch and Young, 2008).  Overall,  Oct4,  Nanog  and  Sox2  are  the  main  intrinsic  factors  that perpetuate  pluripotency,  functioning  in  concert  to  control  the  ES  cell transcriptional network and restrain differentiation into extra‐embryonic tissues or the embryonic lineages (Boyer et al., 2006a).  
 
1.2.3 Mouse ES and EG cells 
 Mouse  ES  cells  are  derived  from  pEct  of  the  ICM  and  maintained undifferentiated  in  culture  in  media  containing  fetal  calf  serum  and supplemented  with  Leukemia  Inhibitory  Factor  (LIF),  a  JAK‐STAT3  pathway ligand  (Niwa  et  al.,  1998).  LIF  binding  produces  the  heterodemerization  of  LIF receptor  with  the  gp130  membrane  protein  that  leads  to  JAK  tyrosine  kinase activation,  which  in  turn  activates  STAT  through  phosphorylation.  In  addition serum  present  in  the  culture  media  provides  Bone  Morphogenetic  Proteins (BMPs)  that  contribute  to  maintain  ES  cell  self‐renewal  via  activation  of  the SMAD pathway. Therefore, undifferentiated ES cells can be grown in a serum‐free condition  if LIF and BMP are supplied (Ying et al., 2003). More recently a study 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A key feature of pluripotent ES cells consist in their capacity to self‐renew undifferentiated  and  differentiate  upon  appropriate  stimulation.  These  two opposite  constraints  are  coupled  in  mechanisms  that  maintain  ES  cells epigenetically plastic through the unique state of their chromatin  (Meshorer and Misteli,  2006;  Spivakov  and  Fisher,  2007).  Several  studies  have  argued  that  ES cell  chromatin  displays  characteristic  of  ‘transcriptional  permissive’  or  ‘open’ euchromatin,  such  as  an  abundance  of  acetylated  histone  and  increased accessibility  to  nucleases  (Boyer  et  al.,  2006a).  Differentiation  towards  specific lineages  generally  results  in  decreased  acetylation  and  increased heterochromatin  formation,  suggesting  that  restriction  in  developmental potential is associated with reduction in genomic plasticity (Boyer et al., 2006a). Several  ATP‐dependent  remodelling  factors  are  highly  expressed  in  ES  cells (Kurisaki et al., 2005) and mutations in components of the SWI/SNF chromatin‐remodelling  complex  such as Brg1,  results  in developmental  arrest  at  the 2‐cell stage (Bultman et al., 2006). At  the  global  level,  a  study  employing  Fluorescence  Recovery  After Photobleaching (FRAP) technology has revealed the high nuclear dynamic of ES cells. In particular it has been shown that chromatin structural proteins (such as the  linker  histone  H1  and  the  heterochromatin  associated  protein  HP1α)  are highly  dynamic  in  the  nucleus  of  undifferentiated  mouse  pluripotent  cells, compared  to  differentiated  cells.  Although  the  mechanisms  that  control  the binding  of  these  factors  to  chromatin  have  yet  to  be  clarified,  this  study  also shows that replacement of H1 with a tightly chromatin‐interacting version blocks the capacity of ES cells to differentiate upon stimulation (Meshorer et al., 2006). This data has been confirmed  in human ES cells, where nuclear HP1α  immuno‐staining  displays  a  diffused  pattern,  opposite  to  the  punctate  labeling characterizing  more  committed  neural  progenitors  and  fully  differentiated fibroblasts (Bártová et al., 2005).  At the level of individual gene loci, a series of studies have shown that in mouse  ES  cells  several  tissue‐specific  genes,  which  are  non‐transcribed  in 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undifferentiated  cells,  carry  chromatin  marks  associated  with  active transcription.  For  example  it  has  been  shown  that  in  ES  cells,  the    silent  B‐cell specific  λ5­VpreB1  locus  is  marked  by  H3K4me2  and  H3  acetylation  prior  to activation  during  B‐cell  commitment.  These  marks  are  lost  upon  ES  cell differentiation towards a non‐lymphoid lineage (Szutorisz et al., 2005). Interestingly,  studies  that  focused  on  either  a  panel  of  developmental regulator  genes  or  performing  genome‐wide  analysis  have  reported  that many non‐transcribed genes carry both active and  inactive modifications  in mouse ES cells.  In  particular  the  promoter  regions were  shown  by  sequential  Chromatin Immuno Precipitation (‘re‐ChIP’) to be enriched for both H3K4me3 (active mark, catalyzed by TrxG proteins) and H3K27me3 (repressive mark, catalyzed by PcG group)(Azuara,  2006;  Bernstein  et  al.,  2006).  Functional  evidence  for  this “bivalent state” was provided by showing that despite not being expressed, these loci  replicate  early  during  S‐phase  of  the  cell  cycle  in  ES  cells,  similar  to  active genes  (Azuara  et  al.,  2006).  Furthermore,  it  has  been  shown  that  promoter regions  of  bivalent  genes  are  marked  by  the  presence  of  RNA  pol  II phosphorylated  at  Serine  5  residue  (Ser5P‐RNAP),  characteristic  of  poised  but not elongating polymerase (Stock et al., 2007). Therefore,  it has been suggested that  this bivalent  chromatin might allow  the maintenance of  the pluripotent ES cell  condition  in  which  differentiation‐associated  genes  are  not  productively transcribed but are kept ‘primed’ for rapid activation in response to appropriate developmental cues (Spivakov and Fisher, 2007).  The repressive mark H3K27me3 is catalyzed  in ES cells by the Polycomb Repressor Complex 2 (discussed in more details in section 1.1.2). Thus, in ES cells ablation of PRC2 core components (namely Ezh2, Suz12 and Eed) results in loss the  of  H3K27me3 marks  and  an    inappropriate  upregulation  of  tissue‐specific genes (Azuara, 2006; Boyer et al., 2006b; Jørgensen et al., 2007). Interstingly, lack of  Eed  expression  in  mouse  ES  cells  is  reported  to  predispose  cells  to spontaneous differentiation (Boyer et al., 2006b), but not loss of pluripotency as Eed‐depleted ES cells can still contribute to most cell lineages both in vivo and in 
vitro (Morin‐Kensicki et al., 2001). Several  laboratories  have  independently  identified  an  additional  ES‐specific  PRC2  component,  Jarid2.  Despite  belonging  to  the  Jumonji  family  of 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histone  demethylases,  Jarid2  does  not  have  any  known  enzymatic  activity (Landeira  and  Fisher,  2011),  but  is  required  for  efficient  PRC2  binding  to  their targets. In Jarid2‐deficient ES cells H3K27me3 levels at target genes are reduced but  not  absent  and  bivalent  genes  are  not  inappropriately  upregulated.  Also Jarid2  ‐/‐  ES  cells  still  express  pluripotency‐associated  genes  comparably with wild‐type cells.  Interestingly, one of  the studies has observed that  lack of  Jarid2 expression in ES cells is associated with loss of Ser5P‐RNAP at bivalent domains and ultimately results in the inability to differentiate upon appropriate stimulus (Landeira et al., 2010). Therefore, these data have suggested that although Jarid2 is  dispensable  for  pluripotency,  it  might  be  important  for  allowing  ES  cells  to successfully  commit  to  differentiation  (Landeira  and  Fisher,  2011).  Bivalent chromatin  at  many,  but  not  all  (Mazzarella  et  al.,  2011),  developmental  genes seems  to  be  resolved  as  lineage‐appropriate  genes  became  activated  and depleted  for  H3K27me3,  while  lineage‐inappropriate  genes  lose  histone acetylation and H3K4m3 (Bernstein et al., 2006); (Mikkelsen et al., 2007).  
 
1.3.Reprogramming  
 Development  of  multicellular  organisms  is  a  highly  ordered  process during which gradual  loss of  ‘genomic potential’ eventually results  in unipotent, or  fully  differentiated  cells.  It  is  however  possible  to  experimentally  revert  a committed  cell  back  to  a  pluripotent  state  (reprogramming)  or  to  re‐direct somatic  identities  into  alternative  cellular  lineages  (transdifferentition) (Yamanaka and Blau, 2010). Several experimental methods have been developed during  the  last  few  decades  including  the  transfer  of  somatic  nuclei  into enucleated  oocytes  (or more mature  eggs),  the  ectopic  expression  of  a  defined combination  of  transcription  factors  and  cell‐to‐cell  fusion  (Figure  1.9).  Using these  techniques  it  is  possible  to  reprogram  mammalian  somatic  cells  to pluripotency and induce a global epigenetic reorganization (including loss of DNA methylation  at  pluripotency  associated  gene  promoters).  The  three  methods 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Pioneering cell fusion experiments began in the late 1960s with the aim to combine  different  cellular  traits  and  assess  their  relative  influences  (Harris, 1965). These experiments provided much of the ground work for concepts such as  malignancy  and  tumor‐suppressor  activity.  For  example,  studies  employing fusion between cancerogenic and healthy cells provided early evidence that  the malignant  state  is  in  some  cases  recessive  to  the  ‘normal’  condition  while  is dominant  in  others  (Harris  et  al.,  1969;  Wieser  and  Harris,  1971).  Later,  by combining  features  of  different  parental  cells,  cell  fusion  was  used  to  produce unlimited amount of monoclonal antibodies, when cloned plasma cells  from the spleen are fused with melanoma cells cultured in vitro  (Köhler G and C., 1975). Experimental cell fusion has also been used to investigate the mechanisms underlying genomic plasticity and dominance (Blau HM et al., 1985). Experiments in which melanocytes or hepatocytes were fused with less specialized fibroblasts, resulted  in  loss  of  melanin  or  albumin  synthesis  respectively  (Davidson  et  al., 1966;  Mével‐Ninio  M  and  MC.,  1981).  Interestingly,  the  principle  of  mutual exclusion  seen  during  normal  development  also  has  been  demonstrated  in experiments of cell  to cell  fusion. Hence, when two somatic cell  types are  fused the  resulting  tetraploid  cell  has  the  potential  to  exhibit  either one  or  the other phenotype, but not both (Fougère and Weiss, 1978). Cell  fusion generates cells  that accommodate two or more nuclei sharing the  same  cytoplasm  that  are  termed  heterokaryons.  Heterokaryons  exist  only transiently after fusion and, if maintained in culture for up to three‐four days, the two  nuclei  will  eventually  merge  and  stable  tetraploid  hybrids  will  form. Tetraploid hybrids are efficiently formed only when the two fusion partners are compatible;  hence  belong  to  the  same  species.  On  the  contrary  interspecies heterokaryons  will  die  soon  after  hybrids  formation  accumulating  severe chromosomal abnormalities  Nevertheless,  in  order  to  assess  changes  in  cellular  identity  that  occurs early  at  the  heterokaryon  stage,  before  functional  phenotypes  become  evident, researchers  have  taken  advantage  of  interspecies  fusions.  Thus,  applying  this method is possible to examine species‐specific changes in each individual fusion 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partner.  For  example,  it  has  been  shown  that  upon  heterokaryon  formation nuclear  factors  in mouse muscle  can  activate  human muscle genes  (Blau  et  al., 1983). Subsequent studies have confirmed and extended this  initial observation showing  that  within  2  days  after  fusion  human  lymphocyte‐nuclei  adopt  a muscle‐like architecture and then initiate the expression of muscle‐specific genes, while  several  lymphocyte‐associated  genes  are  silenced.  Interestingly,  the investigators  observed  that  following  heterokaryon  formation  histone deacetylase  (HDAC)  activity  is  required  for  the  erasure  of  lymphocyte  identity, but  not  for  the  establishment  of  the  muscle‐specific  gene  expression  program (Terranova et al., 2006).  Similarly to the ectopic expression of specific master regulators, cell fusion can induce changes in cellular identity. In addition, the fact that following fusion one of  the  cell  results dominant on  the other,  indicates  that trans­active  factors that normally participate  in  restraining a  cell‐type,  are also able  to  impose  that identity  to  fusion  partners.  The  mechanism  by  which  a  given  somatic  cell  is dominant  over  another  from  a  different  cell  type  is  not  fully  understood  yet. However,  one  hypothesis  is  that  upon  fusion  less  differentiated  cells  maintain their identity more firmly than more specialized ones, resulting in the dominance of the first over the second cell‐type upon fusion. Consistent with this hypothesis, pluripotent  cells  have  been  shown  to  dominantly  reprogram  different  types  of somatic cells upon cell fusion (Tada et al., 1997; Tada et al., 2001). Several studies have shown that when mouse somatic cells are fused to mouse pluripotent cells the  resultant  tetraploid  hybrids  retain  an  undifferentiated  status.  Thus reprogrammed hybrids display ES‐like  features  including growth property, self‐renewal capacity, colonies formation and alkaline phosphatase expression (Tada 
et  al.,  2001;  Do  and  Schöler,  2004;  Ambrosi  et  al.,  2007).  In  addition,  fusion experiments using somatic cells carrying an Oct4‐GFP transgene have shown that GFP expression is re‐activated in 40‐45 hours after fusion with ES cells (Do and Schöler, 2004) (Han et al., 2008; Pereira et al., 2008). Reprogrammed hybrid cells are able  to  re‐differentiate  into  the  three germ  layers, both  in  vitro  and  in vivo. (Tada  et  al.,  2001)  (Do  and  Schöler,  2004).  In  early  fusion  experiments  using pluripotent  EG  cells  erasure  of  genomic  imprinting  in  the  somatic‐derived genome was reported (Tada et al., 1997).  This observation indicates that EG cells 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(derived  from  PGCs)  can  reprogram  and  in  addition  reset  DNA methylation  at imprinted loci. An  advantage  of  the  cell  fusion  approach  compared  with  other reprogramming methods consists in the possibility to apply gain‐of‐function and loss‐of‐function strategies with the aim to identify factors and processes required for successful reprogramming. For example, a marked increase of reprogrammed hybrids has been observed in fusion experiments where ES cells overexpressing the  transcription  factor  Nanog  were  used  (Silva  et  al.,  2006).  On  the  contrary, when ES cells conditionally depleted for Oct4 or Sox2 are used, reprogramming of somatic  cells  is  not  achieved  (Pereira  et  al.,  2008).  In  particular,  these  studies have  revealed  that  Oct4  is  essential  for  the  initiation  of  the  reprogramming process as it rapidly enters the somatic nucleus after fusion, but is not required to maintain  pluripotency  in  reprogrammed  hybrids  once  somatic‐derived  Oct4 expression  is  established  (Pereira  et  al.,  2008).  In  the  same  study,  the investigators  have  also  demonstrated  that  reprogramming  capacity  of  Sox2‐depleted ES cells can be rescued by the overexpression of Oct4.         The  central  role  of  ES‐derived  Oct4  expression  in  initiating  somatic  cell reprogramming after fusion is consistent with its role during iPS generation. The fact  that  pluripotent  ES  cells  express  all  Yamanaka  factors  suggests  that  these transcription factors might reprogram somatic cells upon cell fusion similarly to what  has  been  shown  following  their  ectopic  expression  in  somatic  cells. However  the  cell  fusion  reprogramming  process  is  dramatically  faster  than  iPS cell  generation  as  somatic  derived  pluripotent  gene  transcripts  are  detected already 24 hours after fusion, whereas iPS cells require at least 12 days in culture to emerge (Yamanaka and Blau, 2010). Also, while only a small portion of somatic cells expressing Yamanaka  factors  is reprogrammed, 15‐70% of human somatic cells  have  been  reported  to  acquire  pluripotency  features  (such  as  SSEA4  and 
NANOG expression) three days after  fusion (Pereira et al., 2008) (Bhutani et al., 2010).  Therefore  it  is  possible  that  following  fusion  with  pluripotent  cells, somatic nuclei are reprogrammed by the  four Yamanaka’s  transcription  factors, which  are  in  this  case  assisted  by  other  ES‐specific  factors  or mechanisms  in  a combined  process  the  overall  results  faster  and  more  efficient  than  iPS generation. 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mOct4       Goat  polyclonal  anti‐mouse  Oct4  (sc‐8628;  Santa  Cruz  Biotechnology Inc., Santa Cruz, CA). 1:100 for IF; 1:2000 for wb 
mNanog      Rabbit polyclonal anti Nanog (Cosmo Bio, REC‐RCAB0002P‐F) 1:5000 
mLamin B       Goat  polyclonal  anti‐mouse  Lamin  B  antibody  (sc‐6216;  Santa  Cruz Biotechnology).  1:20000 
mTubulin       Rabbit monoclonal anti‐Tubulin (Sigma). 1:10000 
mNestin      Rabbit polyclonal anti‐Nestin (Covance PRB314C). 1:100 
mGata6      Goat polyclonal anti‐Gata6 (R&D AF1700). 1:200 
mCD44      Rat polyclonal anti‐CD44 (BD 553134). 1:100 
mTuj1      Mouse monoclonal anti‐Tuj1 (Covance MMS‐435P). 1:500 
mEed       Mouse monoclonal anti‐mouse Eed. Antibody kindly provided by A. Otte (University of Amsterdam, The Netherlands).  1:500 
mSuz12       Rabbit polyclonal  anti‐mouse Suz12  (CS‐029‐050;  Diagenode SA, Liège, Belgium). 1:1000 
mEzh2       Rabbit polyclonal anti‐mouse Ezh2 (CS‐039‐050; Diagenode). 1:1000 
H3         Rabbit  polyclonal  anti‐histone  3  carboxy  terminal  (ab1791;Abcam). 1:1000 
H3K9me3       Rabbit  polyclonal  anti‐histone  3  lysine  9  trimethylation  (07‐442; Upstate). 1:100 
H3K27me3      Rabbit  polyclonal  anti‐histone  3  lysine  27  trimethylation  (07‐449; Upstate). 1;100 for IF; 1:1000 for wb 
H3K27m1       Rabbit  polyclonal  anti‐histone  3  lysine  27  monomethylation  (07‐448; Upstate). 1:1000 
H3K27m2       Rabbit  polyclonal  anti‐histone  3  lysine  27  dimethylation  (07‐452; Upstate). 1:1000 
H4K20m3       Rabbit  polyclonal  anti‐histone  4  lysine  20  trimethylation  (07‐463; Upstate). 1:1000 
H3K4m3       Rabbit  polyclonal  anti‐histone  3  lysine  4  trimethylation  (ab8580; Abcam). 1:1000 
H3K9m3/S10ph  Rabbit  polyclonal  anti‐histone  3  lysine  9  trimethylation/  serine  10 phosphorylation (ab5819, Abcam, Cambridge, UK). 1:200 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HP1α   Mouse  monoclonal  anti‐HP1a  antibody  (MAB3584,  Millipore,  Lake Placid, NY). 1:100 
B23  Rabbit  polyclonal  anti‐B23  (sc‐5564;  Santa  Cruz  Biotechnology  Inc., Santa Cruz, CA). 1:250 









hB       Human Epstein‐Barr Virus transformed adult B cell clones obtained from E. Eden (MRC Clinical  Sciences Centre, London, UK) (Eden et al., 2002). This cells were transfected with puromycin resistant cassette.  
Oct4­GFP B    Abelson transformed mouse pre‐B cell lines derived from the transgenic mice  GOF18ΔPE  (Palmieri  et  al.,  1994)  bone  marrow;  C5Bl/6  genetic background.  Once  derived,  this  cells  were  transfected  with  puromycin resistant cassette. 
2RB      Abelson transformed mouse pre‐B cell lines derived from fetal liver of a transgenic  mouse  resulted  from  mating male  GOF18ΔPE  (T  Yoshimizu 1999)  and  female Mest/Peg1‐βgeo  (Lefebvre  1998).  Once  derived,  this cells were transfected with puromycin resistant cassette. 
MEFs      Mouse embryonic fibroblasts isolated from wild type embryos (E13.5).  
SNLs       Clonally  derived  cell  line  from  a  STO  cell  line  (mouse  embryonic fibroblasts) that stably express LIF and neomycin‐resistance gene.  
E14tg2A     Hprt  deficient  mouse  ES  cell  line  derived  from  Lesch‐Nyhan  embryos (Hooper et al., 1987); feeder‐independent; 129 genetic background.  
ZHBTc4     Genetically  engineered  mouse  ES  cell  line  carrying  a  tetracycline‐regulatable Oct4  transgene  replacing  endogenous Oct4  alleles  (Niwa  et al., 2000); feeder‐independent; 129 genetic background. 
B1.3 / G8.1     Eed­/­ mouse ES cell lines (Azuara et al., 2006), derived from eed3354SB mutant mice obtained  from  the Oak Ridge National Laboratory;  feeder‐dependent; C5Bl/6 genetic background.  
B1.3BAC     Rescued Eed deficient mouse ES cell line (B1.3) with a bacterial artificial chromosome  (BAC)  carrying  Eed  and  neomycin  resistance  gene  (see 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section 2.2.4); feeder‐ dependent; C5Bl/6 genetic background.  
B1.3Neo     Eed‐/‐ mouse ES  cell  line (B1.3)  carrying the neomycin  resistance gene (see section 2.2.4); feeder‐dependent; C5Bl/6 genetic background.  
ESL32     Eed­/­ mouse ES cell  line derived  from Eed deficient embryos (Wang et al., 2001); feeder‐dependent; 129/C5Bl/6 mixed genetic background.  
ESL12     Eed+/­ mouse ES cell  line; feeder‐dependent; 129/C5Bl/6 mixed genetic background.  
ESL21     Eed+/+ mouse ES cell line, matching wild‐type control for ESL32; feeder‐dependent;  129/C5Bl/6 mixed  genetic  background;  ESL  cell  lines were kindly provided by N. Brockdorff and M. Casanova (University of Oxford, UK). 
Suz12KO     Suz12­/­ mouse ES cell  line (Fujimura et al., 2006);  feeder‐dependent; a gift from H. Koseki (RIKEN Yokahama institute, Japan).  
Suz12WT     Wild‐type  mouse  ES  cell  line;  matching  control  for  Suz12  ‐/‐  ES  cells; feeder‐dependent;  a  gift  from  H.  Koseki  (RIKEN  Yokahama  institute, Japan).  
Ezh2­1.3     Mouse ES  cell  line Ezh2flx/flx  expressing Cre‐ERT2  recombinase which activation  is  inducible  by  tamoxifen.  Mice  with  both Ezh2  alleles  (SET domain) flanked by loxP sites were crossed with mice carrying Cre‐ERT2 cassette.  ES  cells  were  then  derived  and  clones  isolated,  characterised and kindly provided by S.  Sauer  (MRC clinical  Sciences  Centre, London, UK); feeder‐independent.  
58G      Mouse Embryonic germ cells derived from E12.5 genital ridges of female embryos  (TMA‐58G)  (Tada  et al.,  1997)  (feeder dependent). A kind gift from Prof Takashi Tada (Kyoto University, Japan). 
PGK12      Mouse ES  cell  line derived  from  female embryo (Zvetkova  et al.,  2005), kindly provided by Prof. Neil Brockdorff (University of Oxford, UK)  
DNMT1­/­    DNMT1‐/‐ mouse ES cells kindly (feeder independent) were provided by En Li (Harvard Medical School, Massachusetts, USA) 
DNMT3a/b dKO  DNMT3a  and  b  double  KO  mouse  ES  cells  (feeder  independent)  were kindly provided by En Li (Harvard Medical School, Massachusetts, USA) 
 
2.3. Cell culture 
 All  tissue  culture  reagents  used  here  were  from  Invitrogen  (Invitrogen  Ltd, Paisley,  UK),  unless  stated  otherwise.  MEFs  and  SNLs  were  cultured  in  DMEM supplemented  with  10%  FCS,  2  mM  L‐Glutamine  and  antibiotics,    grown  until 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confluence,  dissociated  with  trypsin‐EDTA,  irradiated  with  γ‐irradiation  (300 rad) and frozen for future use in 10% dimethyl sulfoxide (DMSO), 90% FCS.  EBV‐transformed hB clones were maintained  in RPMI‐1640 supplemented with 10% FCS, 2 mM L‐Glutamine and antibiotics. The B‐cell lines was grown in RPMI‐1640 supplemented with 20% FCS, non‐essential amino acids, 2 mM L‐glutamine, 50  µM  β‐mercaptoethanol,  antibiotics  and  interleukin  (IL)‐7  (5  ng/ml;  R&D systems, Minneapolis, MN).   ES  cells  were  grown  and  maintained  undifferentiated  either  on  irradiated MEF/SNL feeder layers or directly on 0.1% gelatin‐coated surfaces (Sigma), and dissociated  with  trypsin‐EDTA.  Feeder  dependent  ES  cells  were  grown  in  KO‐DMEM medium plus 10% FCS (PAA Laboratories Gmbh, Pasching, Austria), non‐essential  amino  acids,  L‐Glutamine,  β‐mercaptoethanol,  antibiotics  and  1000 U/ml  of  LIF  (Esgro,  Chemicon/Millipore).  Feeder‐free  ES  cells  were  grown  on 0.1%  gelatin‐coated  flasks  (Fisher  Scientific  UK  Ltd,  Leicestershire,  UK)  in Glasgow’s Minimal Eagle medium (GMEM‐BHK 21) supplemented with 10% FCS (PAA  Laboratories  Gmbh),  non‐  essential  amino  acids,  1 mM  sodium pyruvate, 0.075%  sodium  bicarbonate,  antibiotics,  0.1  mM  β‐mercaptoethanol  and  LIF (1000  U/ml).  Doxycycline  (1  µg/ml,  Sigma),  retinoic  acid  (10‐6  M,  Sigma),  4‐hydroxy‐tamoxifen  (800  nM,  Sigma),  cycloheximide  (0.1  µg/ml,  Sigma)  were added  to  the media when  indicated.  All  cells were maintained  at  37°C  and  5% (v/v) CO2. Mouse  EG  (TMA58G  and  TMA55G,  named  here  as  58G  and  55G  respectively) (Zvetkova et al., 2005) and ES (ESL21) cell  lines were maintained on  irradiated mouse  primary  embryonic  fibroblast  (PEFs)  feeder  layers  and  0.1%  gelatin‐coated  surfaces  and  grown  in  DMEM/F12  medium  (Gibco),  20%  FCS  (Sigma) non‐essential  amino  acids,  L‐glutamine,  2‐mercaptoethanol,  antibiotics,  Sodium Pyruvate Solution (Gibco), Sodium Bicarbonate solution (Gibco) and 1000 U/ml of  leukaemia  inhibitory  factor  (ESGRO‐LIF,  Chemicon/Millipore).  EG  (58G  and 55G) cells were treated for 1 week with Plasmocin (25 µg/ml, InvivoGen), and all experiments were performed between passage 24 and passage 28.  Human ES cell lines H1 cells  were cultured in medium conditioned by mitotically inactivated MEFs supplemented with 8 ng/ml of bFGF (FGF2; Peprotech, London, UK) on matrigel‐coated plates (BD Biosciences). Cells were routinely passaged at 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a  1:3  dilution  by  treatment  with  200  U/ml  collagenase  IV  and  mechanical dissociation.  
2.4. Fusion experiments 




  RNA was extracted from 5x106 cells with the Qiagen RNA Extraction kit following the manufacturer’s instructions. Residual DNA was eliminated using the DNA‐free kit (Ambion, Austin, TX) according to manufacturer’s instructions. RNA was then reverse  transcribed  using  SuperscriptTM  First‐Strand  Synthesis  system (Invitrogen). 3 µg of total RNA was diluted in Rnase free water to a final volume of 11 μl and supplemented with 1 μl of 10 mM dNTP mix (invritogen) and 1 μl of oligo (dT)12‐18 (Invitrogen). The mixture was  incubated at 65°C  for 5 min and 
 67 
put on ice for 1 min, when 1 μl of 0.1 M DTT, 4 μl of 5X first strand buffer, 1 μl of RnaseOUT  (Invitrogen)  and  1  μl  of  200  U/μl  Superscript  III  were  added.  A reaction mixture without the enzyme was also set up as a control (designated “‐RT”). The mixture was incubated at 25°C for 5 min, 50°C for 1 h and at 75°C for 15 min. cDNAs of  interest were then detected by semi‐quantitative PCR or real‐time PCR.  
2.5.2. Real­time quantitative PCR analysis (qPCR)  
  Real‐time  PCR  analysis  was  carried  out  on  a  OpticonTM  DNA  engine  using  Opticon Monitor 3 software (MJ Research Inc., Waltham, MA), under the following  cycling  conditions:  an  initial denaturating  step  at  95°C  for 15 min, 40  cycles  of denaturation at 94°C for 15 sec, annealing at 60°C for 30 sec, elongation at 72°C for 30 sec at which point the fluorescence was read at 72°C, 75°C, 78°C and 83°C. The  melting  curve  was  determined  from  70°C  to  90°C,  at  0.2°C  intervals.  PCR reactions included 2X Sybr‐Green PCR Mastermix (Qiagen), 300 nM primers and 2 µl of template in a 35 µl reaction volume. A reaction without DNA was included to  control  for  the  formation  of  primer  dimers  and  each  measurement  was performed  in  triplicate.  The  analysis  of  the  qPCR data was  performed with  the Opticon  Monitor  3  software  and  the  relative  abundance  of  sequences  was calculated using the ΔΔC(T) method (Pfaffl et al., 2001). When the amplification efficiency is close to 2, the relative amount of PCR products between reactions 1 and 2 can be calculated as 2‐ΔC(T)1/2‐ΔC(T)2, being C(T) the threshold cycle at which fluorescence due to PCR products becomes detectable above background. hGapdh  was  generally  used  for  gene  expression  data  normalization  of  human transcripts and mUBC  for mouse  transcripts. Primer  sequences  can be  found  in Appendix I.  
2.6. Immunofluorescence analysis 
hB‐lymphocytes were attached to glass coverslips pre‐coated with poly‐L‐lysine (Sigma).  Heterokaryons  were  cultured  in  0.5%  gelatin‐coated  Thermanox® coverslips  (Nalge‐Nunc  Inc.,  Rochester,  NY).  Mouse  and  human  nuclei  were distinguished  in  the  resulting  heterokaryons  by  counterstaining  with  4,6‐
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diamidino‐2‐phenylindole  (DAPI)  and/or  human‐specific  Lamin  A/C  staining (Figure  2.3).  Shared  cytoplasm  was  confirmed  by  F‐actin  staining  (Phalloidin; A12380, Molecular Probes). At appropriate time points coverslips were removed, washed in PBS and fixed in 2% paraformaldehyde (PFA) in PBS for 20 min. Fixed samples were washed  in PBS and,  for  intracellular  staining, permeabilised with 0.4% Triton  X‐100  for  5 min.  Samples were  incubated  sequentially  in  blocking solution [2.5% bovine serum albumin (BSA), 0.05% Tween20, 10% Normal Goat Serum (Vector)  in PBS]  for 30 min and  in primary antibody diluted  in blocking solution (2 h at room temperature) in a humid chamber. Coverslips were washed in wash buffer (0.2% BSA, 0.05% Tween20 in PBS; 3x5 min) and incubated with secondary  antibodies  coupled  with  appropriated  fluorophores  (Molecular Probes) diluted in blocking solution for 45 min. Finally, cells were washed twice in wash buffer (5 min), once in PBS (3 min) and mounted in Vectashield (Vector) with  DAPI  (0.1  µg/ml).  Samples  were  visualised  using  a  TCS  SP5  Leica  laser‐scanning  confocal  microscope.  Images  were  processed  using  Leica  Confocal software and Adobe Photoshop CS2. Microscope  settings  and  laser power were kept constant between the controls and samples.  
2.6.1 Identification of human nuclei in heterokaryons 




Figure  2.1.  Different  patterns  of  Dapi  counterstaining  allow  to  discriminate  between 
human  (somatic)  and  mouse  (pluripotent)  nuclei  in  heterokaryons.  Snapshot  of  a representative heterokaryon labeled with Phalloidin (Actin, red) and Dapi (Nuclei, blue).  
 
2.6.2 Measurement of nuclear volumes  To  estimate  nuclear  volumes,  z‐stacks  (0.5   µm  distance)  spanning  individual nuclei  (labeled  with  Dapi)  were  acquired  on  the  laser  scanning  confocal microscope  (Leica).  Volocity  image  processing  software  was  used  for  3D reconstructions and to quantify the volume of individual nuclei.  
2.6.3 Alkaline phosphatase assays  Hybrid colonies 12 days after cell fusion were fixed for 30 seconds with a solution of acetate citrate and formaldehyde and then stained with alkaline phosphatase assay kit  (Sigma) according to manufacturer’s instructions. Stained dished were scanned with Epson Scan software and number of positive colony was counted.   
2.6.4 X­gal staining  Undifferentiated  and  differentiating  (EG+2RB  or  ES+2RB)  hybrid  clones  were fixed  for 15 minutes at room temperature  in 0.1M phosphate buffer (pH 7.3), 5 mM  EGTA,  2  mM  MgCl2  ,  0.2%  glutareldahyde,  washed  in  wash  buffer  (0.1M phosphate buffer (pH 7.3), 500 ml 2 mM MgCl2) and incubated in staining buffer (0.1M  phosphate  buffer  (pH  7.3),  500  ml  2  mM  MgCl2,  5mM  potassium ferrocyanide,  5mM potassium  ferricyanide  and  1 mg/ml  X‐gal)  for  16  hours  at 37ºC. Upon  three  final washes  in wash buffer  the  stained plates were  analysed using an inverted widefield microscope equipped with a 10X objective  
2.7. Western blot analysis 
 Whole  cell  extracts  were  prepared  by  direct  lysis  of  cells  (5  min  at  95°C  and subsequent vortexing) in protein sample buffer (50 mM Tris‐HCL pH 6.8, 1% SDS, 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10% glycerol, 0.001% Bromophenol Blue, 5% β‐mercaptoethanol).  For western blot  analysis  of  modified  histones,  histone  proteins  were  isolated  from  whole cells by acid extraction. ES cells were pelleted and resuspended in 1 ml PBS (4°C), centrifuged  (500g  for  5 min)  and  the  supernantant  removed.  Cell  pellets were resuspended  in  180 μl of  ice  cold  lysis  buffer  (100 mM HEPES pH 7.9, 1.5 mM MgCl2 10 mM KCl, 0.5 mM DTT and 1.5 mM PMSF), 20 μl of 2M HCl and incubated on ice for 30 min. Following acid lysis the solution was centrifuged 11,000g for 10 min at 4°C,  the supernantant of  acid soluble proteins collected and sequentially dialyzed against 0.1 M acetic acid (twice for 1 hour) and water (1 hour, 3 hours and overnight, respectively). The protein solution was quantified and stored at ‐70°C.  Sodium  dodecyl  sulfate‐polyacrylamide  gel  electrophoresis  (SDS‐PAGE)  was carried  out with  the  Bio‐Rad minigel  system.  20  μg  of  protein  sample  and  the benchmark  pre‐stained  protein  ladder  (Invitrogen)  were  loaded  on  an acrylamide  (BioRad)  stacking gel  [5% (w/v) acrylamide, 0.125 M Tris  (pH 6.8), 0.1% (w/v) SDS, 0.1% (w/v) ammonium persulphate, and 0.1% (v/v) N,N,N’,N’‐tetramethylethylenediamine]  and  separated  in  a  10%  acrylamide  resolving  gel [10%  (w/v)  acrylamide,  0.4  M  Tris  (pH  8.8),  0.1%  (w/v)  SDS,  0.1%  (w/v) ammonium  persulphate,  and  0.1%  (v/v)  N,N,N’,N’‐tetramethylethylenediamine] using  Tris‐glycine  electrophoresis  buffer  [1.5%  (w/v)  Tris,  7.2%  glycine,  0.5% (w/v)  SDS].  Resolved  acrylamide  gels  were  blotted  to  a  Protan  nitrocellulose transfer  membrane  (Schleicher  &  Schuell  Bioscience,  Dassel,  Germany)  in transfer buffer (48 mM Trizma base, 39 mM glycine, 0.037% (w/v) SDS and 20% (v/v) methanol) using the trans‐blot semi‐dry electrophoretic transfer apparatus (BioRad). The membranes were  incubated  for 30 min with blocking buffer [5% (w/v) fat free milk powder (Marvel), 1.2 g/L Tris pH7.4, 8.75 g/L NaCl], followed by  primary  antibody  incubation  diluted  in  blocking  buffer  for  2  h  at  room temperature, with agitation. After washing 3  times  in wash buffer  [1.2 g/L Tris pH7.4,  8.75  g/L  NaCl]  for  5  min,  blots  were  incubated  with  horseradish peroxidase‐ coupled secondary antibodies (anti‐rabbit and anti‐mouse were from Amersham and used at 1:5000 and 1:2000 dilutions, respectively; anti‐goat used at  1:2000  dilution  from  Santa  Cruz)  in  blocking  buffer  for  1  h  at  room temperature. Detection was  done with  the  ECL‐Plus western  blotting  detection 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kit  (Amersham)  following manufacturer’s  instructions and using Kodak X‐Omat photographic films.  
 
2.8. DNA methylation and hydroxymethylation analysis 
 Genomic DNA was  isolated  from cells by overnight  incubation  in 500 μl of  lysis buffer  (200 mM NaCl, 100 mM Tris‐HCl pH 7.4, 5 mM EDTA, 0.2% SDS, 250 μg Proteinase K) at 55ºC and subsequent phenol/chlorophorm/isoamylalcohol and chlorophorm/isoamylalcohol  extractions.  DNA  was  then  precipitated  with isopropanol  (50%),  followed  by  70% ethanol wash,  and  ressuspension  in  Tris‐EDTA  (TE;  10  mM  Tris‐Hcl  pH  8.0,  1  mM  EDTA).  DNA  concentration  was quantified by spectrophotometry.  
 
2.8.1. Bisulfite sequencing 
 Genomic  DNA  was  isolated  from  cells  as  described  in  section  2.2.4.1.  Bisulfite modification  of  genomic  DNA was  carried  out with  the  EZDNA methylation  kit (Zymogenetics  Inc.,  Orange,  CA)  according  to  the  manufacturer’s recommendations. 1‐2 μg of genomic DNA was converted at 50ºC (protected from light) with CT conversion reagent and column purified (provided in the kit). DNA was  then  eluted  in  10  μl  and  2  μl  of  recovered  DNA  was  used  for  PCR amplification (section 2.2.4.2). PCR primers were designed to recognise bisulfite converted human DNA only using MethPrimer (www.urogene.org) and tested in 




Genomic DNA (10μg) was digested with either 50U of HpaII (NEB), 100U of MspI (NEB) or no enzyme (mock digestion) at 37°C for 4 hours, followed by Proteinase K  treatment  for  30min  at  40°C.  The  HpaII‐resistant  fraction was  quantified  by qPCR using primers designed around at  least one HpaII/MspI site (qF+qR), and normalized to a region lacking HpaII/MspI sites (nF+nR) and the mock digestion control (Figure 6.2). Primers used for this analysis are listed in Appendix.   
  
Figure  2.2.  Schematic  representation  of  the  strategy  used  to  design  primers  for  qPCR 
analysis following HpaII/MspI digestion. Ct values obtained from qPCR using primers flanking at least one HpaII/MspI site (CCGG, qF+qR) were normalized to Ct values obtained using primers amplifying regions lacking HpaII/MspI sites (nF+nR).   
2.8.3. 5hmC quantification  Genomic  DNA  (10μg)  was  treated  (+T4)  or  not  (‐T4)  with  T4  Phage  β‐glucosyltransferase (T4‐BGT, NEB) according to the manufacturer’s instructions. Glucosylated genomic DNA was digested with either 100U of MspI or no enzyme (mock  digestion)  at  37°C  for  4  hours,  followed  by  Proteinase  K  treatment  for 30min at 40°C. The MspI‐resistant fraction was quantified by qPCR using primers designed around at least one MspI site, and normalized to a region lacking MspI sites  (Figure  6.2)  and  to  the  mock  digestion  control.  MspI  resistance  (+T4  ) subtracted of MspI resistance (‐T4 ) translates into percentage of 5hmC.  
2.9 Cloning and DNA delivery into ES cells 
 
2.9.1 Engineering of protein expression and shRNA constructs   For Eed  reconstitution,  a  bacterial  artificial  chromosome  (BAC) was  inserted  in 
Eed  deficient  ES  cells  (B1.3  clone).  The  Eed  containing  BAC  clone  was  called RP23‐ 370F10 and includes the 97076839‐97260535 region of the forward DNA 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strand  of  mouse  chromosome  7.  The  BAC  clone  was  ordered  in  the  supplied vector  (BACPAC  resources,  Oakland,  CA)  which  contains  a  chloramphenicol acetyltransferase (CAT) gene for selection in bacteria. The CAT gene was replaced with  the neomycin  resistance  cassette  from  the pL452 plasmid  (NCI, Frederick, MD) by recombineering. The CAT gene is 660 bp, 330 bp of the 5' and 330 bp of the 3' regions were PCR‐ amplified and cloned into the pL452 plasmid, 5' and 3' respectively of the neomycin resistance cassette. Recombination was induced by the  transformation  (as  described  in  section  2.9.2)  of  the  recombineering competent bacterial strain SW102 (NCI,  Frederick, MD) with the BAC clone and posterior introduction of the pL452 plasmid by electroporation. Short hairpin RNA (shRNA) sequences were cloned into pSuper.neo+gfp vectors (Oligoengine).  shTet1:  tgtagaccatcactgttcgac  (Williams  et  al.,  2011b);  shTet2: gctctgaacagtattcaaagc (Ito et al., 2010).  
2.9.2 Plasmid construction and bacterial transformation  




  The DNA BAC clone was delivered  into ES cells by electroporation. ES cells plus DNA  (30 μg) were  transferred  into  a  cold  electroporation  cuvette  (Gene  Pulser Cuvette, 165‐2088, Bio Rad Laboratories Inc., Waltham, MA) and left on ice for 5 min before electroporation (200V, 960 μF, BioRad). Cells were  incubated on  ice for  an  additional 5 min  for  recovery  and  cultured  in  complete  ES  cell medium. When required selection was applied 24 h after  transfection (G418, 400 μg/ml; Invitrogen) and resistant ES cell colonies manually isolated after 10 days.   15 μg of empty (control) or shRNA containing vectors were electroporated  into 5x106  mouse  Embryonic  Germ  cells  by  Amaxa  Nucleofector  2b  (VPH  ‐1001, Lonza).  GFP+  EG  cells were  FACS‐sorted  12  hours  after  elctroporation  and  re‐plated  for  24  hours  before  being  harvested  and  used  for  characterizations  and fusion  experiments.  Finally,  the  transfection  mix  was  replaced  for  2  ml  of complete ES cell culture medium.  To make hB, mB and m2RB cells puromycin resistant, pMSCV (containing a Puror cassette) was transfected into 293T cells with helper virus vectors  (p10A1 for hB cells  and  pΨeco  for  mB  and  m2RB  cells)  using  a  calcium  phosphate  protocol. Culture  supernatants  containing  the  retrovirus  particles were  harvested  48,  60 and 72 hours post‐transfection. For infection, the virus supernatant was added to 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a sub‐confluent plate of cells with 2μg/ml polybrene, cells were spun at 2500 rpm for 1hr at 37°C,  after which  the  cells were  fed with  fresh media. 24 hours after infection puromycin (2µg/ml) was added to the media to select for resistant cells for 2 weeks. Cells were then maintained in culture in puromycin (1µg/ml).  
2.10. Fluorescence activated cell sorting (FACS) analysis  
  To analyse DNA content of mB, ES, EG and hybrids, 5‐10x106 cells were washed in and  resuspended  in  950μl  of  PBS  (‐Ca/‐Mg),  50μl  of  Propidium  Iodide (PI,1mg/ml,  Sigma),  10μl  NP‐40  5%,  100μl  RNAse  A  (10mg/ml,Invitrogen)  for 20min  at  RT.  The  cells  were  then  washed  twice  in  FACS  buffer  and  then resuspended  in  100  μl  of  FACS  buffer  and  analysed  in  a  FACScalibur  (BD Biosciences) with CellQuest software.  To  assess  the  re‐activation  of  Oct4‐GFP  transgene,  1x106  hybrid  cells  were dissociated  with  trypsin‐EDTA  and  collected;  then  they  were  washed  twice  in FACS  buffer  and  then  resuspended  in  100  μl  of  FACS  buffer  and  analysed  in  a FACScalibur (BD Biosciences) with CellQuest software. FACS purification was performed using a FACSAria cell sorter (BD Biosciences).    CHAPTER 3. CELL FUSION‐BASED REPROGRAMMING TOWARDS PLURIPOTENCY  The reversion of the cellular identity from a differentiated state back to an undifferentiated state can be achieved through different methods. In addition to nuclear transfer and iPS approaches (discussed in 1.3.1 and 1.3.2 respectively), it is possible  to reprogram somatic cells  toward pluripotency by  fusing them with undifferentiated  stem  cell  partners  (introduced  in  1.3.3).  Following  fusion, pluripotent mouse ES  cells  can dominantly  impose  their undifferentiated  status 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on  somatic  cells,  which  are  reprogrammed  to  pluripotency  (Tada  et  al.,  2001; Pereira  et  al.,  2008).  In  this  chapter  I  will  outline  basic  concepts  of  the experimental  cell  fusion‐mediated  reprogramming  approach  that  I  will  further develop in the following chapters. 
3.1  Reprogramming  of  hB­lymphocytes  is  initiated  in 
heterokaryons formed after fusion with mouse ES cells. 
The  cell  fusion‐based  reprogramming  process  consists  in  a  first  phase, which  is  transient and generates a heterokaryon  in which discrete nuclei  share the same cytoplasm. The heterokaryon phase persists without cell division for up to  3  days  (72  hours)  (Figure  3.1  A,  framed  in  red  dashed  line)  before  the  two nuclear partners merge to generate tetraploid hybrids. In order to  investigate somatic reprogramming at early  time points after fusion,  I  have  fused  human  B‐lymphocytes  with  mouse  ES  cells  in  a  1:1  ratio (Figure  3.1A)  using  polyethylene  glycol  (PEG)  (fully  detailed  in  2.4).    By performing interspecies fusion experiments, it  is possible to monitor changes in gene expression that the somatic cell undergoes at the heterokaryon stage by RT‐qPCR using primers that specifically amplify human genes. With this approach, I could verify  that human B cells start expressing human pluripotency‐associated genes  (such as hOCT4, hNANOG and  hCRIPTO)  in heterokaryons with mouse ES cells  so  that  RT‐qPCR  analysis  before  and  48  to  72 hours  after  fusion  revealed significant up‐regulation of human pluripotent genes (Figure 3.1 B). On the other hand, human B cell nuclei down‐regulated  the expression of hCD45, hCD37 and 




human  somatic­associated  genes  in  heterokaryons  formed  with  mouse  ES  cells.  (A) Schematic  representation  of  the  strategy  for  generating  inter‐species  heterokaryons  between human B  lymphocyte (hB,  in grey) and mouse Embryonic Stem cells (ES,  in white),  in which the heterokaryon  (analyzed  48  and  72  hours  after  fusion)  is  highlighted  red  line.  (B)  RT‐qPCR analysis of human pluripotent genes OCT4, NANOG and CRIPTO in hB before (0h) and after fusion (48  and  72  hours) with mouse  ES  cells.  (C)  RT‐qPCR  analysis  of  human  lyphocyte  genes CD45, 
CD37 and  CD20  in hB before (0h) and after  fusion (48 and 72 hours) with mouse ES cells. Data were  normalized  to  human  GAPDH  expression.  Error  bars  represent  SD  of  3  independent experiments where where statistical significance  is indicated as *** pvalue < 0.0005, ** pvalue < 0.005, * pvalue < 0.05 calculated with student t‐tests   Overall,  exploiting  inter‐species  fusions,  I  showed  here  that reprogramming  is  initiated at  the heterokaryon stage (48‐72 hours post  fusion) when  expression  of  pluripotency‐associated  genes  is  induced  and  lymphocyte‐associated gene expression is extinguished. 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3.2  Fusion  of  mouse  ES  and  mouse  B  cells  generates 
reprogrammed hybrids 
The  reprogramming  process  that  initiates  early  after  fusion  in  transient heterokaryons  continues  in  newly  formed  hybrids,  when  the  two  nuclei  fuse (Pereira  et  al.,  2008). When  the  two  fusion‐partners  belong  to  the  same  specie their  chromosomes are  compatible and may give  rise  to a  karyotypically  stable hybrid cell line (Figure 3.2 A, framed in dashed red line).  In order to identify reprogrammed hybrids I have used PEG treatment to fuse mouse ES cells with a puromycin resistant mouse B cell line (mBPur) in a 1:1 ratio.  Thus,  by  performing  same‐specie  fusions  it  is  possible  to  generate  and select hybrid cells by culturing the fused cells in the presence of puromycin for 12 days. During  this period non‐fused ES  cells, which are not puromycin  resistant, are  eliminated  and  non‐fused  B  cells  (non‐adherent)  are  washed  away.  The resulting puromycin resistant mES+mB hybrid colonies stably self‐renew, display an ES‐like morphology and are mostly positive for Alkaline Phosphatase staining (AP, Figure 3.2 B). These cells also express the pluripotent Oct4 protein, detected by IF analysis (Figure 3.2 C).  Interestingly,  by  using  a  puromycin  resistant  mouse  B  cell  line  that contains  a  silent  Oct4‐GFP  transgene  (mBOct4­GFP)  for  fusion  experiments  it  was possible to examine  Oct4 re‐expression during reprogramming. This allowed me to  confirm  the  reprogramming  capacity  of  mouse  ES  cells  by  their  ability  to reactivate GFP expression in hybrids formed with mBOct4­GFP (Figure 3.2 D). Thus, using these experimental approaches I could isolate reprogrammed hybrid clones (fully described in 2.4) from puromycin resistant GFP positive colonies obtained 10‐12 days after fusion. In order to acquire enough material, I also expanded the isolated  reprogrammed  hybrid  clones  in  the  same  culture  condition  for  10 additional days  following  isolation.  FACS  analysis  of  GFP  and Propidium  Iodide (PI)  staining  showed  that  these  hybrid  clones  were  reprogrammed  and tetraploid, as anticipated (2n+2n=4n) (Figure 3.2 E). 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Figure  3.2  Fusion  of  mouse  ES  and  mouse  B  cells  generates  reprogrammed  hybrids.  (A) Schematic  representation  of  the  strategy  for  generating  and  selecting  intra‐specie  hybrids between mouse B  lymphocytes  puromycin  resistant or  carrying an Oct4‐GFP  transgene  (mB,  in grey) and mouse Embryonic Stem cells (ES,  in white),  the hybrid analyzed 12 and 21 days after fusion is framed in red. (B) Alkaline Phosphatase (AP) staining of hybrid colonies obtained from fusions of puromycin‐resistant mouse B cells with mouse ES cells. Fused cells (+PEG) or un‐fused controls  (‐PEG)  were  plated  on  puromycin‐resistant  feeder  cells  in  ES  medium  supplemented with puromycin for 12 days and then stained for AP actitvity. (C) Immunoﬂuoresence labeling of Oct4 (green), in a representative hybrid colony generated from fusing mouse B cells with mouse ES  cells. Actin  (red)  staining  is  shown as a  control.  Scale bars  represent 50µm.  (D) Bright  Field and  fluorescent  (GFP)  images  of  a  representative  hybrid  colony  formed  12  days  after  fusion  of mouse ES  cells  and mouse B‐lymphocytes  carrying an Oct4‐GFP  transgene.  (E) FACS analysis of Propidium  Iodide  staining  (PI,  left  panel)  and  GFP  expression  (right  panel)  of  a  representative tetraploid  (4n)  hybrid  clone  obtained  21  days  after  fusion  of  mouse  ES  cells  and  mouse  B‐lymphocytes carrying an Oct4‐GFP transgene. Un‐fused diploid (2n) mES and mB cells are used as controls.    These data show that by performing intra‐species fusion experiments, it is possible to monitor reprogramming at later time points (12 and 21 days) (Figure 3.2 A).  In particular,  employing mBPur  lymphocytes allowed me  to generate and 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select  stable  reprogrammed  hybrids,  and  to  show  that  these  adopt  an undifferentiated  status,  display  self‐renewal  capacity,  ES‐like  colony  formation, AP activity and Oct4 expression (Figure 3.2 B).   
3.3  Loss  of  DNA  methylation  at  somatic  Oct4  promoter  is 
initiated in heterokaryons and completed in hybrids.  




completed  in  hybrids.  (A)  HpaII  digestion  resistance  analysis  of  human  OCT4  promoter  (red solid  line)  in hB cells before  (0h) and after  (48 and 72  hours)  after  fusion with mouse ES  cells. Level of HpaII resistance at hOCT4 promoter  in hES cells (used as control) is represented with a dashed  red  line.  **  p‐value  <  0.005,  calculated  with  student  t‐tests.  (B)  Genomic  Bisulfite sequencing analysis of mouse Oct4 promoter (red solid  line)  in reprogrammed hybrids obtained 21 days after  fusion of mES and mB cells. Un‐fused mES and mB cells are used as control. Day 0 sample  corresponds  to  1:1  mixture  of  the  two  cell  types  at  the  moment  of  the  fusion.  Closed circles  represent  methylated  CpG  while  open  circles  represent  un‐methylated  CpG.  Overall methylation levels are indicated in red as a percentage of total. (C) Bisulfite sequencing analysis of Oct4‐GFP  transgene  promoter  (red  solid  line,  obtained  from  GOF18 ΔPE  mice)  in  hybrids obtained  between  mES  and  mBOct4‐GFP  cells  at  fusion  (Day0)  and  several  indicated  time  points afterwards.  Closed  circles  represent  methylated  CpG  while  open  circle  un‐methylated  CpG. Overall methylation levels are indicated in red as a percentage of total.   To  assess  whether  this  DNA  de‐methylation  process  continued  at  later time points, I performed bisulfite genomic sequencing on reprogrammed hybrids. This showed that the somatic Oct4 promoter was highly methylated before fusion (in  mB  cells),  but  became  demethylated  21  days  after  fusion  (Figure3.3  B, compare  closed  and  open  circles).  To  determine  the  kinetics  of  this  DNA  de‐methylation  of  the  Oct4  promoter  during  reprogramming,  Hakan  Bagci  and  I fused mBOct4­GFP  lymphocytes with mES  cells  and  purified  GFP+  reprogrammed 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hybrids by  cell  sorting at  several  time points  after  fusion. Then we  tested each sample using bisulfite genomic sequencing to assess the DNA methylation status at  the  Oct4‐GFP  transgene  promoter.  This  showed  that  the  Oct4  transgene promoter  was  methylated  in  somatic  cells  before  fusion,  became  partially demethylated 3 days (72 hours) after fusion and was largely unmethylated by 6 days  (Figure  3.3  C).  Overall,  this  showed  that  the  DNA  of  the  somatic  Oct4 promoter  is  demethylated  in  the  course  of  cell  fusion  reprogramming.  In particular  this  de‐methylation  process  is  initiated  in  heterokaryons  (up  to  72 hours after fusion) and is completed as hybrids are formed (6 days after fusion).  
3.4 Somatic  cells  can establish multi­lineage potential after  cell 
fusion­mediated reprogramming.  
 To assess  the extent  to which  somatic  cells  are  reprogrammed upon cell fusion,  together with  Jorge Ried and David Landeira,  I  tested the differentiation capacity  of  isolated  reprogrammed  hybrids. We  induced  differentiation  via  LIF withdrawal in two independently isolated GFP+ hybrids clones. RT‐qPCR analysis revealed  that  removal of  LIF  from  the  culture media  induced  the  expression  of extra‐embryonic  associated  (Hand1),  mesodermal  (Flk1  and  Bry)  and endodermal  (Gata6  and  Gata4)  genes  after  6  and  12  days  (Figure  3.4  A).  In addition, we  performed  IF  staining  of  these  hybrid  clones  before  and    after  12 days of LIF withdrawal, to determine the expression of several lineage‐associated markers. The analysis showed that differentiated clones had lost Oct4 expression but  acquired  the  expression  of  markers  of  the  three  germ  layers,  such  as ectodermal Nestin and Tuj1,  endodermal Gata6    and mesodermal CD44  (Figure 3.4 B). 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al., 2010; Piccolo et al., 2011). This process results in the acquisition of features that  are  normally  associated  with  an  undifferentiated  status.  Previous  studies have shown that reprogramming in experimental heterokaryons using adult cells from  different  lineages  (Blau  HM  et  al.,  1985;  Terranova  et  al.,  2006)  can  be initiated  prior  to  chromosome  replication  and  cell  division.  In  addition, heterokaryons  formed  by  fusing  adult mouse  erythroleukemia  (MEL)  cells  and human  embryonic/foetal  erythroid  (K562)  cells  revealed  that  transcriptionally inactive mouse  globin  genes  could  be  re‐activated within 24 hours  in  transient heterokaryons  (Baron  and  Maniatis,  1986).  Here  I  show  that  conversion  of unipotent  lymphocytes  towards  multipotency  is  initiated  in  transient heterokaryons  before  nuclear  fusion  and  cell division.  Performing  inter‐species fusions,  I  show  that  human  lymphocytes  begin  to  re‐express  genes  that  are normally expressed by human ES cells within 48 hours. This result is consistent with  previous  studies,  which  employed  similar  experimental  strategies  and showed  that  expression  of  human  pluripotency  associated  genes  is  induced  in human B cells and human fibroblasts 24 hours after  fusion with mouse ES cells (Pereira et al., 2008; Bhutani et al., 2010). The rapid re‐activation of endogenous pluripotency‐associated genes  seen  in  inter‐species heterokaryons  is  consistent with  studies  showing  early  Oct4‐GFP  transgene  re‐activation  in  B‐lymphocytes (described herein) and in MEFs (Wong et al., 2008) or neural stem cells (Han et 
al., 2008) that had been fused with mouse ES or EC cells. Likewise, re‐activation of human OCT4  and NANOG  in human somatic nuclei, has been  shown  to occur rapidly upon Tpt1 activation induced by Xenopus oocytes (Koziol et al., 2007). In our  studies,  extinction  of  lymphocyte‐specific  gene  expression  (hCD45,  hCD37 and  hCD20) was achieved after 48‐72 hours. This data is consistent with earlier work examining gene extinction  in hybrid cells (Massa et al., 2000). Lymphoma cells  fused  with  fibroblasts  resulted  in  extinction  of  immunoglobulin  gene expression very  shortly after  fusion  (Junker and Pedersen, 1985). Lymphocyte‐specific  gene  silencing  was  shown  to  be  maintained  in  both  inter‐  and  intra‐
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species hybrids as shown by genome‐wide analysis of gene expression in human and mouse hybrid cells (Cowan et al., 2005; Ambrosi et al., 2007). 
The  epigenetic  remodelling  of  the  somatic  genome  for  pluripotency includes the  loss of DNA methylation at  the Oct4 promoter region as previously reported (Simonsson and Gurdon, 2004; Cowan et al., 2005; Freberg et al., 2007). Here  I  show  that  this  demethylation  process  begins  at  the  heterokaryon  stage, where DNA methylation of  somatic Oct4 promoter  is  reduced approximately  to 50%, and is complete only by day 6 after hybrid formation. This data is consistent with  a  previous  study,  which  showed  that  human  B  cell  OCT4  promoter undergoes  a  partial  loss  of  DNA methylation  in  heterokaryons  generated  with mouse  ES  cells  (Pereira  et  al.,  2008).  However  other  studies  have  shown  that 
OCT4 demethylation  in  fibroblasts or neuronal progenitors  is complete within 3 days after fusion (Han et al., 2008; Bhutani et al., 2010). This discrepancy might be due  to  the different  types of  the  somatic  cells used  in  these experiments, or their  differentiation  stage.  Several  studies  have  argued  that  the  differentiation stage may affect  the reprogramming potential of somatic cells. For examples,  in NT experiments neural stem cells have been shown to produce embryonic stem cells  at  a  higher  efficiency  than  terminally  differentiated  neuronal  donor  cells (Blelloch et al., 2006). Similar results were obtained comparing the efficiency of iPS generation of hematopoietic stem cells with terminally differentiated B and T cells; progenitor cells gave rise to iPS cells up to 300 times more efficiently than fully  differentiated  lymphocytes  (Eminli  et  al.,  2009).  Whether  the  partial demethylation  at  the  lymphocyte  OCT4  promoter  observed  here  depends  on inefficient reprogramming or slow kinetics in DNA demethylation is not currently known.  However  previous  studies  have  shown  that  only  a  fraction  of  somatic cells  is  successfully  reprogrammed  upon  fusion  with  ES  cells  (Pereira  et  al., 2008). 
Pluripotent cells have the ability to differentiate into the three embryonic layers  upon  appropriate  stimulation  (Chambers  and  Smith, 2004). Here  I  show that  following  fusion  with  pluripotent  stem  cells,  B‐lymphocytes  acquire  the ability  to  express  markers  of  the  three  embryonic  lineages  in  differentiating hybrids. This data is consistent with previous studies in which hybrids generated 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by  fusing  NPC  with  EC  cells  or  lymphocytes  with  EG  cells  were  able  to  form embryo bodies and differentiate in vivo when injected into blastocyst (Tada et al., 1997; Do et al., 2007). My results show that ES‐like cells can be rapidly generated from  lymphocytes  following  fusion with  a mouse  ES  cell  partner.  This  process begins  within  the  heterokaryon,  but  is  probably  stabilized  by  hybrid  cell formation,  in which  somatic  cells  are  fully  reprogrammed  as  evidenced  by  the pluripotent  function of hybrids. Experimental heterokaryons can therefore offer an unrivalled opportunity to trace the events and factors required to reprogram human somatic cells towards a multipotent state. 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CHAPTER 4. FACTOR AND EARLY MOLECULAR EVENTS IN SOMATIC CELL FUSION REPROGRAMMING   Reprogramming by cell fusion is reported to induce 15‐70% of human or mouse  somatic  cells  to  express  pluripotency  markers  as  evidenced  by  the expression  of  surface makers  and  pluripotency‐associated  genes  (Pereira  et  al., 2008;  Bhutani  et  al.,  2010).  The  high  reprogramming  efficiency  and  the  short latency of this method, as compared to iPS approaches suggest that more factors than  the  canonical  Yamanka  factors  are  probably  required  for  efficient conversion  to  pluripotency  (Yamanaka  and  Blau,  2010).  Thus,  using  the experimental cell fusion approach it may be possible to dissect alternative factors and  processes  required  for  converting  differentiated  cells  efficiently  towards pluripotency. 
4.1 PRC2­depleted ES cells  fail  to reprogram somatic cells upon 
cell­fusion. 




Figure  4.1  Prc2­depleted  ES  cells  fail  to  fully  reprogram  human  somatic  cells  in 
heterokaryons and are unable to successfully generate reprogrammed hybrids after fusion 
with mouse somatic cells. (A) RT‐qPCR analysis of 72 hours heterokaryons generated between human  B  lymphocytes  and  mouse  ES  cells  lacking  expression  of  the  PRC2  members  Eed  and Suz12  (white  bars),  Jarid2,  Dnmt1,  Dnmt3a/b,  Mll,  G9a,  and  Dicer  (black  bars).  Data  were normalized  to  human  GAPDH  expression.  Error  bars  indicate  the  SD  of  2–3  independent experiments.  (B)  Alkaline  phosphatase  staining  of  hybrid  colonies  obtained  from  fusions  of puromycin‐resistant mouse B cells with either Eed‐deﬁcient (Eed‐/‐) or wild‐type (Eed+/+) ESCs. Fused cells (+PEG) or unfused controls (‐PEG) were plated on puromycin‐resistant feeder cells in ESC  medium  supplemented  with  puromycin  for  12  days  and  stained  for  alkaline  phosphatase activity.  Number  of  AP+  colonies  per  plate  is  reported  as  avarege  ±  SD  of  three  independent experiments for each condition (C) Oct4 expression, detected by IF labeling (green), is retained by hybrid  clones  generated  from  fusing  Eed+/+  ESCs  with mouse  B  cells,  but  is  not  expressed  by hybrid clones generated from fusing Eed‐depleted ES cells with mouse B cells. Actin (red) staining is shown as a control. Scale bars represent 50 µm.   To extend the analysis of Prc2‐deficent ES cell reprogramming capacity  I performed  long‐term  fusion hybrid analysis  (Figure 3.2B). Fusion of puromycin resistant  mouse  B‐lymphocytes  with  wild‐type  ES  cells  (following  puromycin selection) generated around 2,000 alkaline‐phosphates positive tetraploid hybrid colonies  which  are  mainly  Oct4  positive  by  IF  staining  (Figure  4.1B  and  C). However, under the same experimental conditions, Eed‐deficient ES cells failed to 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generate  reprogrammed‐hybrids  (around  20  colonies,  Figure  4.1B).  Moreover, the  rare  alkaline‐phosphatase  positive  colonies  obtained  in  fusion  experiments with Eed‐deficient (Eed‐/‐) cells failed to express Oct4 (Figure 4.1C). These data indicated that ES cells lacking PRC2 activity cannot efficiently reprogram somatic cells  in  fusion  experiments.  At  early  time  points  following  heterokaryon formation  reprogramming was  partial  and  at  later  time  points  reprogrammed‐hybrids were few and reprogramming was incomplete.  
4.2  Oct4  is  essential  but  not  sufficient  for  accomplishing 
successful reprogramming. 
The pluripotent transcription factor mOct4 is required to initiate somatic cell reprogramming mediated by cell fusion. In particular, it was shown that ES‐derived  Oct4  accumulates  in  the  somatic  nucleus  12  hours  after  cell  fusion precedes pluripotent conversion of somatic cells (Pereira et al., 2008). Therefore I assessed whether the lack of reprogramming potential of PRC2‐depleted ES cells was  due  to  reduced  Oct4  expression  or  a  failure  to  enter  the  somatic  nucleus. Both  Eed‐  and  Suz12‐depleted  ES  cells  express  pluripotency‐associated  factors (mOct4, mNanog and mCripto) at comparable levels with their wild‐type matched controls  (Figure  4.2A).  Confocal microscopy  analysis  of  heterokaryons  allowed me  to  distinguish  between  mouse  and  human  nuclei  according  to  DAPI(4',6‐diamidino‐2‐phenylindole)  staining.  DAPI  preferentially  binds  A‐T  rich  DNA regions  that  surround  mouse,  but  not  human  centromeres.  Therefore  DAPI counter‐staining  generates  punctuate  patterns  in  mouse  nuclei  while  a  human nuclei  display  a  more  diffuse  labelling  (Figure  2.1,  compare  arrowed  human nuclei  and  mouse  fusion  partner  sharing  their  cytoplasm).  mOct4 immunofluorescence  (IF)  analysis  of  fused  cells  12  hours  after  heterokaryon formation revealed no significant differences in mOct4 influx into somatic nuclei between  PRC2 wt  and PRC2‐deficient  heterokaryons;  non‐reprogramming Eed‐deficient  ES  cells  were  able  to  transfer  Oct4  into  somatic  nuclei  (labeled  with arrow head) to a similar extent as wild‐type matched ES cells (Figure 4.6 B and C). 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Figure  4.2  Lack  of  PRC2  components  in  ES  cells  does  not  affect  the  induction  of 
pluripotency­associated  genes  expression  and  the  translocation  of Oct4  into  the  somatic 
nucleus upon heterokaryon formation. (A) RT‐qPCR analysis of mouse pluripotency‐associated genes (Oct4, Nanog and Cripto) in ES cells deficient of Eed or Suz12 depleted (white histograms). Wild‐type matched ES cells are used as control (black histograms). Data are normalized to mouse UBC expression. Error bars  indicate the SD of 2–3  independent experiments. (B) Mouse Oct4  IF analysis  (green)  in  heterokaryons  obtained  12  hours  after  fusion  between  hB‐lymphocytes (labeled with white  arrow head)  and  Eed‐deficient mES  cells  (bottom panel)  or with wild‐type matched control (top panel). Scale bar represent 10 µm. Dapi is depicted in blue and actin in red.  The table on the bottom reports percentages of relative amount of Oct4 staining between mouse (m)  and  human  (h)  nuclei  in  the  two  experimental  conditions.  n=  number  of  analysed heterokaryons.   This data indicates that despite the fact that Oct4 is essential for initiating somatic  conversion  towards  pluripotency,  its  expression  and  its  translocation into  somatic  nuclei  is  not  sufficient  to  induce  the  successful  reprogramming  of differentiated cells.  
4.3  Nuclear  volume  of  somatic  nuclei  increased  upon 
heterokaryon formation  
As  discussed  in  the  previous  paragraph,  human  specific  DAPI  labelling allowed me to monitor (by immunostaining) changes within the somatic nucleus that  occur  immediately  after  heterokaryon  formation.  Using  this  experimental approach,  the macro‐reorganization  events  that  somatic  nuclei  undergo  during the  reprogramming  process  could  be  followed  to  try  and  pinpoint  why  PRC2‐depleted ES cells fail to fully reprogram differentiated cells following fusion. After 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heterokaryon formation,  the volume of human nuclei gradually  increase  so that by 24 hours after fusion they resemble human ES cells (Figure 4.3A).   
 
Figure  4.3  Human  somatic  nuclei  enlarge  following  fusion  with  both  Eed­deficient  and 
wild­type matched ES cells. (A) Representative human B nuclei (depicted in blue, Dapi counter‐staining) before (hB) and at several time points after fusion with wt ES cells. Human ES cells (hES) are shown as  control.  Scale bar represent 10 µm. (B) Nuclear volume average of hB cells before (0hr)  and  24  hours  (24hr)  after  fusion with  Eed+/+  or  Eed‐/‐  ES  cells.  Human  ES  cells  (in white histogram) are used as control. *** p‐value < 0.0005, calculated with student t‐tests. n= number of human nuclei analysed (C) Nuclear volume average of mouse Eed‐depleted or wild‐type matched ES  cells  before  (0hr)  or  24  hours  after  fusion with  human  B  cells.  n=  number  of mouse  nuclei analysed. (D) Volume ratio of human somatic and mouse pluripotent nuclei before (0hr) and after fusion (24hr).   To  measure  the  extent  of  somatic  nuclear  enlargement  following  cell  fusion,  I performed  a  3D  reconstruction  of  serial  confocal  stacks  in  order  to  obtain volumetric  estimates  of  individual  nuclei.  Using  this  in­silico  approach  (fully detailed  in  2.6.2)  I  measured  the  volumes  of  somatic  and  pluripotent  nuclei before (hB, 0h) and 24 hours after heterokaryon formation (24h). This analysis showed that human somatic nuclei undergo approximately a 2.5‐fold increase in volume  following  fusion.  This  somatic  nuclear  swelling  occured  in  fusion experiments  using  wild‐type  ES  cells  or  PRC2‐depleted  ES  cells  (Figure  4.3B). Interestingly, while  the somatic‐derived nuclei significantly enlarged,  the mouse 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pluripotent  nuclear  volume  seemed mainly  unaffected  at  24  hours  after  fusion (Figure  4.4B  and  C).  This  suggests  that  the  increase  in  nuclear  volume  is associated with  the  reprogramming process  rather  than with  the  fusion per  se. Collectively,  this  data  indicates  that  although  significant  increase  in  somatic nuclear  size  is  related  to  the  reprogramming process,  it  is not predictive of  , or sufficient for successful conversion towards pluripotency. 
4.4.  Global  reorganization  of  somatic  nuclei  following 
heterokaryon formation. 
Nucleolar  organelles  undergo  morphological  changes  during differentiation  (Meshorer  and  Misteli,  2006).  Consistent  with  this,  IF  staining analysis  for  nucleolar  component  Nucleophosmin‐B23  (Figure  4.4  A,  in  red) revealed  different  patterns  between  human  undifferentiated  (hES)  and differentiated  (hB)  cells.  In  particular,  hES  generally  contain  one  or  two  big nucleoli situated in the center of the nucleus, while hB are characterized by three or more of these organelles distributed throughout the nucleus.   
 
Figure  4.4  hB  nucleoli  reorganized  after  fusion  with  both  Eed­deficient  and  wild­type 
matched ES cells. (A) Human B23‐Nucleophosmin IF analysis that allow to determine number on of nucleoli in hB cells before (0h) and 24 hours (24h) after fusion with Eed‐depleted or wild‐type matched  ES  cells.  Human  ES  cells  (hES)  are  used  as  control.  Scale  bar  represent  10  µm.  (B) Quantification of number of nucleoli foci in hB before (0hr) and 24 hours (24hr) after fusion with Eed+/+ or Eed‐/‐ ES cells. Human ES cells (hES) are used as control.  I  tested  whether  nucleoli  reorganized  during  cell  fusion  reprogramming.  To address  this  IF  analysis was perfomed on human B‐lymphocytes before and 24 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hours after  fusion with Eed‐deficient or wild‐type matched control ES cells. The Nucleophosmin structures of differentiated hB cells changed during the course of cell  fusion  reprogramming  to  assume  a  structure  with  fewer,  bigger  and centralized nucleoli  typical of human ES  cells. As  this  conversion occurred with both (ESEed+/+) and (ESEed‐/‐) cells, this shows that the mechanism by which PRC2‐deficent ES cells  fail  to reprogram somatic cells upon cell  fusion does not affect nuclear enlargement or nucleoli reorganization processes (Figure 4.4 A and B). 
4.5  HP1α   is  redistributed  during  successful  reprogramming  of 
somatic nuclei. 









To prove that the loss of Eed in ES cells was causative of defects observed in reprogramming, Eed expression was restored in the Eed­null ES cell line (B1.3) by  providing  a  180  Kb  BAC  clone  carrying  the  Eed  genomic  fragment  and neomycin resistance gene (see section 2.9). ES cell colonies resistant to neomycin were screened for the presence of Eed protein and H3K27 tri‐methylation marks by western blotting and confocal microscopy immunostaining (Figure 4.6A, B and C). ES cells  in which Eed  isoforms were re‐expressed and H3K27 trimethylation was re‐established (B1.3BAC) were then fused to hB‐lymphocytes. Together with Filipe Pereira, I then assessed whether Eed complemented ES cells could induce human‐pluripotency  gene  expression  (by  RT‐qPCR)  and  the  somatic  HP1α redistribution  (by  confocal  microscopy  immunostaining)  upon  fusion  with human B  cells.  These  analyses  showed  that  reconstitution  of Eed  expression  in 
Eed‐deficient  ES  cells  rescued  their  reprogramming  capacity  (Figure  4.6D, compare white and black histograms) together with their ability  to redistribute HP1α in the human nuclei (Figure 4.6 E). This data confirms that Eed expression is required for maintaining the reprogramming properties of ES cells. 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Figure  4.6  Restoration  of  Eed  expression  in  Eed­deficient  mouse  ES  cells  rescues 










I  tested  whether  ES  cells  deficient  in  Oct4  expression  were  able  to redistribute  HP1α  in  hB  nuclei  following  cell  fusion.    Although  mES  cells conditionally depleted for Oct4 (Figure 4.7A) fail to reprogram differentiated cells (Pereira et al., 2008), they were still able to induce somatic HP1α redistribution 24 hours after fusion (Figure 4.7D and E, compare Oct4wt with Oct4ko). Likewise, ES cells lacking the PRC2 components Ezh2, Suz12 and Jarid2 could redistribute human HP1α in their somatic fusion partner comparably with wild‐type matched controls. ESSuz12‐/‐ cells together with ES cells conditionally depleted for the PRC2 catalytic  domain  Ezh2,  failed  to  generate  H3K27  trimethylation marks  (Figure 4.7B and C) and to reprogram differentiated cells upon cell fusion (Figure 4.1 and not  shown),  but were  still  capable  of mobilizing HP1α  in  the majority  of  fused somatic  nuclei.  In  addition,  the  PRC2  component  Jarid2,  whose  ablation  only partially  reduces  H3K27  tri‐methylation  capacity  and  does  not  affect reprogramming potential  (Landeira and Fisher, 2011)(Figures 4.1 A and 4.7 C), also appears to be not required  for somatic HP1α  redistribution.  In  fact ESJarid‐/‐ cells  induced HP1α  de‐condensation  in  human  somatic  nuclei  similarly  to  their wild‐type matched control (Figure 4.7D). Together, these data exclude that HP1α redistribution is predictive of successful reprogramming. They indicate that Eed, but not other PRC2 components, is required for reprogramming‐mediated HP1α mobilization. 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Figure  4.7  Redistribution  of  HP1α   in  the  somatic  nucleus  is  an  Eed­dependent,  Prc2­
independent phenomena that does not correlate with reprogramming achievement. (A) IF analysis for Oct4 on ZHBTc4 (Z4) ES cell line in which endogenous Oct4 was replaced by an Oct4 trans‐gene whom knock out  is doxycycline‐inducible (Niwa 2000). Z4 ES cells have been treated for  12  hours  with  doxycycline  (1  µg/ml,  +Dox,  Oct4ko  right  panel)  without  affecting  other pluripotency associated genes (Pereira 2008) or left untreated as control (Nill, Oct4wt left panel). Dapi is depicted in blue and actin in red. (B) IF analysis for H3K27me3 (green) in Suz12‐depleted (Suz12‐/‐) and wild‐type matched ES (Suz12+/+). Dapi staining is shown in blue and actin in red. (C) IF staining for H3K27me3 of an ES cell line carrying two floxed endogenous Ezh2 alleles (1.3) after  treatment with 800nM  tamoxifen  for 96 hours  (+OHT, Ezh2ko,  left panel) or  left untreated (Nill,  Ezh2wt,  right  panel).  (D) Whole‐cell  lysates  from  Jarid2‐depleted  (Jarid2‐/‐)  and wild‐type matched  ES  cells  (Jarid2+/+)  analyzed  by western  blotting with  antibodies  to  the  Jarid2  protein and  anti‐H3K27me3.  Lamin  B  (Lam.B)  and  total  H3  detection  shows  loading  control.  (E) Representative  hB  nuclei  stained  for  HP1α  (green)  24  hours  after  fusion  with  Oct4wt,  Oct4ko, Suz12+/+, Suz12‐/‐, Ezh2wt, Ezh2ko, Jarid2+/+ and Jarid2‐/‐ ES cells. Dapi staining is shown in blue. Percentages  correspond  to  pattern  reported  in  pictures.  n=number  of  human  nuclei  analyzed. Scale bar represent 10 µm.  
4.8  Eed­deficient  mouse  ES  cells  are  unable  to  induce  H3S10 
phosphorylation  in  somatic  nuclei  following  heterokaryon 
formation 
HP1α was reported to interact with chromatin through its chromodomain that  allows  binding  to  H3K9me3  sites.  To  address whether  HP1α  mobilization was due to a loss these sites, I performed a H3K9me3 IF analysis of human nuclei following  fusion  with  ES  cells.  There  were  no  global  differences  in  H3K9me3 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labelling  observed  between  undifferentiated  hES  cells  and  hB‐lymphcytes. Consistent with this, no dramatic change in the H3K9me3 staining pattern of hB‐lymphocyte  nuclei  was  induced  by  fusion  with  either  ESEed+/+  or  ESEed‐/‐  cells (Figure 4.8 A).   
 
 
Figure  4.8  Eed­deficient  mouse  ES  cells  lose  the  capacity  to  phosphorylated  somatic 
chromatin  at  H3S10  sites  following  heterokaryon  formation.  (A)  IF  staining  for  H3K9me3 (red) in human B nuclei before (0h) and 24 hours after fusion with Eed‐depleted (Eed‐/‐) or wild‐type  matched  (Eed+/+)    ES  cells.  Human  ES  cells  (hES)  are  used  as  control.  (B)  IF  staining  for H3K9me3/S10ph  double modification  (red)  in  human  B  nuclei  before  (0h)  and  24  hours  after fusion with Eed‐depleted (Eed‐/‐) or wild‐type matched (Eed+/+) ES cells. Human ES cells (hES) are used  as  control.  Dapi  counter‐staining  is  depicted  in  blue.  Percentages  correspond  to  patterns reported  in  pictures.  Scale  bar  represent  10  µm.  (C)  Table  representing  quantification  of H3K9me3/S10ph double modification positive human nuclei before (0h, hB) and at different time points (reported in table) after fusion with Eed‐depleted (Eed‐/‐) or wild‐type matched (Eed+/+) ES cells.  Percentages  of  H3K9me3/S10ph  double  modification‐positive  human  ES  cells  (hES)  are used as controls.  n=number of human nuclei analyzed.  It has been  shown that HP1α is displaced from its H3K9me3 docking site when phosphorylation of the proximal serine 10 (S10ph) residue occurs on the histone H3 tail (Hirota et al., 2005). The H3K9me3/S10ph double modification has been 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well  characterized  as  a  marker  of  mitosis  that  facilitates  correct  chromosome segregation during cell division by displacing HP1 proteins (Fischle et al., 2005; Hirota et al., 2005). To assess whether this might explain the HP1α redistribution during  cell  fusion  reprogramming,  I  stained  human  somatic  nuclei  before  and after  fusion  with  Eed‐depleted  or  wild‐type  matched  mouse  ES  cells. Immunostaining  was  performed  using  an  antibody  that  specifically  binds  the H3K9me3/S10ph  double  modification  (Sabbattini  et  al.,  2007).  Since H3K9me3/S10ph  is  a  well‐characterized  G2/M  marker,  mitotic  nuclei  were excluded from the analysis. Very few non‐mitotic B cells were stained with anti‐ H3K9me3/S10ph  antibody, while  in human ES  cells  the  immunostaining  labels most  cells  in  a  punctate  manner.  hB  cells  started  accumulating  S10 phosphorylation marks 6 hours after fusion with wt ES cells, resembling hES by 24  hours.    Acquisition  of  H3K9me3/S10ph  double  modification  within  the somatic nuclei did not occur  in  fusions using Eed‐deficient ES cells. Collectively, these data  indicate that H3S10 phosphorylation (like HP1α redistribution)  is an early event in reprogramming that is dependent on Eed. 
4.9  Aurora  B  kinase  phosphorylates  H3S10  and  redistributes 
HP1α  in somatic nuclei upon cell fusion 
Phosphorylation  of  the  S10  proximal  to  H3K9me3  and  HP1α redistribution  are  features  of  somatic  cell  reprogramming  (Figure  4.5  and  4.8). S10  phosphorylation  is  catalyzed  by  Aurora  B  kinase  (Hirota  et  al.,  2005).  In order  to  understand  whether  the  redistribution  of  HP1α  during  cell  fusion reprogramming  requires  the  phosphorylation  of  H3S10,  and  whether  this redistribution  is  needed  for  successful  reprogramming  towards  pluripotency,  I performed  cell  fusion  experiments  using  inhibitors  of  Aurora  B  activity.  An Aurora B specific inhibitor, AZD1152 (Keen and Taylor, 2009) (or DMSO vehicle as control condition), was added immediately after fusion of mouse wild‐type ES cells with  human B‐lymphocytes  and was  kept  in  the  culture media  during  the entire length of the experiment. To address the efficiency of Aurora B inhibition, I labeled  heterokaryons  with  antibody  to  H3K9me3/S10ph  (red)  as  well  as antibody  to  HP1α  (green).  Treatment  with  the  Aurora  B  inhibitor  suppressed 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H3K9me3/S10ph acquisition in human nuclei (~4%) compared with the controls (~73%) (Figure 4.9A and B). Importantly, treatment with AZD1152 significantly reduced  HP1α  redistribution  (Figure  4.9A  and  C).  To  assess whether  Aurora  B inhibition blocks the reprogramming of somatic cells, I measured the expression of  human  pluripotency‐associated  genes  48  and  72  hours  after  fusion.  This analysis showed that suppression of Aurora B‐dependent H3S10 phosphorylation (and  reduced  HP1α  redistribution)  did  not  compromise  successful reprogramming  of  human  differentiated  cells.  Following  fusion,  the  human pluripotent  genes  hOCT4,  hNANOG  and  hCRIPTO  were  re‐expressed  despite Aurora B inhibition (Figure 4.9D).  
 
Figure  4.9  Aurora  B  inhibition  blocks  somatic  HP1α   redistribution  without  affecting 
reprogramming towards pluripotency.  (A)  IF analysis of HP1α  (green) and H3K9me3/S10ph (red) on hB cells  fused with wild‐type ES  cells  and culture  in  the presence of 500nM AZD1152 (Aurora  B  inhibition)  or  DMSO  vehicle  (control)  for  24  hours.  Dapi  is  depicted  in  blue.  (B) Quantification  of  H3K9me3/S10ph  positive  human  nuclei  24  hours  after  fusion  under  DMSO (control)  or  AZD1152  (Aurora  B  inhibition)  treatment.  (C)  Quantification  of  HP1α  staining patterns ‐punctuated (white) vs. diffuse (green)‐  in human B nuclei 24 hours after  fusion under DMSO  (control)  or  AZD1152  (Aurora  B  inhibition)  treatment.  Error  bars  represent  SD  of  3 independent experiments. * p‐value < 0.05, *** p‐value < 0.0005,  calculated with student  t‐tests (D) RT‐qPCR analysis of human pluripotent  genes OCT4, NANOG and CRIPTO  in hB  before  (0h) and  after  fusion  (48  and  72  hours) with mouse  ES  cells.  Open  histograms  represent  data  from fusions  cultured  in  the  presence  of  500nM  AZD1152  (Aurora  B  inhib.)  while  solid  histograms report data obtained from fusion culture with DMSO vehicle (Ctrl). Error bars represent SEM of 3 independent  experiments.  Expression  values  are  normalized  to  human  GADPH  amplification signals. 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Overall  this  data  suggests  that  early  after  B  cell  fusion,  Aurora B  kinase phosphorylates S10 residues proximal to H3K9me3; and displaces HP1α from its docking site. However the kinase activity of Aurora B appeared to be dispensable for successful reprogramming. 
4.10 Prc2­depleted ES cells prevent reprogramming by wild­type 
ES cells in experimental tri­karyons 
Since phosphorylation of S10 and redistribution of HP1α are not required to convert somatic cell gene expression towards pluripotency, the failure of Eed‐depleted  ES  cells  to  reprogram  appears  to  be  due  to  other  mechanisms. Consistently,  other  Prc2‐depleted  ES  cells  (Suz12‐deficient  and  Ezh2‐deficient, Figure  4.7) were  able  to  redistribute  HP1α  in  the  somatic  nuclei,  even  though they were unable to induce full reprogramming. A common feature of these non‐reprogramming PRC2‐depleted ES  cells  is  a  lack  of H3K27 methylation  activity (Figure  4.10A)  and  the mis‐expression  of many  developmental  regulator  genes (Azuara et al., 2006; Boyer et al., 2006b). Examples  include Hand1, Cdx2, Gata6 and  Hnf4  (Figure  4.10  B).  In  contrast,  Jarid2‐depleted  ES  cells,  in  which differentiation‐associated genes  are generally not de‐repressed  (Landeira  et al., 2010), were still able to efficiently reprogram somatic cells following cell fusion (Figure  4.1  and  4.7C).  It  is  therefore  possible  that  the  loss  of  reprogramming potential observed in ES cells lacking PRC2 catalytic components was due to a de‐repression  of  lineage‐associated  genes.  These  might  block  the  efficient reprogramming  of  differentiated  cells.  To  test  this  hypothesis,  Filipe  Pereira generated heterokaryons containing a human B‐lymphocyte nucleus, a wild‐type mouse  ES  cell  nucleus  and  an  Eed‐deficient  ES  cell  nucleus.  He  pre‐labelled ESEed+/+ cells with DiI and ESEed‐/‐ cells with DiD, mixed them in a 1:1:1 ratio with puromycin resistant human B‐lymphcyte, cultured for 2 days  in  the presence of puromycin and then purified dual‐labeled heterokaryons by FACS sorting (Figure 4.10C,  top  panel).    Reprogramming  was  assessed  by  RT‐qPCR  of  the  human pluripotency‐associated  genes  OCT4,  NANOG,  CRIPTO  DNMT3B  and  TERT. Heterokaryons  containing  two  Eed‐depleted  nuclei  (red  histograms)  or 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containing one ESEed+/+ and one ESEed‐/‐ nucleus (red‐white histograms)  failed to induce expression of human pluripotent genes. Heterokaryons containing a pair of  wild‐type  nuclei  were  efficiently  reprogrammed  (white  histograms,  Figure 4.10C  lower  panel).  Thus,  the  provision  of  a wild  type  ES  cell  nucleus  did  not restore reprogramming in a heterokaryons containing a deficient ES cell nucleus. This experiment showed that Eed‐deficient ES cell was functionally dominant and suggested that PRC2 catalytic activity of ES cells was required in reprogramming fusions  to  repress  the  expression  of  genes  that would  otherwise  interfere with the conversion of somatic cells to pluripotency.  
 
Figure  4.10  PRC2­deficient  ES  dominantly  repress  wild­type  ES  cell  reprogramming 
function.  (A)  Whole‐cell  lysates  from  Eed+/+,  Eed+/‐,  Eed‐/‐,  Suz12+/+  or  Suz12‐/‐  ES  cells  lines analyzed  by  western  blotting  with  antibodies  versus  Suz12  protein,  Eed  protein,  H3K27me3, H3K27me2 and H3K27me1. Loading control is shown by Lamin B and total H3 detection. (B) RT‐qPCR  analysis  of  developmental  regulators  in  mouse  Eed‐depleted  (red)  or  Suz12‐deficient (white) ES  cells normalized  to  their wild‐type matched  ES  cells  (black  line). Expression of  non‐PRC2  target  genes  (Oct4,  Nanog,  Sox2)  is  shown  as  a  control.  Data  were  normalized  to mouse 
Gapdh expression and the results are mean and SD of  three experiments. (C,  top panel) Strategy used  to  generate  experimental  trinucleate  heterokaryons. Wild‐type  (ES WT)  and  Eed‐deﬁcient (ES  Eed‐/‐)  ES  cells were  separately  labeled with DiI  or DiD membrane  dyes,  respectively,  and 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fused with puromycin‐resistant human B cells (hB Puror). (C, bottom panel) 2 days after culture in puromycin, double (DiI/DiD) labeled heterokaryons were isolated by FACS sorting and successful reprogramming was  estimated  by  RT‐qPCR  for  the  induction  of  human  gene  expression  (white and  red  histograms).  Three‐nucleate  heterokaryons  containing  pairs  of  wild‐type  (white histograms) or pairs of Eed‐deficient ES cells (red histograms) provide controls for this analysis. Data were normalized to human GAPDH and to WT control (white histograms) expression and the results are mean and SD of three independent experiments.  
4.11 Discussion and future perspectives 
PcG proteins were originally characterised in Drosophila melanogaster as a series of multiprotein  complexes  that  are  crucial  for maintaining  the  inactive  state  of homeotic genes as well as of other  important regulators  in developing embryos (Ringrose  and  Paro,  2004).  Subsequent  biochemical  analyses  have  identified distinct Polycomb repressive complexes and revealed the enzymatic activities of some  of  their  components  (Levine  et  al.,  2004).  In  mammals,  PRC2  has  three central  components,  Suz12,  Eed  and  Ezh2,  a  histone  methyltransferase  that catalyses  the  methylation  of  lysine  27  on  histone  H3  (Cao  and  Zhang,  2004) (Kuzmichev  et  al.,  2002).  The  three  components  of  PRC2  are  all  essential  for mouse embryonic development (Faust et al., 1998; O'Carroll et al., 2001; Erhardt 
et  al.,  2003;  Pasini  et  al.,  2004),  but  ES  cells  lacking  Eed  (Morin‐Kensicki  et  al., 2001), Suz12 (Fujimura et al., 2006) and Ezh2 can be derived, despite the lack of global  levels  of  H3K27  methylation  (Bracken  et  al.,  2006).  This  suggests  that PRC2 activity  is not essential  for ES cell self‐renewal. Moreover, ES cells lacking Eed  (and  PRC2  activity)  were  recently  shown  to  be  functionally  pluripotent (Chamberlain et al., 2008). 
Using  a  panel  of  genetically  engineered  mouse  ES  cells  Felipe  Pereira  and  I demonstrated  that  the  reprogramming  activity  of  ES  cells  was  critically dependent  on  PcG  proteins.  Deletion  of  the  PRC2  members  Eed  or  Suz12 abolished  the  ability  of  ES  cells  to  dominantly  reprogram  mouse  and  human lymphocytes.  PRC2‐depleted  ES  cells  did  not  appear  to  lack  factors  that  are critical  for  reprogramming,  such  as  Oct4  and  Nanog.  The  absence  of  Eed expression did not impair the ability of ES cells to transfer Oct4 into the somatic nucleus  –  an  event  that  appears  to  be  essential  to  initiate  reprogramming  to pluripotency  upon  cell  fusion  (Pereira  et  al.,  2008).  These  results  implied  that 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PRC2‐mediated  gene  repression  might  be  essential  for  ES  cell  reprogramming capacity, perhaps by suppressing factors that otherwise interfered with cell type conversion. These results have also allowed the role of PRC2 in pluripotency and in maintaining reprogramming potential to be uncoupled.  
Genome‐wide studies  that have mapped the binding sites of PcG components  in humans  (Bracken  et  al.,  2006)  and mice  (Boyer  et  al.,  2006b)  have  shown  that many  PcG  targets  encode  transcriptional  regulators  that  are  inactive  in pluripotent  cells  but  become  de‐repressed  upon  differentiation.  Many  of  these genes  carry  so‐called  bivalent  domains  (that  is  they  are  enriched  for  histone modifications  associated  with  both  “active”  and  “inactive”  chromatin)  in undifferentiated  ES  cells  (Azuara,  2006;  Azuara  et  al.,  2006;  Bernstein  et  al., 2006).  PcG  proteins  were  demonstrated  to  be  important  for  restricting  the expression  of  these  genes,  since  ES  cells  that  lack  PcG  proteins  showed  an inappropriate upregulation of many tissue‐specific  targets (Azuara, 2006; Boyer 
et  al.,  2006b).  Many  of  these  genes  are  transcriptional  regulators  involved  in developmental  processes  and  consequently  regulate  the  expression  of  other ‘downstream’  genes.  Therefore  it  is  possible  that  PRC2‐deficient  ES  cells  lack ‘activators’ or express ‘repressors’ of reprogramming. 
  
Figure 4.11. A model for the role of PRC2 in maintaining the reprogramming potential of ES 
cells. Reprogramming activity of ES cells requires Polycomb proteins. Deletion of  the Polycomb repressive  complex  2  (PRC2)  components Eed,  Suz12  and Ezh2  and  the  histone mark  that  this complex  catalyses  (H3K27me3)  results  in  de‐repression  of  developmental‐associated transcription  factors.  Following  fusion,  these may  translocate  into  the  somatic  nucleus  (yellow arrow,  ?)  together  with  reprogramming  factors  (green  arrow)  and  doing  so  impair  successful conversion to pluripotency reprogramming. Remarkably,  Filipe  Pereira  and  I  were  able  to  show  that  the  reprogramming phenotype of ES cells with impaired PRC2 function (and therefore lacking H3K27 methylation),  was  dominant  over  wild‐type  ES  cells.  This  result  excludes  that PcG‐deficient ES cells lack factors required for reprogramming and suggest that it 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is unlikely  that Polycomb proteins are themselves acting  in trans  in  the somatic nucleus. It is possible that the mis‐expression of some Polycomb target genes may repress  ES  cell  reprogramming  function  (Figure  4.11).  Studies  of  pluripotent  reprogramming of mouse  lymphocytes  and  fibroblasts  using  iPS  cells  provides some evidence that expression of lineage regulators can repress reprogramming. Mikkelsen  et  al.  suggested  that  the  re‐activation  or  incomplete  repression  of lineage‐specifying  factors  during  the  reprogramming  process  might  block  the endogenous pluripotency regulatory network (Mikkelsen et al., 2008). Consistent with  this,  the  successful  reprogramming  of mouse  B‐lymphocytes  requires  the disruption of the transcriptional network of hB‐lymphocytes by inactivating the B cell‐specific  factor Pax5  or  overexpressing C/EBPα  (Hanna  et  al.,  2008).  A  first attempt to identify these ‘negative‐effectors of reprogramming’ among a cadre of developmentally  restricted PRC2  target genes was been made by Filipe Pereira and Tomomi Tsubouchi. They attempted to rescue the reprogramming potential in PRC2‐depleted ES cells by ablating the expression of several candidate genes (using shRNA) individually and in combination (Pereira et al., 2010). However to date,  these  knockdown  experiments  have  been  unable  to  fully  restore  the  full reprogramming capacity of ESEed‐/‐ cells. 
The spatial organization of chromatin into high‐order structures has emerged as a  key  contributor  to  genome  regulation  (Lodén  and  van  Steensel,  2005).  The genome  of  pluripotent  ES  cells  has  been  described  as  being  in  a  highly  plastic state,  enabling  them  to  enter  any  distinct differentiation  pathway  (Meshorer  et 
al., 2006). Several studies have reported that as differentiation proceeds ES cells progressively  lose  this  plasticity,  accumulating  highly  condensed, transcriptionally inactive, heterochromatin regions (Meshorer and Misteli, 2006) (Cammas et al., 2002; Arney and Fisher, 2004). One of  these reports has shown that  the  presence  of  a  population  of  structural  proteins  (including  HP1)  that loosely  associates with  chromatin  is  a  hallmark  of  pluripotent  cells  and  is  lost upon  differentiation  (Meshorer  et  al.,  2006).  I  have  shown  here  that  during reprogramming  the  global  organization  of  human  somatic  nuclei  is  reverted  in several aspects to resemble hES cells. Aurora B kinase mediates the accumulation of  H3S10  phosphorylation  marks  within  somatic  nuclei  and  in  turn  displaces 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HP1α  from  its  H3K9me3  chromatin  docking  sites.  Similar  chromatin reorganization  has  been  reported  to  occur  upon  reprogramming  via  nuclear transfer  (Murata  et  al.,  2010).  The  phosphorylation  of  H3S10  proximal  to H3K9me3 is a well‐characterized marker of mitosis, when it is known to induce dissociation of HP1 proteins  from chromosomes (Hirota et al., 2005) (Fischle et 
al.,  2005).  Here  I  have  shown  that  H3K9me3/S10ph  double  modification  is present in the majority of human ES cells (84%, Figure 4.8A). This indicates that in undifferentiated ES cells this marker is not only present in mitosis but also in other  phases  of  the  cell  cycle.  This  suggests  that,  apart  from  the  established mitotic  role,  Aurora  B  might  function  throughout  the  cell  cycle  in  pluripotent stem cells maintaining HP1α loosely bound to chromatin. 
 
Figure 4.12. A model for a possible contribution of Eed to HP1α displacement. Apart from it classical  role  in  determining  H3K27me3  marks,  Eed  may  also  be  involved  in  the  Aurora  B mediated phosphorylation of H3S10 residues. This could be mediated by direct  interaction with the co‐factor INCEMP that has to be confirmed (?). The phosphorylation of Serine 10 residues next to H3K9me3 marks results in the displacement of HP1α from its docking site. 
  My  data  indicates  that  during  cell  fusion‐mediated  reprogramming,  Aurora  B activity  depends  on  ES‐derived  expression  of  Eed,  independent  of  Suz12  and Ezh2. This result, although surprising, is consistent with other studies that have indicated  that  individual  PRC2  components  may  have  a  relatively  small 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proportion of unique target genes (Boyer et al., 2006b) and that ES cells depleted of Eed or Suz12 displayed different phenotypes (Pasini et al., 2004) (Chamberlain 
et  al.,  2008).  Interestingly,  mass  spectrometry  analysis  performed  in  our laboratory  (Landeira  et  al.,  2010)  identified  the  Aurora  B  co‐factor  INCEMT among  Eed  interacting  proteins.  Together,  this  data  suggests  that  Eed  may  be involved in H3S10 phosphorylation (independently of its role in PRC2) through a possible direct interaction with Aurora B kinase complex (Figure 4.12). 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CHAPTER 5. EG‐MEDIATED ERASURE OF GENOMIC IMPRINTS DURING CELL FUSION REPROGRAMMING TOWARDS PLURIPOTENCY  I  have  previously  described  early  events  that  lead  to  somatic  cell reprogramming  following  fusion with pluripotent ES  cells.  In  this  chapter,  I use embryonic germ (EG) cells to reprogram B‐lymphocytes. I focus on an EG‐specific ability  to  erase  genomic  imprints  from  somatic  nuclei  that  results  from  EG‐induced reprogramming (Tada et al., 1997), and analyse the molecular details of DNA demethylation at imprinted domains.  
5.1  EG  and  ES  cells  reprogram  differentiated  cells  in 
heterokaryon and hybrids. 
EG cells  are derived  from PGCs  in  the embryo between E8 and E13  (see section  1.2.3)  and,  once  established,  can  be  cultured  indefinitely.  Despite  their different embryonic origins, ES and EG cells have been reported to be remarkably similar  in  many  respects  (Surani  et  al.,  2007).  Consistent  with  this,  RT‐qPCR analysis  revealed  that  mouse  EG  cells  express  many  pluripotency  associated genes (such as Oct4, Nanog and Cripto) (Figure 5.1 A) to a similar extent as mouse ES cell lines (Figure 4.2 A). To  verify  whether,  mouse  EG  cells  are  able  to  reprogram  somatic  cells upon fusion, I generated transient heterokaryons between the mouse EG cell line (58G, (Tada, 1997 #2) and human B‐lymphocytes. Human B‐lymphocytes began expressing human pluripotency genes within 72 hours after fusion with EG cells (Figure  5.1  B).  Consistent  with  previous  observation  in  ES‐fusion  experiments (Figure 4.2 A), EG‐derived Oct4 protein accumulated in the somatic nucleus early after  fusion  initiating the reprogramming process (Figure 5.1 C, human somatic nucleus is labeled with white arrow heads).  Using immunofluorescence analysis I showed that EG cells induced a major reorganization of the B‐lymphocyte nuclei, which  mirrors  the  characteristics  of  human  ES  cells;  H3K9me3/S10ph  double 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modification  accumulated,  HP1α  was  redistributed  and  nucleoli  were reorganized in the somatic nuclei 24 hours after fusion with EG cells (Figure 5.1 D and F). In addition, the volume of differentiated nuclei significantly enlarged after fusion with EG cells, to a size comparable with hES cells (Figure 5.1 E). To extend this analysis, I fused puromycin resistant mouse B cells with mouse EG cells.  Twelve  days  after  fusion  hybrid  cells  were  examined  for  alkaline phosphatase activity (Figure 5.1 G).   Hybrids expressed AP, and had reactivated Oct4‐GFP  expression,  as  judged  by  FACS  and  fluorescent  microscopy  analyses (Figure 5.1 H). Similar to mES+mB hybrids (Figure 3.2 D and E), mEG+mB hybrid clones were  tetraploid  (4n).  Therefore  the  ability  of  EG  cells  to  covert  somatic cells back to pluripotency was confirmed. In addition these experiments allowed me to isolate, expand and analyse reprogrammed hybrid clones in detail. 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Figure  5.1. Pluripotent EG  cells  reprogram B­lymphocytes  in  heterokaryons and hybrids. (A) RT‐qPCR analysis of mouse pluripotency‐associated gene (Oct4, Nanog and Cripto)  in mouse EG  cells.  Data  are  normalized  to  mouse  UBC  expression.  Error  bars  indicate  the  SD  of  3 independent  measurements.  (B)  RT‐qPCR  analysis  of  human  pluripotency‐associated  genes (OCT4, NANOG and CRIPTO) on 72 hour heterokaryons formed between human B and mouse EG cells.  Data  are  normalized  to  human  GADPH  expression.  Error  bars  indicate  the  SD  of    3 independent measurements.  (C)  Mouse  Oct4  IF  analysis  (green)  in  heterokaryons  obtained  12 hours after  fusion between hB‐lymphocyte (labeled with white arrow head) and mEG cells. Scale bar represent 10 µm. Dapi is depicted in blue and actin  in red. The relative accumulation of Oct4 within  mouse (m) and human (h) nuclei is reported in the table below (D) Representative human B  nuclei  stained  for HP1α,  H3K9me3;S10ph  double modification.  and  the  nucleolar  component B23  before  (hB)  and  24  hours  after  fusion with mEG  cells  (hB+mEG).  Dapi  counter‐staining  is depicted  in  blue.  Percentages  correspond  to  pattern  reported  in  pictures.  n=number  of  human nuclei analyzed. Scale bar represents 10 µm. (E) Nuclear volume average of hB cells before (0hr) and 24 hours (24hr) after fusion with mEG cells. Human ES cells (in white histogram) are used as control.  ***  p‐value  <  0.0005,  calculated  with  student  t‐tests.  n=  number  of  human  nuclei analysed. (F) Quantification of number of nucleoli foci in hB before (hB) and 24 hours after fusion with mEG cells  (hB+mEG). Human ES  cells  (hES)  are used as  control.  (G) Alkaline  phosphatase staining of hybrid  colonies 12 days obtained  from  fusions of puromycin‐resistant mouse B  cells with mEG cells. (see figure 4.1 B). (H) Top two panels, FACS analysis of Propidium Iodide staining (PI, left panel) and GFP expression (right panel) of a representative tetraploid (4n) hybrid clone obtained 21 days after fusion of mEG cells and mouse B‐lymphocytes carrying an Oct4‐GFP trans‐gene.  Un‐fused  diploid  (2n)  mB  cells  are  used  as  control.  Bottom  panel,  Bright  Field  (BF)  and fluorescent (GFP) images of a representative hybrid colony formed 21 days after fusion of mouse EG cells and mouse B‐lymphocytes carrying an Oct4‐GFP transgene. 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5.2 EG cells are hypomethylated at several imprinted loci. 
During embryonic development, PGCs undergo a reprogramming process that, together with the re‐expression of pluripotency‐associated genes, includes a wave  of  global  DNA  demethylation  leading  to  the  erasure  of  genomic  imprints (discussed  in  more  details  in  1.2.1).  EG  cells  that  originate  from  PGCs  display reduced  and  variable  DNA  methylation  at  imprinted  loci (Durcova‐Hills  et  al., 2003).  
 
Figure  5.2.  EG  cells  are  hypomethylated  at  ICRs.  Genomic  bisufite  sequencing  analysis  of reported  ICRs  (black  bars)  in  (A)  mEG,  (B)  mB  and  (C)  mES  cells.  Closed  circles  represent methylated CpG while open circles un‐methylated CpG. Overall methylation levels are indicated in red as a percentage of total.   
 To examine the hypomethylation status of EG genomic DNA,  I performed genomic bisulfite sequencing analysis at several imprinted control regions (ICRs) and  compared  this  to  mouse  B  and  ES  cell  controls  (Figure  5.2).  The  analysis revealed  that  EG  cells  show  reduced CpG methylation  at  4  ICRs  analyzed  here; 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namely  H19/Igf2  (paternally  methylated),  Peg3  and  Peg1  (maternally methylated) and the Dlk1/Gtl2 ICR (paternally methylated) (Figure 5.2 A). Mouse B cells exhibited a normally imprinted profile with a monoallelic methylation that accounts  for  levels  of  5mC  in  CpG  dinucleotides  close  to  the  expected  50%  in most of analysed ICRs (Figure 5.2 B). ES cells were generally less methylated than mB at the domains analysed but showed more methylation than EG cells (Figure 5.2 C). 
5.3.  EG  cells  can  dominantly  erase  imprinting  in  somatic  cells 
upon reprogrammed­hybrid formation. 
As well as reprogramming the somatic cells to pluripotency, EG cells have been  reported  to  induce  the  loss  of  methylation  at  somatic  imprinted  loci following  hybrid  formation  (Tada  et  al.,  1997).  ES  cells,  in  contrast  have  been shown  to  convert  somatic  cells  to pluripotency without affecting  imprinted  loci upon cell fusion (Tada et al., 2001; Pereira et al., 2008). I generated reprogrammed hybrids by  fusing mBOct4GFP  lymphocytes with mouse EG cells, or for comparison with mouse ES cells, and isolated Oct4‐GFP re‐expressing hybrid clones.  In agreement with previous studies, genomic bisulfite sequencing analysis of 21 days EG‐hybrids revealed a loss of DNA methylation at three  ICRs  compared  with  Day  0.  In  fact,  following  fusion  with  EG  cells,  the overall  DNA methylation  levels were  reduced  from 30%  (at  Day  0)  to  1.5%  in hybrid cells (day 21)  for H19/Igf2, and  from 34% to 11% and 43 % to 18% for 
Peg3 and Dlk1/Gtl2,  respectively  (Figure 1 A,  top panels).  Similar hybrid  clones generated  with  ES  cells  and  used  here  as  controls,  did  not  show  substantive changes in methylation at these loci (lower panels). Similar results were obtained with  several  other  isolated  hybrid  clones  (Figure  5.3  B).  To  confirm  these differences  in  DNA  methylation  erasure,  I  analysed  the  same  samples  also  by HpaII (a methylation sensitive enzyme) digestion and observed that at the three tested ICRs genomic DNA acquired sensitivity to digestion in hybrids formed with EG  cells  but  not  ES  cells  (Figure  5.3C).  This  indicated  that  EG‐hybrids  were significantly less methylated than ES‐hybrids at imprinted domains (Figure 5.3C). 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Figure  5.3.  Reprogrammed  hybrids  generated  with  mouse  EG  cells  show  reduced  DNA 





The hypomethylated status of EG cells (Figure 5.2) as well as their ability to dominantly  induce  loss of DNA methylation at  imprinted domains  in somatic cells  following  fusion  (Figure  5.3)  could  be  due  to  a  failure  in  establishing  and maintaining 5mC marks. In order to test this hypothesis I assessed the expression levels  of  DNMT1  (DNA  maintenance  methyltransferase),  its  tethering  factor 




Figure 5.4. DNA methyltransferases are normally expressed and nuclear in EG cells. (A) RT‐qPCR analysis of DNMT1, DNMT3a, DNMT3b and UHRF1 in mB (grey), mES (black) and two EG cell  lines (55G and 58G, striped and dotted histograms). Values represent the mean and SD of 3 measurements normalized to mouse UBC   (B) Western blots of DNA methyltransferase proteins detected in whole cell extracts of mB, mES, mEG (55G and 58G), ES DNMT1‐/‐ and ES DNMT3a/b‐/‐. Tubulin  is shown as a  loading control.  (C‐D) IF analysis of DNMT1 (C,  green) and UHRF1 (D, green)  in mouse EG (top panels) and ES cells (bottom panels). DAPI  labeling  is depicted  in blue. Scale bars represent 10 µm. 
5.5.  Hypomethylated  ES  cells  cannot  reset  imprints  in  somatic 
cells following fusion. 
Other pluripotent cell lines, in addition to EG cells, have been reported to exhibit hypomethylated DNA at  imprinted domains. These  include  some  female ES cell clones (Pgk12.1) (Zvetkova et al., 2005; Shovlin et al., 2008) or mutant ES cell lines lacking DNMT1 expression (Okano et al., 1999) or depleted for DNMT3a and DNMT3b  (Chen  et  al.,  2003)(Figure 5.5 A).  To  test whether  these  cell  lines could  dominantly  induce  loss  of  DNA  methylation  at  imprinted  domains  in somatic cells following fusion, I generated reprogrammed hybrids by fusing them with mBOct4GFP  lymphocytes.  Isolated GFP expressing hybrid clones  from each of the three  fusions were examined to determine the amount of 5mC at  imprinted domains  by  genomic  bisulfite  sequencing.  I  showed  that  none  of  the hypomethylated ES cells were able to induce a significant loss methylation in the resulting hybrids (Figure 5.5 B, compare values at Day 0, black, with values at Day 21,  red). These data  rule out  the possibility  that  the EG‐specific  ability  to erase 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fusion. (A) Bisulfite genomic sequence analysis of reported ICRs in female ES cells (Pgk12.1) and mutant ES cells that lack either DNMT1 (DNMT1‐/‐) or DNMT3a and DNMT3b (DNMT3a/b‐/‐) are shown.  Open  circles  represent  unmethylated  CpG,  closed  circles  represent methylated  CpG  and the  percentage  of methylated  alleles  is  summarised  in  red.  (B)  CpG methylation  at  ICRs  before (Day0, black dots) and after fusion (Day21, red dots) of mouse mBOct4GFP lymphocytes with female ES (Pgk12), mutant ES cells lacking DNMT1 (DNMT1‐/‐) or DNMT3a and DNMT3b (DNMT3a/b‐/‐),  estimated  by  bisulfite  sequencing.  Results  shown  are  the  average  DNA  methylation  levels (percentage  5mC‐containing/total  CpG)  of  individual  hybrid  clones  (Pgk12  and  DNMT1‐/‐ fusions)  or  bulk  cultures  (DNMT3a/b‐/‐)  isolated  21  days  after  cell  fusion,  where  black  lines indicate the mean values. 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5.6  Bisulfite  sequencing  of  human  H19/IGF2  ICR  in 
heterokaryons reveals a bias in 5mC detection 
To study how EG cells  initiate  the erasure of genomic  imprints  following fusion,  I  generated  interspecies  heterokaryons  between  human  B‐lymphocytes and  mouse  EG  cells  (or  ES  cells  for  comparison).  Taking  advantage  of  this established  approach,  it  is  possible  to  assess  changes  that  occur  in  the  somatic genome  immediately  after  fusion  and  therefore  address  whether  DNA demethylation  of  imprinted  regions  already  begins  at  the  heterokaryon  stage, ahead of hybrid  formation. Interestingly,  in sequencing the H19/IGF2 domain of the  human B  cell  clone  employed  in  this  study,  I  identified  a  single  nucleotide polymorphism (SNP) within the ICR of the locus. This enabled me to discriminate the  paternal  (methylated)  allele  from  the  maternal  (unmethylated)  allele independently from their DNA methylation status (Figure 5.6 A, left panel). Thus, genomic  bisulfite  sequencing  analysis  of  hB  cells  before  fusion  confirmed  that methylated  sequences  of  the  hH19/IGF2  ICR  originate  exclusively  from  the paternal  allele  accounting  for  40%  of  5mC  sites  (Figure  5.6  A,  right  panel).  In samples  collected  48  and 72 hours  following  fusion with EG  cells, most human 
H19/IGF2  DNA  sequences  detected  after  bisulfite  conversion  were  apparently already  unmethylated  (99%  and  90%,  respectively,  Figure  5.6  B,  left  panel). However,  analyzing  presence  of  the  SNP  in  these  sequences  I  have  discovered that this surprising result reflected a preferential detection of the unmethylated maternal  allele,  rather  than  bona  fide  changes  to  the methylated  paternal  ICR. Importantly,  in parallel  fusions performed using hB and mouse ES  cells  (Figure 5.6 B, right panels) I detected the SNP in half of the sequences analysed indicating that  both  parental  alleles were  equally  represented  in  this  analysis,  confirming that ES cells do not affect DNA methylation at somatic  imprinted domains upon fusion. 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Figure  5.6. Detection  of  paternally  derived H19  alleles  by  bisulfite  analysis  is  selectively 
compromised in EG­induced heterokaryons. (A) A single nucleotide polymorphism (SNP) T/A within the human H19/IGF2  ICR was  identified by sequencing of bisulfite treated genomic DNA isolated  from  a  human  B  cell  clone  (hB).  This  was  used  to  discriminate  between  the  paternal (methylated, labeled with grey dot) and the maternal (unmethylated, labeled with a red dot) allele allele as illustrated in the nucleotide sequence traces (left panel). Approximately 40% of total CpG sites  are methylated  at  the  H19/IGF2  ICR  in  hB  cells  before  fusion  (right  panel).  (B)  Bisulfite genomic  sequencing  at  human  H19/Igf2  ICR  in  heterokaryons  generated  between  hB+EG  (left panels)  and  hB+ES  (right  panels)  48  and  72  hours  after  fusion.  Allelic  origin  (A/O)  was determined  according  to  SNP analysis,  and  depicted  in  red  (maternal) or  grey  (paternal).  Open circles represent unmethylated CpG, closed circles represent methylated CpG where overall levels of methylated CpG (as a percentage of total) are shown in red. 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5.7.  HpaII  digestion  analysis  confirms  bias  in  bisulfite 
sequencing and reveals altered methylation at human imprinted 
loci in heterokaryons formed with EG cells.  
Genomic  bisulfite  sequencing  analysis  of  an  additional  human  imprinted locus  (the maternally methylated SNRPN/SNURF  ICR)  in  heterokaryons  formed with  hB  and  mEG  cells  revealed  an  apparent  loss  of  5mC  sites  that  gradually reduced  to 30% and  to 17% 48 and 72 hours after  fusion.  In  samples  collected following control fusions with ES cells I did not detect DNA demethylation at this ICR, but rather 5mC sites were maintained around the expected 50% levels (41 and 48% of CpGs were methylated 48 and 72 hours after  fusion) (Figure 5.7 A, left panel). To test whether the EG‐mediated loss of methylation measured at the hSNRPN/SNURF  ICR  by  bisulfite  sequencing  was  also  due  to  a  bias,  I  have assessed DNA methylation levels of this region by HpaII digestion analysis. Using this alternative technique I observed a slight decline in methylated DNA levels at the hSNRPN/SNURF ICR 48 and 72 hours after fusion of hB with mEG or ES cells (Figure 5.7 A, right panel). This suggests that, similarly to the hH19/IGF2 ICR, the apparent loss of methylation assessed by bisulfite sequencing for hSNRPN/SNURF ICR might be due to a preferential amplification of  the unmethylated (paternal) allele.  Similar  results were obtained  from  the analysis of  two additional human ICRs    (namely  hH19/IGF2  and  hPEG3).  Confirming  a  modest  decrease  of  DNA methylation  levels exclusively  in heterokaryons generated with EG cells (Figure 5.7 B, compare black dots‐continuous lines with white dots‐dashed lines). These data  show  that  early  after  fusion,  bisulfite‐sequencing  detection  of methylated imprinted  alleles  is  selectively  impaired  in  heterokaryon  formed with  EG  cells, but not with ES cells.    
 120 
  
Figure  5.7.  HpaII  digestion  analysis  confirm  bias  in  the  bisulfite  sequencing  analysis  of 
heterkaryon  formed  with  EG  cells.  (A,  left  panel)  Bisulfite  genomic  sequencing  at  human 
SNRPN/SNURF ICR in heterokaryons generated between hB+EG and hB+ES 48 and 72 hours after fusion. Open circles represent unmethylated CpG, closed circles represent methylated CpG where overall levels of methylated CpG (as a percentage of total) are shown in red. (A, right panel) HpaII digestion followed by qPCR analysis performed with oligos specific for human SNRPN/SNURF ICR before (0H) 48 and 72 hours after EG+hB fusion (depicted in back dots and continuous  lines) or ES+hB  fusion  (shown  with  white  dots  and  dashed  lines).  (B)  HpaII  digestion  analysis  of 
hH19/IGF2  and  hPEG3  ICR  before  and  follwing  fusions.  (C)  HpaII  digestion  analysis  of  human 
OCT4  promoter  (left)  or  downstream  of  its  TSS  (right)  before  and  after  fusions.  ICRs  are represented  with  black  bars  and  the  genomic  regions  analysed  are  depicted  with  red  lines. Statistical significance is indicated as ** pvalue < 0.005, calculated with student t‐tests  
 121 
Although only EG cells have  the potential  to erase  imprinting  in  somatic cells upon fusion, both ES and EG cells are able to reprogram their somatic fusion partners to pluripotency. As discussed  in  sections 1.3 and showed in Figure 3.3 the  reprogramming  capacity  of  ES  cells  is  associated  with  its  ability  to  induce DNA demethylation at the promoter of OCT4 in the somatic genome. Therefore I tested whether somatic OCT4 promoter becomes demethylated  following  fusion with EG cells. HpaII digestion analysis revealed that indeed EG cells were able to induce rapid (within 72 hours from fusion) DNA demethylation of this region in the  somatic  nucleus,  similarly  to  ES  cells  (Figure  5.7  C,  left  panel).  On  the contrary,  following  heterokaryon  formation,  neither  EG  cells  nor  ES  cells were able to demethylate the genomic region downstream of the OCT4 TSS in somatic cells, which remained fully methylated at this time point (Figure 5.7 right panel).  
5.8.  EG­dependent  5mC  to  5hmC  conversion  precedes  DNA 
demethylation at imprinted domains. 
The  inability  to  detect  methylated  DNA  sequences  following  bisulfite conversion might  be  due  to  the  presence  of  5hmC  residues.  It was  shown  that under  bisulfite  treatment  5hmC marks  (but  not  5mC  or  unmodified  cytosines) yield  cytosine  5‐methylenesulfonate  sites,  which  can  stall  DNA  polymerase resulting  in  inefficient  amplification  by  PCR  (Huang  et  al.,  2010).  To  test  this possibility I used a restriction protection assay to compare 5hmC levels at several imprinted domains before and after  fusion with EG cells (depicted  in Figure 5.8 A).  This  approach  uses  T4  glucosyltransferase  pre‐treatment  (that  selectively protects 5hmC containing DNA template from MspI digestion) to estimate 5hmC abundance (fully detailed in material and methods, section 2.8). 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Figure 5.8. 5hmC accumulates at somatic ICR in heterokaryons generated with EG cells. (A) Schematic  representation  of  the  strategy  used  to  detect  5hmC  (red  asterisk);  genomic  DNA samples were divided and  either  left untreated  (H2O)  or  treated with  T4‐β‐glucosyltransferase which binds glucose groups selectively at 5hmC sites and creates 5hgmC (open hexagon). Samples were then either digested with MspI (which does not digest 5hgmC) or left undigested (H2O). The abundance of undigested material corresponding to each locus in each preparation was compared by  qPCR  using  primers  specific  for  human  genes.  Amplification  of  MspI‐digested  sample  was normalized  to undigested  control  to  estimate % MspI  resistance.  (B) 5hmC detection  at human 
H19/Igf2, Peg3 and SNRPN/SNURF ICRs evaluated in human B cells DNA before (0h), and 48 or 72 hours after fusion with EG (black histograms) or ES cells (white histograms). The position of the ICR is indicated in black and red bars mark the position of primer‐amplified PCR product. Values shown  are  mean  and  standard  error  of  3‐5  independent  experiments  where  statistical significance is indicated as * p‐value < 0.05, ** p‐value < 0.005, calculated with student t‐tests. (C) 5hmC  detection  at  OCT4  promoter  (left  panel)  and  downstream  of  its  TSS  in  hB  genomic  DNA before  (0h)  and  after  fusion  (48  and  72  hours)  with  EG  (black  histograms)  or  ES  cells  (white histograms).   After  heterokaryon  formation  with  EG  cells  (EG+hB),  I  detected  an increase  in  MspI‐resistant  template  at  several  human  ICRs  (hence  hH19/IGF2, hSNRPN/SNURF  and  hPEG3)  (Figure  5.8  B,  black  histograms).  No  such accumulation  of  5hmC  sites  was  seen  in  heterokaryons  formed  with  ES  cells (Figure 5.8 B, white histograms).  These  results  together  with  the  bias  observed  at  hH19/IGF2  domain (Figure  5.6)  and  the  discrepancy  between  bisulfite  sequencing  and  HpaII digestion assay (Figure 5.7), support the assumption that EG cells may selectively induce 5hmC accumulation at  imprinted domains  in  the  somatic genome at  the 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heterokaryon stage, ahead of the erasure of imprints observed in hybrids (Figure 5.3)  Using  this  glucosyltransferase  protection  assay  I  could  not  detect  5hmC traces accumulating in the somatic OCT4 promoter regions following fusion with ES or EG cells (Figure 5.8 C, left panel). However both ES and EG cells were able to convert 5mC into 5hmC in the somatic region downstream of the human OCT4 TSS  (Figure  5.8  C,  right  panel),  which  might  be  induced  during  the  process  of somatic conversion towards pluripotency.  
5.9. Evidence of Tet1 mediated conversion of 5mC into 5hmC at 
imprinted  domains  in  somatic  cells  early  after  fusion  with  EG 
cells. 




reprogramming capacity. (A) RT‐qPCR analysis of Tet1, Oct4, Nanog, Brachyury (Bry) and Gata4 in mouse  EG  cells  after  transfection with  shRNA  for  Tet1  (white  histograms)  or  control  vector (black histograms). Values are normalized to mouse UBC and correspond to mean and SEM of 4 independent experiments. (B) Western blot detection of Tet1, Oct4 and Nanog proteins in whole‐cell extracts of mouse ES  cells (mES), mouse B  cells (mB) and mouse EG cells after transfection with shRNA for Tet1 or control vector. Antibodies specific  for Tet1, Oct4, Nanog and Tubulin (a loading control) were used throughout (details  in materials and methods). (C) RT‐qPCR analysis of human OCT4, NANOG  and CRIPTO  in hB‐lymphocytes before  (Oh)  and 48 and 72 hours after fusion with  EG cells transfected with shRNA for Tet1 (white histograms) or control vector (black histograms).  Values  are  normalized  to  human  GADPH  and  represent  mean  and  SEM  of  4 independent  experiments.  (D)  5hmC  detection  (as  in  depicted  in  Figure  5.8  A)  at  human 
H19/IGF2, PEG3  and  SNRPN/SNURF  ICRs  and Oct4  TSS  evaluated  in  human B  cells  DNA  before (0h), and 48 or 72 hours after fusion with EG cells transfected with shRNA for Tet1 (white dots in dashed lines) or control vector (black dots in continuous lines). Values represent mean and SEM 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of 4 independent experiments. (E) genomic bisulfite sequencing analysis of human H19/IGF2 ICR in hB‐lymphocytes before (0h) and 48 hours after fusion with EG cells transfected with shRNA for Tet1  (sh Tet1) or  control  vector  (Ctrl). Black dots  represent methylated CpG while open circles represent unmethylated CpGs. Overall 5mC levels are reported below in red. A/O indicates Allelic Origins  and  red  dots  represent  maternal  alleles  while  grey  circles  represent  paternal  alleles discriminated with SNP analysis. The frequency of paternal alleles detection  in each condition  is reported below in grey.   To verify that the efficient depletion of Tet1 in EG cells did not impair their undifferentiated  status,  I  examined  the  expression  of  pluripotency  genes  after shRNA  targeting.  Oct4  and  Nanog  remained  expressed  and  lineage‐associated genes were not induced (Figure 5.9 A and B). Tet1‐depleted EG cells retained the potential  to  reprogram  somatic  cells  in  heterokaryons  to  a  similar  extent  than control  wild‐type  EG  cells;  human  pluripotency  genes  were  induced  to comparable  levels  (Figure  5.9  C,  compare  black  and  white  histograms).  Using MspI protection assays  to monitor 5hmC  levels  in heterokaryons,  I noticed that depletion  of Tet1  reduced  the  ability  of  EG  cells  to  induce  5hmC  conversion  at 
hH19, hSNRPN  and hPEG3  ICRs  in  heterokaryons,  while  it  did  not  dramatically affect 5hmC accumulation at somatic OCT4 TSS (Figure 5.9 D, compare black and white dots). Interestingly, and consistent with Tet1 participating in 5mC to 5hmC conversion at  ICRs,  knock down of Tet1  in EG cells  restored  the equivalence of detection  of  the  two  parental  human  H19  alleles  in  heterokaryon  samples following bisulfite  conversion  (Figure 5.9 E). This  implicates Tet1  in  the biased amplification of methylated alleles discussed previously (Figure 5.6 and 5.7).  
5.10.  Tet2  ablation  in  EG  cells  reduces  their  reprogramming 
potential 
Ablation  of  Tet2  expression  did  not  seem  to  affect  the  undifferentiated status of EG cells  as pluripotent genes were expressed at  similar  levels  in Tet2 knock‐down EG cells as controls and lineage‐associated gene expression was not induced (Figure 5.10 A and B). Surprisingly, Tet2 depletion in EG cells resulted in less  efficient  reprogramming  of  hB‐lymphocytes  towards  pluripotency.  In particular,  the  abundance  of  human  pluripotency‐associated  gene  transcripts induced by EG cells  lacking Tet2 expression was consistently  reduced by about 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50%  compared with  levels  induced  in  control  fusions  (Figure  5.10  C,  compare black  and white  histograms).  Interestingly,  lack  of  Tet2  expression  by  EG  cells impaired  the  accumulation  of  5hmC  at  the  somatic  OCT4  TSS  (Figure  5.10  D), whereas  the  ability  of  EG  cells  to  induce  5hmC  at  somatic  ICRs  was  not significantly affected by Tet2 ablation (Figure 5.10 D).  
 
Figure  5.10.  Tet2  ablation  impairs  reprogramming  potential  but  not  EG­mediated 
generation  of  5hmC  at  somatic  ICRs.  (A)  RT‐qPCR  analysis  of  Tet2,  Oct4,  Nanog,  Brachyury (Bry) and Gata4  in mouse EG cells after transfection with shRNA for Tet1 (white histograms) or control vector (black histograms). Values are normalized to mouse UBC and correspond to mean and  SEM  of  4  independent  experiments.  (B)  Western  blot  detection  of  Tet2,  Oct4  and  Nanog proteins  in whole  cell extracts of mouse ES cells (mES), mouse B  cells (mB) and mouse EG cells after transfection with shRNA for Tet2 or control vector. Antibodies specific for Tet1, Oct4, Nanog and Tubulin (a loading control) were used throughout (details in materials and methods). (C) RT‐qPCR analysis of human OCT4, NANOG and CRIPTO in hB‐lymphocytes before (Oh) and 48 and 72 hours after  fusion with   EG cells  transfected with shRNA for Tet2 (white histograms) or  control vector (black histograms). Values are normalized to human GADPH and represent mean and SEM of  4  independent  experiments.  (D)  5hmC  detection  (as  in  depicted  in  Figure  5.8  A)  at  human 
H19/Igf2, Peg3 and SNRPN/SNURF ICRs and Oct4 TSS evaluated in human B cells DNA before (0h), and  48  or  72  hours  after  fusion with  EG  cells  transfected  with  shRNA  for  Tet2  (white  dots  in dashed lines) or control vector (black dots in continuous lines). Values represent mean and SEM of 4 independent experiments.   Together,  these  two  sets  of  experiments  suggest  that  Tet1  and  Tet2 function  differently  in  the  EG‐mediated  reprogramming.  In  particular,  I  found 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that Tet1 expression, despite being dispensable  for  the pluripotency conversion of somatic cells, was required  for  the early remodeling of  imprinted domains  in heterokaryons induced by EG cells. This occurred before loss of DNA methylation was complete (in hybrids). On the other hand, expression of Tet2 enhanced EG‐mediated  reprogramming,  consistent  with  a  role  in  the  conversion  of  5mC  to 5hmC at the OCT4 TSS of hB cells.  
5.11.  A  role  for  DNA  replication  in  reprogramming  and  DNA 
demethylation 
Recently  in our  laboratory  Jorge Ried and Karen Brown have discovered that DNA synthesis occurs in somatic nuclei during heterokaryon reprogramming and  is  required  for  initiating  pluripotent  gene  expression  (Tsbouchi  et  al. 
submitted). To test whether EG cells also induce DNA synthesis in somatic targets upon fusion,  I  treated heterokaryons generated between hB and mEG cells with the DNA Polymerase inhibitor aphidicolin, mimosine (a drug that arrests cells in late  G1)  or  I  left  them  untreated  for  60  hours.  RT‐qPCR  analysis  revealed  that both aphidicolin and mimosine treatments blocked the induction of human OCT4, 
NANOG and CRIPTO expression, confirming the DNA replication requirement for inducing pluripotency reprogramming also in EG‐heterokaryons (Figure 5.11 A). To  ask  whether  EG‐mediated  5hmC  accumulation  at  imprinted  domains  also depends  on  DNA  synthesis,  I  measured  5hmC  levels  at  somatic  imprinted domains in these samples and observed that increased 5hmC levels occur at both 
hH19/IGF2  and  hPEG3  ICRs  in  hB‐lymphocytes  following  fusion,  despite inhibition of DNA polymerase activity (Figure 5.11 B).  These  results  suggest  that  although  the  conversion  of  somatic  cells  to pluripotency mediated  by  EG  cells  (like  ES  cells)  requires  DNA  replication,  the conversion of 5mC to 5hmC at somatic ICRs was not dependent on DNA synthesis and it may be therefore an active process. 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Figure  5.11.  Early  DNA  replication  is  required  for  initiating  pluripotent  reprogramming 
but  not  for  5hmC  accumulation  at  somatic  ICR  in  hB+EG  heterokaryons.  (A)  RT‐qPCR analysis of human pluripotency genes in heterokaryons formed between mouse EG and human B cells cultured with aphidicolin (2µg), mimosine (350 µM) (grey circles and squares) for 60 hours or  left  untreated  (black  circles).  Values  normalized  to  human  GADPH  represent  mean  and standard errors of 3 independent experiments. (B) 5hmC levels estimated as described in Figure 5.8 A  in hB before  (0h) and 60 hours after  fusion with mEG cells  and cultured with aphidicolin (2µg), mimosine (350 µM) (grey histograms) or left untreated (black histograms). Values indicate mean and standard errors of 3 independent experiments where * shows p‐value< 0.05, calculated with student t‐test.  
5.12.  EG  cells  induce  functional  resetting  of  imprinted  genes  in 
reprogrammed hybrids. 
To monitor the dynamics of pluripotent reprogramming and ask whether the erasure of imprinting directed by EG cells has functional consequences, I have established  a  puromycin  resistant  dual‐reporter  mouse  B  cell  line  (2RB)  that carries  a  maternal  LacZ  knock‐in  allele  of  Peg1/Mest  (Peg1Mβ‐gal;  which  is methylated and unexpressed) (Lefebvre et al., 1998), and an Oct4‐GFP transgene (Yeom et al., 1996) (Figure 5.12 A). Thus, together with Karen Brown and David Landeira,  I monitored Oct4‐GFP and βgal activity  in B cells after  fusion with EG cells. 2RB cells began re‐expressing the Oct4‐GFP transgene after 3 days, while β‐gal activity was not detected (Figure 5.12 B). At the hybrid stage while Oct4‐GFP was  robustly  expressed  (indicating  full  reprogramming),  the  Peg1M‐β‐gal reporter gene remained silent (Figure 5.12 C). This result was anticipated as the paternal Peg1 gene is expressed specifically in differentiated cells (Lefebvre et al., 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1998)  (Figure  5.12  G).  Therefore  to  test  whether  the  reprogrammed  cells  had reset  the  maternally  inherited  Peg1M‐β‐gal  reporter  gene,  2RB‐hybrids  were differentiated by withdrawing LIF from the culture media.   
 
Figure  5.12. EG cells  functionally  convert  somatic  cells  to pluripotency and  reset  somatic 
genomic  imprints. (A) Schematic  representation of  the experimental strategy for progressively monitoring  the  dynamics  of  pluripotent  reprogramming  and  erasure  of  imprinting  at  a  model 
Peg1  locus using mouse 2RB cells (a puromycin resistant mouse B cell  line that carries an Oct4‐GFP  transgene  and  a  maternal  LacZ  knock‐in  allele  of  Peg1/Mest  (Peg1M‐β‐gal).  (B)  Confocal Images of Oct4‐GFP (green) and DAPI staining (blue) of 2RB cells 3 days after fusion with EG cells (right). Bright  field analysis of X‐gal staining (left).  (C) Oct4‐GFP expression (green, right panel) but  lack  of  maternal  Peg1M‐β‐gal  activity  (X‐gal  staining,  left  panel)  detected  in  representative reprogrammed  mEG+2RB  hybrid  colony  obtained  12  days  after  fusion.  (D)  Genomic  bisulfite sequencing of Peg1  ICR at  fusion  (Day0) and  in  reprogrammed hybrid generated between mEG and  mB  cells.  Black  dots  represent  methylated  cytosine  while  open  circles  represent unmethylated CpGs. The overall methylation  level  is reported bellow in red. (E) HpaII digestion analysis  of  mouse  Peg1  ICR  at  fusion  (Day0)  and  in  reprogrammed  hybrids  obtained  by  fusing mB‐lymphocytes with mEG (black histograms) or mES cells (white histograms). Values represent mean  and  standard  error  of  2‐3  independent  experiments.  Anticipated  50%  levels  of  HpaII resistance are marked  in grey.  Statistical significance  is  indicated as * p‐value < 0.05,  calculated with student t‐tests. (F) X‐gal staining (blue) of differentiated (10 days following LIF withdrawal) reprogrammed  hybrids  obtained  by  fusing  2RB  cells with  EG  cells  (left  panel)  or with  ES  cells (right panel) used as negative control. (G) RT‐qPCR analysis of mouse Oct4 and Peg1 expression in reprogrammed hybrids generated between mEG cells and 2RB‐lymphcytes (mEG+2RB hybrid) before  (0)  and  5,  7  and  10  days  after  LIF  withdrawal.  Values  are  normalized  to  mouse  UBC transcripts and represent mean and standard errors of 2 independent experiments. 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This  resulted  in  silencing of Oct4  and  the  induction of Peg1  expression  (Figure 5.12 F) and RT‐qPCR analysis confirmed that up‐regulation of Peg1 in EG‐derived differentiated  hybrids  (Figure  5.12  G).  Parallel  cultures  of  hybrids  established using  ES  cells,  although  reprogrammed  failed  to  express  β‐gal  upon differentiation  (Figure  5.12  F,  right  panel).  Overall  this  experiment  provides evidence  that  EG  cells  can  fully  reprogram  somatic  cells  upon  cell  fusion  and functionally erase somatic imprints.   
5.13. Discussion and future perspectives 
In  mice,  germ  cells  arise  from  a  subset  of  posterior  proximal  epiblast  cells  by forming a nascent population of approximately 40 Primordial Germ Cells (PGCs) at  around  E7.5  (Ohinata  et  al.,  2005).  Following  specification,  PGCs  start migrating  into  the  genital  ridges  by  approximately  E10.5  (Surani  and  Hajkova, 2010), where  they  continue  to  proliferate  until  E13.5.  Subsequently  germ  cells will enter mitotic arrest  in male and meiotic prophase  in  female. Because these cells  are  specified  from  cells  of  the  epiblast  that  are  already  primed  towards somatic fate, nascent PGCs repress the ongoing somatic program and activate the germ  cell  transcriptional  network  (Surani  et  al.,  2007).  Early  during  germ  cell development (approximately by E9.5), PGCs initiate a process of reprogramming that leads to the establishment of a chromatin environment similar to that of ES cells,  and  to  the upregulation of key pluripotency  specific  genes,  such as Nanog (Seki  et  al.,  2005;  Seki  et  al.,  2007;  Surani  et  al.,  2007;  Hajkova  et  al.,  2008). Several studies have shown that this reprogramming process ultimately leads to a  global  loss  of  DNA  methylation  including  the  erasure  of  imprints  by  E13.5 (Hajkova  et  al.,  2002;  Seki  et  al.,  2007;  Popp  et  al.,  2010).  Importantly, methylation erasure  in PGCs  is more  complete  than  in preimplantation embryo where  a  high  number  of  genomic  domains  (including  ICRs)  resist  global demethylation  after  fertilization.  EG  cells,  which  are  derived  from  E8.5‐E12.5 PGCs, are pluripotent (Labosky et al., 1994) and exhibit hypomethylated DNA at ICR  (Tada  et  al.,  1998;  Durcova‐Hills  et  al.,  2003;  Durcova‐Hills  et  al.,  2006).  I have  shown  here  that,  similar  to  mouse  ES  cells,  EG  cells  can  dominantly 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reprogram  lymphocytes  towards  pluripotency  and  this  process  begins  within transient heterokaryons.  Conversion  involves  early global  reorganization of  the somatic nuclei to mirror EG/ES cell characteristics and eventually leads to the re‐expression of pluripotency‐associated genes, such as Oct4 and Nanog. In addition, I confirmed that EG cells have the unique ability to induce the erasure of genomic imprints within the lymphocyte genome upon fusion, which is in agreement with previous  studies  in  hybrid  cells  (Tada  et  al.,  1997;  Tada  et  al.,  2001).  This indicates  that  EG  cells  retain  the  ability  of  PGCs  to  target  and  demethylate imprinted domains. However, not all mouse EG cell lines share this property and it is noteworthy that the EG cell line used here was derived relatively late during PGC  development  (E12.5)  and  required  a  low  passage  number  and  specialized culture  conditions  to  retain  its  hypomethylated  DNA  status  and  the  ability  to reset imprints. 
A  recent  study  has  assessed  the  kinetics  of  the  global  DNA  demethylation  that PGCs  undergo  during  development  between  E.8.5  and  E.13.5  (Guibert  et  al., 2012) (Figure 5.13 A).  In this report the authors showed that most genomic loci initiate progressive erasure of methylation in early PGCs between E8.5 and E9.5, and  that  complete  demethylation  occurs  approximately  at  E11.5.  Herein, imprinted and non‐imprinted genomic domains do not  follow the same kinetics of  demethylation.  Non‐imprinted  genes  showed  progressive  erasure  of  DNA methylation  in  early  PGCs,  while  ICRs  were  erased  by  a  second  wave  of demethylation that started at around E11.5 (Guibert et al., 2012). My data show some similarity to these kinetics. DNA demethylation of the somatic genome was induced by EG cells upon cell fusion (Figure 5.13 B). The Oct4 promoter of B cells was  rapidly demethylated at  the heterokaryon stage, while DNA methylation at somatic  ICRs  was  partially  maintained  and  only  completely  erased  in  hybrids. This  suggests  that  following  fusion,  EG  cells  induced  changes  in  the  somatic genome  that  may  recapitulate  in  vitro  the  processes  of  reprogramming  and imprinting erasure that occur in vivo as PGCs develop in the embryo. 
My  data  show  that  somatic  ICRs  begin  to  be  remodeled  in  EG  heterokaryons, ahead of hybrid  formation. EG‐derived Tet1 expression seems to be required to induce the conversion of 5mC to 5hmC at  imprinted domains  in heterokaryons. 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This  suggests  that  Tet1  is  involved  in  the  accumulation  of  5hmC  sites,  which might be an early intermediate in the DNA demethylation process induced by EG cells at somatic  ICRs. This hypothesis  is however, not easily reconciled with the recent report showing that Tet1‐null mice are both viable and fertile (Dawlaty et 
al., 2011). Tet1 mutant mice show mild embryonic growth retardation, decreased body size, and small litter sizes. To formally test whether lack of Tet1 expression results  in an  inefficient erasure of  imprints  in the germ line,  I collaborated with Rudolf Jaenisch to assess DNA methylation levels at maternally methylated ICRs in  genomic  DNA  isolated  from  sperm  of  Tet1‐null  mice.  Bisulfite  sequencing analysis  revealed  that  genomic  imprints were  successfully  erased  despite  Tet1 ablation (Appendix II). Since this analysis was performed on mature sperm, it is possible that the individual gametes that did not efficiently erase imprints might have  been  selected  against  before  maturation.  Alternatively,  other  factors  or redundant mechanisms might compensate for the lack of Tet1 expression in vivo, that are not available in our in vitro reprogramming model. 
 
Figure  5.13. Schematic  representation  of DNA demethylation kinetics  in  developing PGCs 
and B  lymphocytes  following  fusion with EG cells.  (A) DNA methylation  levels  in developing PGCs, global methylation is depicted in grey while DNA methylation at ICRs is shown in blue. (B) DNA methylation levels  in B‐lymphocytes following fusion with EG cells. DNA methylation levels at  the  Oct4  promoter  are  shown  in  black  while  methylation  levels  at  ICRs  are  shown  in blue. Accumulation  of  5hmC  is  depicted  in  red.  Nuclear  reorganization  events  are  labelled  in green. 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CHAPTER 6. GENERAL DISCUSSION  In mammals, CpG methylation and the protein complexes that bind to methylated DNA  are  normally  associated  with  epigenetic  repression.  Although  DNA methylation  has  been  generally  considered  to  be  more  stable  than  histone methylation,  loss  of  DNA  methylation  occurs  in  several  biological  systems, including  in  the  formation  of  the  zygote  and  germ  line  determination  in  the embryo,  as  well  as  during  experimental  somatic  cell  reprogramming  (Wu  and Zhang, 2010). How CpG methylation is reversed is still highly controversial (Ooi and  Bestor,  2008).  DNA methylation  can  be  gradually  lost  during  replication  if DNMT1  activity  is  impaired,  leading  to  an  overall  dilution  of  genomic  5mC content.  This  has  been  termed  ‘passive  demethylation’.  Alternatively,  several active mechanisms have been proposed that may act to remove or convert 5mC, or  replace  nucleotides  wholesale,  and  these  processes  are  thought  to  be independent  of  the  cell  cycle  (Wu  and  Zhang,  2010;  Chen  and  Riggs,  2011; Teperek‐Tkacz et al., 2011). My research has focused on two DNA demethylation processes  that  are  induced  in  lymphocytes  upon  cell  fusion  reprogramming. These are the loss of methylation at Oct4 promoter, resulting from the fusion with both ES and EG cells, and the erasure of genomic imprints induced exclusively by EG cells.   
 
6.1 DNA demethylation at somatic Oct4 promoter. 
Several  methods  have  been  developed  to  experimentally  reprogram differentiated  cells  to  a  pluripotent  state.  These  reprogramming  strategies employ different approaches and show different kinetics  that  can be applied  to study early and  late events. Regardless of  the system used, only a proportion of somatic  cells  is  successfully  converted  to  pluripotency  (Yamanaka  and  Blau, 2010). This probably  reflects a variable  stability of  the differentiated  state  that may,  according  to  the  developmental  stage,  be  more  or  less  able  to  resist 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reprogramming. For example, several  studies have shown that most specialized cells are generally more resistant to pluripotent conversion than less specialized cells (Gurdon, 1962; Meissner and Jaenisch, 2006; Eminli et al., 2009; Halley‐Stott 
et  al.,  2010).  This  indicates  that  during  embryonic  development,  cells progressively  accumulate  epigenetic  restrictions,  which  represent  a  barrier  to reprogramming.  Among  these,  a well‐known mechanism postulated  to  create  a “roadblock”  to  the pluripotency  conversion of somatic  cells  is DNA methylation (Jaenisch  and Young,  2008;  Pasque  et  al.,  2011).  Studies  on  cloned mammalian embryos  have  shown  that  incomplete  epigenetic  reprogramming  of  donor genomic  DNA  correlates with  developmental  abnormalities  (Kang  et  al.,  2001). On the other hand, somatic cells that lack DNMT1 expression appear to be more efficiently  reprogrammed  than  wild  type  cells  upon  nuclear  transfer  into enucleated  oocytes  (Blelloch  et  al.,  2006).  Additionally,  inhibition  of  DNMT1 activity has been shown to enhance complete pluripotency conversion in partially reprogrammed iPS cells (Mikkelsen et al., 2008).  Regardless of the experimental strategy  used,  successful  reprogramming  seems  to  be  strongly  associated with the efficient removal of 5mC at regulatory regions of key pluripotency‐associated genes, such as Oct4 and Nanog (Cowan et al., 2005; Freberg et al., 2007; Jaenisch and  Young,  2008;  Pereira  et  al.,  2008;  Bhutani  et  al.,  2010).  Simonsson  and Gurdon  showed  that  DNA  demethylation  was  essential  for  the  reactivation  of silent genes during reprogramming in studies focused on the dynamics of murine 
Oct4 mRNA expression by mouse thymocyte nuclei transferred into Xenopus eggs (Simonsson  and  Gurdon,  2004). Chemical  depletion  of  thymocyte  chromatin proteins substantially accelerated Oct4 transcript accumulation from 96 hours to 40 hours, while  injection of unmethylated plasmid DNA containing the genomic 
Oct4  region  resulted  in  detection  of  transcripts  within  few  hours.  This  data  is consistent  with  data  shown  here  in  which  the  successful  reprogramming  of  B cells  upon  fusion  with  ES  or  EG  cells,  induced  a  loss  of  CpG  methylation  at selected  sites  within  the  Oct4  promoter  ahead  of  Oct4  re‐expression. Demethylation began at the heterokaryon stage and was complete within 6 days in selected hybrid clones. Exactly  how  DNA  methylation  is  removed  from  the  Oct4  promoter  in somatic cells during reprogramming is still unclear and controversial. In a recent 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study,  AID  was  reported  to  be  required  for  successful  reprogramming  in heterokaryons generated between mouse ES cells and human fibroblast (Bhutani 
et al., 2010).  In particular  the authors claimed that AID  induced deamination of 5mC at somatic OCT4 and NANOG promoters. However, as AID expression by ES cells or fibroblasts has not been detected by others (Foshay et al., 2012) (Piccolo and Bagci,  unpublished)  the  significance  of  this  observation  remains  uncertain. Moreover,  a  recent  study  employing  AID‐overexpressing  ES  cells  in  cell  fusion experiments  showed  no  change  in  the  kinetics  or  success  of  reprogramming (Foshay et al., 2012).  It has recently been suggested that mitotic conditioning may be crucial to reset  the  chromatin  structure  of  differentiated  adult  donor  cells  to  facilitate reprogramming towards pluripotency (Lemaitre et al., 2005; Ganier et al., 2011). In agreement with this, Tomomi Tsbouchi and Jorge Soza Ried in our laboratory recently  showed  that  ES  cells  are most  effective  at  reprogramming when  they contain a high proportion of cells in the S and G2/M phases of the cell cycle (data not  shown).  Pioneering  cell  cycle  experiments  by  Rao  and  Johnson  (Rao  and Johnson, 1970) established that cells in S‐phase are able to induce DNA synthesis when fused to a G1 cell. These studies suggest  that reprogramming may require an  initial  round  of  somatic  DNA  replication  in  order  for  chromatin  to  be remodeled effectively by ES‐derived factors. Consistent with this idea, it has been shown  that  the  long  latency  period  required  for  iPS  generation  relates  to  a requirement for multiple cell divisions rather than an extended induction time (at least 18 cell divisions are required)(Hanna et al., 2009). Therefore  it  is possible that  dilution  of  epigenetic  marks  through  DNA  replication  may  be  critical  for remodeling the somatic cell’s epigenetic state during reprogramming.  Whether DNA  replication  is  required  for  overcoming  epigenetic  barriers towards  reprogramming  (such  as  DNA  methylation)  has  been  widely  debated (Egli  et  al.,  2008).  Although  the  absence  of  somatic  DNA  replication  in heterokaryons has been reported (Bhutani et al., 2010), recent data obtained  in our laboratory by Jorge Soza‐Ried and Karen Brown provides evidence that early DNA  synthesis  is  induced  in  the  somatic  genome  following  fusion with ES  cells (data  not  shown).  In  parallel  studies,  we  have  shown  that  inhibition  of  DNA replication in heterokaryons blocks the reprogramming of somatic cells towards 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pluripotency  (Figure  5.11).  In  fusions  treated  with  drugs  that  block  DNA replication the  somatic Oct4  locus  remains  fully methylated (not  shown). These observations are consistent with recent cell  fusion reprogramming experiments that have suggested that some key pluripotency genes (such as Oct4 and Nanog) require DNA replication to be remodeled and be eventually re‐activated (Foshay 
et al., 2012).  
 The recent demonstration that Tet proteins are capable of catalyzing the conversion of 5mC to 5hmC (Tahiliani et al., 2009) has raised the possibility that these  proteins  may  be  involved  in  DNA  demethylation.  A  recent  study  has suggested  that  5hmC  may  act  as  an  epigenetic  mark  per  se  by  recruiting chromatin‐remodelling  factors  (Yildirim  et  al.,  2011).  In  my  experiments,  the 
OCT4 locus in human lymphocytes begins to be remodeled early after fusion with both  ES  and  EG  cells.  In  these  heterokaryons,  while  the  promoter  of  OCT4  is gradually  demethylated,  at  the  region  immediately  downstream  of  the  TSS  a proportion of 5mC is converted to 5hmC. This apparently requires Tet2 activity, since  conversion  is  not  seen  if  EG  cells  are  pretreated  with  shRNA  for  Tet2. Interestingly Tet2 also seems to be required for efficient reprogramming since its ablation reduced (but did not completely abolish) the ability of EG cells to induce B‐lymphocytes  to  express  pluripotency‐associated  genes  after  fusion.  This  is  in agreement with a recent study showing that Tet2‐dependent 5hmC conversion is required  for  iPS  reprogramming,  without  affecting  DNA  methylation  levels (Doege et al., 2012). These results suggest  that 5hmC does not only represent a possible  intermediate  of  DNA  demethylation,  but  may  also  function  as  an epigenetic mark, potentially recruiting other factors.  
6.2 Erasure of genomic imprints  
Parent  of  origin  expression  of  imprinted  genes  is  determined  by monoallelic DNA methylation at ICRs (John and Lefebvre, 2011). 5mC marks are established  at  these  domains  during  gametogenesis  and  are  generally  stably maintained in any somatic cell of the generated offspring (Reik and Dean, 2001). Genomic imprints need to be erased in the germ line at each generation so as to 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be  re‐established  according  to  the  gender  (Hajkova  et  al.,  2002;  Guibert  et  al., 2012). Recent findings have linked AID‐mediated deamination in the global DNA demethylation processes  that  PGCs  undergo  in  the  embryo  (Popp  et  al.,  2010). However it is questionable whether AID contributes to the erasure of imprints as AID  mutant  mice  are  viable  and  are  fertile  (Muramatsu  et  al.,  2000).  Another study  has  suggested  that  components  of  the  base  excision  repair  pathway may function to remove DNA methylation marks at imprinted domains (Hajkova et al., 2010). However, the mechanism by which DNA methylation marks are removed from these loci is not fully understood (Surani et al., 2007).   
 
Figure 6.1. The re­expression of a silent  imprinted locus involves active and passive DNA 
demethylation processes A schematic representation of sequential changes to a model maternal imprinted  locus  (Peg1M‐β‐gal)  induced  in  2RB  cells  upon  fusion  with  EG  cells,  in  which  DNA replication‐dependent (green) and DNA replication‐independent processes (red) are highlighted.  In reprogramming experiments,  I have confirmed that EG cells are able  to reset genomic  imprints  in  lymphocytes  (Tada  et  al.,  1997).  My  data  also  shows accumulation  of  5hmC  at  imprinted  domains  early  after  fusion,  preceding complete DNA demethylation in hybrids. I have provided some evidence that the conversion of 5mC to 5hmC, that may occur at some somatic ICRs after EG‐fusion, is mediated by Tet1 and that this is an ‘active process’ that does not require DNA replication. However, several rounds of cell division were subsequently required to functionally reactivate a silent imprinted gene using this experimental model. Although  these  data  do  not  exclude  that  5hmC  is  resolved  by  active  processes, erasure  of  somatic  imprints  could  be  mediated  by  a  two‐step  mechanism  that couples active  conversion of 5mC  to 5hmC and passive dilution of  the modified 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cytosine (Figure 6.1). Such a bi‐modal mechanism was also reported to occur in the paternal pronucleus upon zygote formation (Inoue and Zhang, 2011).   My  study  focused  on  two  DNA  demethylation  processes  that  occur  during experimental  cell  fusion  reprogramming. DNA methylation marks  are  passively diluted  from  the  somatic  Oct4  promoter  while  imprinted  domains  seem  more resistant  to  demethylation  and  may  require  an  intermediate  step  of hydroxylation. These experiments  support  the  idea  that  in mammals  there may be multiple mechanisms that lead to loss of 5mC and that each route may be used depending on the biological context (Wu and Zhang, 2010).  
 











Table II. MspI/HpaII digestion primers   Mouse Primers   ICR Digest./Normaliz. Forward Reverse Digestion CTGGATGCTCGTGTGAATGT GCCTACAGTTCCCGAATCAC H19/Igf2 Normalization ACAGCATTGCCATTTGTGAA GACCATGCCCTATTCTTGGA 
Locus Forward Reverse H19/Igf2 ICR AAGGAGATTATGTTTTATTTTTGGA  AAAAAAACTCAATCAATTACAATCC  Peg3 ICR TTGATAATAGTAGTTTGATTGGTAGGGTGT  ATCTACAACCTTATCAATTACCCTTAAAAA DLK1/GTL2 ICR GGAAGGAAAAGATAAAATGTAGAAA  CATAAATAAATAAACCCATAATCCC  Peg1/Mest ICR  GATTAGAGATTTATAAGGAAAGAG  CAACAAAAACAACAAACAACAAC Oct4  promoter  TGGGTTGAAATATTGGGTTTATTT  TGGGTTGAAATATTGGGTTTATTT Oct4GFP promoter  GGGGTTAGAGGTTAAGGTTAGAGG  ACCAAAATAAACACCACCCC 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Digestion CCTCGGGCAAAATATAGTGG CGCAGCCTTCTCTGTGATCT Dlk1/Gtl2 Normalization AAATGCAGAAAAGGGGGTGT CAAAAGCCTTCAACACGTCA Digestion CCCCAAACACCATCTGAACT GTGCGTAGAGTGCTGTGCTC Peg3 
 Normalization TGGACATCTCTCCGCTTCTC CAGAGGACCCTGACAAGGAG Digestion AGGATGGGCGGGTTAGAG AGGCAGCAAGCAGCAACT Peg1/Mest 
 Normalization AGGGGGTAGCGGGTCAATAC AAGCAGAGAGGAGCAAGCAG     Human Primers   Locus Digest./Normal Forward Reverse Digestion ACTGAAGCCCTCGGAGTGT AGATCTTCAGGTCGGGCATT H19/Igf2 ICR Normalization GATAATGCCCGACCTGAAGA GGGGTCATCTGGGAATAGGA Digestion AAAACCCCTACAGGCAGGAC GCGAAAATGCCCCTTCCT Peg3 ICR Normalization GAAAACCCCTACAGGCAGGA TTGTTTGCCGCAGTGGTG Digestion ACTGCGGCAAACAAGCAC CTCCTCAGACAGATGCGTCA SNRPN/SNRPN ICR Normalization ACTGCGGCAAACAAGCAC CAGGCTTCGCACACATCC Digestion GGTTGGTGTGTGTCGAAGAA GGTCTCCACTGGGTGCTC Peg10 ICR Normalization AGTCTGCGCTCCTGGTACAC ACCTTCTCCGCTGTTCTCCT Digestion GTGTCTGTGGAAGGGGAAAA AGTTTCTGTGGGGGACCTG Oct4 Upstream TSS Normalization CCACTAGCCTTGACCTCTGG CCACCATTAGGCAAACATCC Digestion CTTGGAAGCTTAGCCAGGTC CTCCAGGTGGTGGAGGTG Oct4 Downstream TSS Normalization ATCACCTCCACCACCTGGA GACACCTGGCTTCGGATTT    
Table III. qRT­PCR Primers  Human primers   Gene  Forward  Reverse GADPH  TCTGCTCCTCCTGTTCGACA  AAAAGCAGCCCTGGTGACC OCT4  TCGAGAACCGAGTGAGAGGC  CACACTCGGACCACATCCTTC NANOG  CCAACATCCTGAACCTCAGCTAC  GCCTTCTGCGTCACACCATT CRIPTO  AGAAGTGTTCCCTGTGTAAATGCTG  CACGAGGTGCTCATCCATCA DNMT3b  GTCAAGCTACACACAGGACTTGACAG  AGTTCGGACAGCTGGGCTTT 
 141 










Ambrosi, D.J., Tanasijevic, B., Kaur, A., Obergfell, C., O'Neill, R.J., Krueger, W., and 
Rasmussen, T.P. (2007). Genome-wide reprogramming in hybrids of somatic cells and 
embryonic stem cells. Stem Cells 25, 1104-1113. 
Arita, K., Ariyoshi, M., Tochio, H., Nakamura, Y., and Shirakawa, M. (2008). 
Recognition of hemi-methylated DNA by the SRA protein UHRF1 by a base-flipping 
mechanism. Nature 455, 818-821. 
Arney, K.L., and Fisher, A.G. (2004). Epigenetic aspects of differentiation. J Cell Sci 
117, 4355-4363. 
Avvakumov, G.V., Walker, J.R., Xue, S., Li, Y., Duan, S., Bronner, C., Arrowsmith, 
C.H., and Dhe-Paganon, S. (2008). Structural basis for recognition of hemi-methylated 
DNA by the SRA domain of human UHRF1. Nature 455, 822-825. 
Azuara, V. (2006). Profiling of DNA replication timing in unsynchronized cell 
populations. Nat Protoc 1, 2171-2177. 
Azuara, V., Perry, P., Sauer, S., Spivakov, M., Jørgensen, H.F., John, R.M., Gouti, M., 
Casanova, M., Warnes, G., Merkenschlager, M., and Fisher, A.G. (2006). Chromatin 
signatures of pluripotent cell lines. Nat Cell Biol 8, 532-538. 
Balhorn, R. (2007). The protamine family of sperm nuclear proteins. Genome Biol 8, 
227. 
Barlow, D.P., Stöger, R., Herrmann, B.G., Saito, K., and Schweifer, N. (1991). The 
mouse insulin-like growth factor type-2 receptor is imprinted and closely linked to the 
Tme locus. Nature 349, 84-87. 
Baron, M.H., and Maniatis, T. (1986). Rapid reprogramming of globin gene 
expression in transient heterokaryons. Cell 46, 591-602. 
Barreto, G., Schäfer, A., Marhold, J., Stach, D., Swaminathan, S.K., Handa, V., 
Döderlein, G., Maltry, N., Wu, W., Lyko, F., and Niehrs, C. (2007). Gadd45a 
promotes epigenetic gene activation by repair-mediated DNA demethylation. Nature 
445, 671-675. 
Bartolomei, M.S., Zemel, S., and Tilghman, S.M. (1991). Parental imprinting of the 
mouse H19 gene. Nature 351, 153-155. 
Bartolomei, M.S., and Ferguson-Smith, A.C. (2011). Mammalian genomic imprinting. 
Cold Spring Harb Perspect Biol 3. 
Bártová, E., Pacherník, J., Harnicarová, A., Kovarík, A., Kovaríková, M., Hofmanová, 
J., Skalníková, M., Kozubek, M., and Kozubek, S. (2005). Nuclear levels and patterns 
of histone H3 modification and HP1 proteins after inhibition of histone deacetylases. J 
Cell Sci 118, 5035-5046. 
Bernstein, B.E., Mikkelsen, T.S., Xie, X., Kamal, M., Huebert, D.J., Cuff, J., Fry, B., 
Meissner, A., Wernig, M., Plath, K., et al. (2006). A bivalent chromatin structure 
marks key developmental genes in embryonic stem cells. Cell 125, 315-326. 
Bestor, T., Laudano, A., Mattaliano, R., and Ingram, V. (1988). Cloning and 
sequencing of a cDNA encoding DNA methyltransferase of mouse cells. The 
carboxyl-terminal domain of the mammalian enzymes is related to bacterial restriction 
methyltransferases. J Mol Biol 203, 971-983. 
Bhattacharya, S.K., Ramchandani, S., Cervoni, N., and Szyf, M. (1999). A mammalian 
protein with specific demethylase activity for mCpG DNA. Nature 397, 579-583. 
 144 
Bhaumik, S.R., Smith, E., and Shilatifard, A. (2007). Covalent modifications of 
histones during development and disease pathogenesis. Nat Struct Mol Biol 14, 1008-
1016. 
Bhutani, N., Brady, J.J., Damian, M., Sacco, A., Corbel, S.Y., and Blau, H.M. (2010). 
Reprogramming towards pluripotency requires AID-dependent DNA demethylation. 
Nature, 1-7. 
Bird, A. (2002). DNA methylation patterns and epigenetic memory. Genes & 
Development 16, 6-21. 
Bird, A.P., and Wolffe, A.P. (1999). Methylation-induced repression--belts, braces, 
and chromatin. Cell 99, 451-454. 
Blau, H.M., Chiu, C.P., and Webster, C. (1983). Cytoplasmic activation of human 
nuclear genes in stable heterocaryons. Cell 32, 1171-1180. 
Blau HM, Pavlath GK, Hardeman EC, Chiu CP, Silberstein L, Webster SG, Miller SC, 
and C., W. (1985). Plasticity of the differentiated state. Science. 
Blelloch, R., Wang, Z., Meissner, A., Pollard, S., Smith, A., and Jaenisch, R. (2006). 
Reprogramming efficiency following somatic cell nuclear transfer is influenced by the 
differentiation and methylation state of the donor nucleus. Stem Cells 24, 2007-2013. 
Bourc'his, D., Xu, G.L., Lin, C.S., Bollman, B., and Bestor, T.H. (2001). Dnmt3L and 
the establishment of maternal genomic imprints. Science 294, 2536-2539. 
Boyer, L.A., Lee, T.I., Cole, M.F., Johnstone, S.E., Levine, S.S., Zucker, J.P., 
Guenther, M.G., Kumar, R.M., Murray, H.L., Jenner, R.G., et al. (2005). Core 
transcriptional regulatory circuitry in human embryonic stem cells. Cell 122, 947-956. 
Boyer, L.A., Mathur, D., and Jaenisch, R. (2006a). Molecular control of pluripotency. 
Curr Opin Genet Dev 16, 455-462. 
Boyer, L.A., Plath, K., Zeitlinger, J., Brambrink, T., Medeiros, L.A., Lee, T.I., Levine, 
S.S., Wernig, M., Tajonar, A., Ray, M.K., et al. (2006b). Polycomb complexes repress 
developmental regulators in murine embryonic stem cells. Nature 441, 349-353. 
Bracken, A.P., Dietrich, N., Pasini, D., Hansen, K.H., and Helin, K. (2006). Genome-
wide mapping of Polycomb target genes unravels their roles in cell fate transitions. 
Genes & Development 20, 1123-1136. 
Branco, M.R., and Pombo, A. (2007). Chromosome organization: new facts, new 
models. Trends Cell Biol 17, 127-134. 
Brown, K.E., Guest, S.S., Smale, S.T., Hahm, K., Merkenschlager, M., and Fisher, 
A.G. (1997). Association of transcriptionally silent genes with Ikaros complexes at 
centromeric heterochromatin. Cell 91, 845-854. 
Bruniquel, D., and Schwartz, R.H. (2003). Selective, stable demethylation of the 
interleukin-2 gene enhances transcription by an active process. Nat Immunol 4, 235-
240. 
Bultman, S.J., Gebuhr, T.C., Pan, H., Svoboda, P., Schultz, R.M., and Magnuson, T. 
(2006). Maternal BRG1 regulates zygotic genome activation in the mouse. Genes & 
Development 20, 1744-1754. 
Busslinger, M., Nutt, S.L., and Rolink, A.G. (2000). Lineage commitment in 
lymphopoiesis. Curr Opin Immunol 12, 151-158. 
Byrne, J.A., Pedersen, D.A., Clepper, L.L., Nelson, M., Sanger, W.G., Gokhale, S., 
Wolf, D.P., and Mitalipov, S.M. (2007). Producing primate embryonic stem cells by 
somatic cell nuclear transfer. Nature 450, 497-502. 
Cammas, F., Oulad-Abdelghani, M., Vonesch, J.-L., Huss-Garcia, Y., Chambon, P., 
and Losson, R. (2002). Cell differentiation induces TIF1beta association with 
centromeric heterochromatin via an HP1 interaction. J Cell Sci 115, 3439-3448. 
 145 
Cao, R., and Zhang, Y. (2004). The functions of E(Z)/EZH2-mediated methylation of 
lysine 27 in histone H3. Curr Opin Genet Dev 14, 155-164. 
Cardoso, M.C., and Leonhardt, H. (1999). DNA methyltransferase is actively retained 
in the cytoplasm during early development. J Cell Biol 147, 25-32. 
Chamberlain, S.J., Yee, D., and Magnuson, T. (2008). Polycomb repressive complex 2 
is dispensable for maintenance of embryonic stem cell pluripotency. Stem Cells 26, 
1496-1505. 
Chambers, I., Colby, D., Robertson, M., Nichols, J., Lee, S., Tweedie, S., and Smith, 
A. (2003). Functional expression cloning of Nanog, a pluripotency sustaining factor in 
embryonic stem cells. Cell 113, 643-655. 
Chambers, I., and Smith, A. (2004). Self-renewal of teratocarcinoma and embryonic 
stem cells. Oncogene 23, 7150-7160. 
Chambers, I., Silva, J., Colby, D., Nichols, J., Nijmeijer, B., Robertson, M., Vrana, J., 
Jones, K., Grotewold, L., and Smith, A. (2007). Nanog safeguards pluripotency and 
mediates germline development. Nature 450, 1230-1234. 
Chambers, I., and Tomlinson, S.R. (2009). The transcriptional foundation of 
pluripotency. Development 136, 2311-2322. 
Chen, T., Ueda, Y., Dodge, J.E., Wang, Z., and Li, E. (2003). Establishment and 
maintenance of genomic methylation patterns in mouse embryonic stem cells by 
Dnmt3a and Dnmt3b. Mol Cell Biol 23, 5594-5605. 
Chen, Z.-x., and Riggs, A.D. (2011). DNA methylation and demethylation in 
mammals. J Biol Chem 286, 18347-18353. 
Cheutin, T., McNairn, A.J., Jenuwein, T., Gilbert, D.M., Singh, P.B., and Misteli, T. 
(2003). Maintenance of stable heterochromatin domains by dynamic HP1 binding. 
Science 299, 721-725. 
Christman, J.K. (2002). 5-Azacytidine and 5-aza-2'-deoxycytidine as inhibitors of 
DNA methylation: mechanistic studies and their implications for cancer therapy. 
Oncogene 21, 5483-5495. 
Cliffe, L.J., Kieft, R., Southern, T., Birkeland, S.R., Marshall, M., Sweeney, K., and 
Sabatini, R. (2009). JBP1 and JBP2 are two distinct thymidine hydroxylases involved 
in J biosynthesis in genomic DNA of African trypanosomes. Nucleic Acids Res 37, 
1452-1462. 
Cortázar, D., Kunz, C., Selfridge, J., Lettieri, T., Saito, Y., MacDougall, E., Wirz, A., 
Schuermann, D., Jacobs, A.L., Siegrist, F., et al. (2011). Embryonic lethal phenotype 
reveals a function of TDG in maintaining epigenetic stability. Nature 470, 419-423. 
Cortellino, S., Xu, J., Sannai, M., Moore, R., Caretti, E., Cigliano, A., Le Coz, M., 
Devarajan, K., Wessels, A., Soprano, D., et al. (2011). Thymine DNA glycosylase is 
essential for active DNA demethylation by linked deamination-base excision repair. 
Cell 146, 67-79. 
Cowan, C.A., Atienza, J., Melton, D.A., and Eggan, K. (2005). Nuclear 
reprogramming of somatic cells after fusion with human embryonic stem cells. 
Science 309, 1369-1373. 
Craig, J.M. (2005). Heterochromatin--many flavours, common themes. Bioessays 27, 
17-28. 
Daniel, J.A., Pray-Grant, M.G., and Grant, P.A. (2005). Effector proteins for 
methylated histones: an expanding family. Cell Cycle 4, 919-926. 
Davidson, R.L., Ephrussi, B., and Yamamoto, K. (1966). Regulation of pigment 
synthesis in mammalian cells, as studied by somatic hybridization. Proc Natl Acad Sci 
USA 56, 1437-1440. 
 146 
Davis, R.L., Weintraub, H., and Lassar, A.B. (1987). Expression of a single 
transfected cDNA converts fibroblasts to myoblasts. Cell 51, 987-1000. 
Dawlaty, Meelad M., Ganz, K., Powell, Benjamin E., Hu, Y.-C., Markoulaki, S., 
Cheng, Albert W., Gao, Q., Kim, J., Choi, S.-W., Page, David C., and Jaenisch, R. 
(2011). Tet1 Is Dispensable for Maintaining Pluripotency and Its Loss Is Compatible 
with Embryonic and Postnatal Development. Cell stem cell 9, 166-175. 
Deb-Rinker, P., Ly, D., Jezierski, A., Sikorska, M., and Walker, P.R. (2005). 
Sequential DNA methylation of the Nanog and Oct-4 upstream regions in human NT2 
cells during neuronal differentiation. J Biol Chem 280, 6257-6260. 
DeChiara, T.M., Robertson, E.J., and Efstratiadis, A. (1991). Parental imprinting of 
the mouse insulin-like growth factor II gene. Cell 64, 849-859. 
Dillon, N., and Festenstein, R. (2002). Unravelling heterochromatin: competition 
between positive and negative factors regulates accessibility. Trends Genet 18, 252-
258. 
Do, J.T., and Schöler, H.R. (2004). Nuclei of embryonic stem cells reprogram somatic 
cells. Stem Cells 22, 941-949. 
Do, J.T., Han, D.W., Gentile, L., Sobek-Klocke, I., Stehling, M., Lee, H.T., and 
Schöler, H.R. (2007). Erasure of cellular memory by fusion with pluripotent cells. 
Stem Cells 25, 1013-1020. 
Doege, C.A., Inoue, K., Yamashita, T., Rhee, D.B., Travis, S., Fujita, R., Guarnieri, P., 
Bhagat, G., Vanti, W.B., Shih, A., et al. (2012). Early-stage epigenetic modification 
during somatic cell reprogramming by Parp1 and Tet2. Nature. 
Doi, A., Park, I.-H., Wen, B., Murakami, P., Aryee, M.J., Irizarry, R., Herb, B., Ladd-
Acosta, C., Rho, J., Loewer, S., et al. (2009). Differential methylation of tissue- and 
cancer-specific CpG island shores distinguishes human induced pluripotent stem cells, 
embryonic stem cells and fibroblasts. Nat Genet 41, 1350-1353. 
Durcova-Hills, G., Wianny, F., Merriman, J., Zernicka-Goetz, M., and McLaren, A. 
(2003). Developmental fate of embryonic germ cells (EGCs), in vivo and in vitro. 
Differentiation 71, 135-141. 
Durcova-Hills, G., Adams, I.R., Barton, S.C., Surani, M.A., and McLaren, A. (2006). 
The role of exogenous fibroblast growth factor-2 on the reprogramming of primordial 
germ cells into pluripotent stem cells. Stem Cells 24, 1441-1449. 
Edwards, C.A., and Ferguson-Smith, A.C. (2007). Mechanisms regulating imprinted 
genes in clusters. Curr Opin Cell Biol 19, 281-289. 
Egli, D., Birkhoff, G., and Eggan, K. (2008). Mediators of reprogramming: 
transcription factors and transitions through mitosis. Nat Rev Mol Cell Biol 9, 505-
516. 
Eminli, S., Foudi, A., Stadtfeld, M., Maherali, N., Ahfeldt, T., Mostoslavsky, G., 
Hock, H., and Hochedlinger, K. (2009). Differentiation stage determines potential of 
hematopoietic cells for reprogramming into induced pluripotent stem cells. Nat Genet 
41, 968-976. 
Engel, N., Tront, J.S., Erinle, T., Nguyen, N., Latham, K.E., Sapienza, C., Hoffman, 
B., and Liebermann, D.A. (2009). Conserved DNA methylation in Gadd45a(-/-) mice. 
Epigenetics : official journal of the DNA Methylation Society 4, 98-99. 
Erhardt, S., Su, I.-H., Schneider, R., Barton, S., Bannister, A.J., Perez-Burgos, L., 
Jenuwein, T., Kouzarides, T., Tarakhovsky, A., and Surani, M.A. (2003). 
Consequences of the depletion of zygotic and embryonic enhancer of zeste 2 during 
preimplantation mouse development. Development 130, 4235-4248. 
Eskeland, R., Leeb, M., Grimes, G.R., Kress, C., Boyle, S., Sproul, D., Gilbert, N., 
Fan, Y., Skoultchi, A.I., Wutz, A., and Bickmore, W.A. (2010). Ring1B compacts 
 147 
chromatin structure and represses gene expression independent of histone 
ubiquitination. Mol Cell 38, 452-464. 
Faust, C., Lawson, K.A., Schork, N.J., Thiel, B., and Magnuson, T. (1998). The 
Polycomb-group gene eed is required for normal morphogenetic movements during 
gastrulation in the mouse embryo. Development 125, 4495-4506. 
Fazzari, M.J., and Greally, J.M. (2004). Epigenomics: beyond CpG islands. Nat Rev 
Genet 5, 446-455. 
Feldman, N., Gerson, A., Fang, J., Li, E., Zhang, Y., Shinkai, Y., Cedar, H., and 
Bergman, Y. (2006). G9a-mediated irreversible epigenetic inactivation of Oct-3/4 
during early embryogenesis. Nat Cell Biol 8, 188-194. 
Ferguson-Smith, A.C., Cattanach, B.M., Barton, S.C., Beechey, C.V., and Surani, 
M.A. (1991). Embryological and molecular investigations of parental imprinting on 
mouse chromosome 7. Nature 351, 667-670. 
Ferguson-Smith, A.C. (2011). Genomic imprinting: the emergence of an epigenetic 
paradigm. Nat Rev Genet 12, 565-575. 
Festenstein, R., Sharghi-Namini, S., Fox, M., Roderick, K., Tolaini, M., Norton, T., 
Saveliev, A., Kioussis, D., and Singh, P. (1999). Heterochromatin protein 1 modifies 
mammalian PEV in a dose- and chromosomal-context-dependent manner. Nat Genet 
23, 457-461. 
Ficz, G., Branco, M.R., Seisenberger, S., Santos, F., Krueger, F., Hore, T.A., Marques, 
C.J., Andrews, S., and Reik, W. (2011). Dynamic regulation of 5-
hydroxymethylcytosine in mouse ES cells and during differentiation. Nature. 
Fischle, W., Wang, Y., Jacobs, S.A., Kim, Y., Allis, C.D., and Khorasanizadeh, S. 
(2003). Molecular basis for the discrimination of repressive methyl-lysine marks in 
histone H3 by Polycomb and HP1 chromodomains. Genes & Development 17, 1870-
1881. 
Fischle, W., Tseng, B.S., Dormann, H.L., Ueberheide, B.M., Garcia, B.A., 
Shabanowitz, J., Hunt, D.F., Funabiki, H., and Allis, C.D. (2005). Regulation of HP1-
chromatin binding by histone H3 methylation and phosphorylation. Nature 438, 1116-
1122. 
Foshay, K.M., Looney, T.J., Chari, S., Mao, F.F., Lee, J.H., Zhang, L., Fernandes, 
C.J., Baker, S.W., Clift, K.L., Gaetz, J., et al. (2012). Embryonic stem cells induce 
pluripotency in somatic cell fusion through biphasic reprogramming. Mol Cell 46, 
159-170. 
Fougère, C., and Weiss, M.C. (1978). Phenotypic exclusion in mouse melanoma-rat 
hepatoma hybrid cells: pigment and albumin production are not reexpressed 
simultaneously. Cell 15, 843-854. 
Freberg, C.T., Dahl, J.A., Timoskainen, S., and Collas, P. (2007). Epigenetic 
reprogramming of OCT4 and NANOG regulatory regions by embryonal carcinoma 
cell extract. Mol Biol Cell 18, 1543-1553. 
Fujimura, Y.-i., Isono, K.-i., Vidal, M., Endoh, M., Kajita, H., Mizutani-Koseki, Y., 
Takihara, Y., van Lohuizen, M., Otte, A., Jenuwein, T., et al. (2006). Distinct roles of 
Polycomb group gene products in transcriptionally repressed and active domains of 
Hoxb8. Development 133, 2371-2381. 
Ganier, O., Bocquet, S., Peiffer, I., Brochard, V., Arnaud, P., Puy, A., Jouneau, A., 
Feil, R., Renard, J.-P., and Méchali, M. (2011). Synergic reprogramming of 
mammalian cells by combined exposure to mitotic Xenopus egg extracts and 
transcription factors. Proc Natl Acad Sci USA 108, 17331-17336. 
 148 
Gilbert, N., Boyle, S., Fiegler, H., Woodfine, K., Carter, N.P., and Bickmore, W.A. 
(2004). Chromatin architecture of the human genome: gene-rich domains are enriched 
in open chromatin fibers. Cell 118, 555-566. 
Glaser, S., Schaft, J., Lubitz, S., Vintersten, K., van der Hoeven, F., Tufteland, K.R., 
Aasland, R., Anastassiadis, K., Ang, S.-L., and Stewart, A.F. (2006). Multiple 
epigenetic maintenance factors implicated by the loss of Mll2 in mouse development. 
Development 133, 1423-1432. 
Graf, T. (2011). Historical origins of transdifferentiation and reprogramming. Cell 
stem cell 9, 504-516. 
Grant, P.A., Sterner, D.E., Duggan, L.J., Workman, J.L., and Berger, S.L. (1998). The 
SAGA unfolds: convergence of transcription regulators in chromatin-modifying 
complexes. Trends Cell Biol 8, 193-197. 
Grohmann, M., Spada, F., Schermelleh, L., Alenina, N., Bader, M., Cardoso, M.C., 
and Leonhardt, H. (2005). Restricted mobility of Dnmt1 in preimplantation embryos: 
implications for epigenetic reprogramming. BMC Dev Biol 5, 18. 
Gu, P., Le Menuet, D., Chung, A.C.-K., and Cooney, A.J. (2006). Differential 
recruitment of methylated CpG binding domains by the orphan receptor GCNF 
initiates the repression and silencing of Oct4 expression. Mol Cell Biol 26, 9471-9483. 
Gu, T.-P., Guo, F., Yang, H., Wu, H.-P., Xu, G.-F., Liu, W., Xie, Z.-G., Shi, L., He, 
X., Jin, S.-G., et al. (2011). The role of Tet3 DNA dioxygenase in epigenetic 
reprogramming by oocytes. Nature. 
Guibert, S., Forné, T., and Weber, M. (2012). Global profiling of DNA methylation 
erasure in mouse primordial germ cells. Genome Res 22, 633-641. 
Guo, J.U., Su, Y., Zhong, C., Ming, G.-L., and Song, H. (2011). Hydroxylation of 5-
Methylcytosine by TET1 Promotes Active DNA Demethylation in the Adult Brain. 
Cell 145, 423-434. 
Gurdon, J.B. (1962). Adult frogs derived from the nuclei of single somatic cells. . 
Developmental biology. 
Hajkova, P., Erhardt, S., Lane, N., Haaf, T., El-Maarri, O., Reik, W., Walter, J., and 
Surani, M.A. (2002). Epigenetic reprogramming in mouse primordial germ cells. 
Mechanisms of Development 117, 15-23. 
Hajkova, P., Ancelin, K., Waldmann, T., Lacoste, N., Lange, U.C., Cesari, F., Lee, C., 
Almouzni, G., Schneider, R., and Surani, M.A. (2008). Chromatin dynamics during 
epigenetic reprogramming in the mouse germ line. Nature 452, 877-881. 
Hajkova, P., Jeffries, S.J., Lee, C., Miller, N., Jackson, S.P., and Surani, M.A. (2010). 
Genome-wide reprogramming in the mouse germ line entails the base excision repair 
pathway. Science 329, 78-82. 
Halley-Stott, R.P., Pasque, V., Astrand, C., Miyamoto, K., Simeoni, I., Jullien, J., and 
Gurdon, J.B. (2010). Mammalian nuclear transplantation to Germinal Vesicle stage 
Xenopus oocytes - a method for quantitative transcriptional reprogramming. Methods 
51, 56-65. 
Han, D.W., Do, J.T., Gentile, L., Stehling, M., Lee, H.T., and Schöler, H.R. (2008). 
Pluripotential reprogramming of the somatic genome in hybrid cells occurs with the 
first cell cycle. Stem Cells 26, 445-454. 
Hanna, J., Markoulaki, S., Schorderet, P., Carey, B.W., Beard, C., Wernig, M., 
Creyghton, M.P., Steine, E.J., Cassady, J.P., Foreman, R., et al. (2008). Direct 
reprogramming of terminally differentiated mature B lymphocytes to pluripotency. 
Cell 133, 250-264. 
 149 
Hanna, J., Saha, K., Pando, B., van Zon, J., Lengner, C., Creyghton, M., van 
Oudenaarden, A., and Jaenisch, R. (2009). Direct cell reprogramming is a stochastic 
process amenable to acceleration. Nature. 
Hansen, J.C. (2002). Conformational dynamics of the chromatin fiber in solution: 
determinants, mechanisms, and functions. Annu Rev Biophys Biomol Struct 31, 361-
392. 
Hark, A.T., Schoenherr, C.J., Katz, D.J., Ingram, R.S., Levorse, J.M., and Tilghman, 
S.M. (2000). CTCF mediates methylation-sensitive enhancer-blocking activity at the 
H19/Igf2 locus. Nature 405, 486-489. 
Harris, H. (1965). Behaviour of differentiated nuclei in heterokaryons of animal cells  
from different species. Nature. 
Harris, H., Miller, O.J., Klein, G., Worst, P., and Tachibana, T. (1969). Suppression of 
malignancy by cell fusion. Nature. 
Hashimoto, H., Horton, J.R., Zhang, X., Bostick, M., Jacobsen, S.E., and Cheng, X. 
(2008). The SRA domain of UHRF1 flips 5-methylcytosine out of the DNA helix. 
Nature 455, 826-829. 
Hashimoto, H., Liu, Y., Upadhyay, A.K., Chang, Y., Howerton, S.B., Vertino, P.M., 
Zhang, X., and Cheng, X. (2012). Recognition and potential mechanisms for 
replication and erasure of cytosine hydroxymethylation. Nucleic Acids Res. 
Hattori, N., Nishino, K., Ko, Y.-G., Hattori, N., Ohgane, J., Tanaka, S., and Shiota, K. 
(2004). Epigenetic control of mouse Oct-4 gene expression in embryonic stem cells 
and trophoblast stem cells. J Biol Chem 279, 17063-17069. 
Hayashi, K., and Surani, M.A. (2009). Resetting the epigenome beyond pluripotency 
in the germline. Cell stem cell 4, 493-498. 
He, Y.-F., Li, B.-Z., Li, Z., Liu, P., Wang, Y., Tang, Q., Ding, J., Jia, Y., Chen, Z., Li, 
L., et al. (2011). Tet-mediated formation of 5-carboxylcytosine and its excision by 
TDG in mammalian DNA. Science 333, 1303-1307. 
Hendrich, B., Guy, J., Ramsahoye, B., Wilson, V.A., and Bird, A. (2001). Closely 
related proteins MBD2 and MBD3 play distinctive but interacting roles in mouse 
development. Genes & Development 15, 710-723. 
Henikoff, S. (2008). Nucleosome destabilization in the epigenetic regulation of gene 
expression. Nat Rev Genet 9, 15-26. 
Hiragami, K., and Festenstein, R. (2005). Heterochromatin protein 1: a pervasive 
controlling influence. Cell Mol Life Sci 62, 2711-2726. 
Hirota, T., Lipp, J.J., Toh, B.-H., and Peters, J.-M. (2005). Histone H3 serine 10 
phosphorylation by Aurora B causes HP1 dissociation from heterochromatin. Nature 
438, 1176-1180. 
Hochedlinger, K., and Jaenisch, R. (2002). Monoclonal mice generated by nuclear 
transfer from mature B and T donor cells. Nature 415, 1035-1038. 
Huang, Y., Pastor, W.A., Shen, Y., Tahiliani, M., Liu, D.R., and Rao, A. (2010). The 
behaviour of 5-hydroxymethylcytosine in bisulfite sequencing. PLoS ONE 5, e8888. 
Inano, K., Suetake, I., Ueda, T., Miyake, Y., Nakamura, M., Okada, M., and Tajima, 
S. (2000). Maintenance-type DNA methyltransferase is highly expressed in post-
mitotic neurons and localized in the cytoplasmic compartment. J Biochem 128, 315-
321. 
Inoue, A., and Zhang, Y. (2011). Replication-Dependent Loss of 5-
Hydroxymethylcytosine in Mouse Preimplantation Embryos. Science. 
Iqbal, K., Jin, S.-G., Pfeifer, G.P., and Szabó, P.E. (2011). Reprogramming of the 
paternal genome upon fertilization involves genome-wide oxidation of 5-
methylcytosine. Proc Natl Acad Sci USA. 
 150 
Ito, S., D'Alessio, A.C., Taranova, O.V., Hong, K., Sowers, L.C., and Zhang, Y. 
(2010). Role of Tet proteins in 5mC to 5hmC conversion, ES-cell self-renewal and 
inner cell mass specification. Nature 466, 1129-1133. 
Ito, S., Shen, L., Dai, Q., Wu, S.C., Collins, L.B., Swenberg, J.A., He, C., and Zhang, 
Y. (2011). Tet proteins can convert 5-methylcytosine to 5-formylcytosine and 5-
carboxylcytosine. Science 333, 1300-1303. 
Jaenisch, R., and Young, R. (2008). Stem cells, the molecular circuitry of pluripotency 
and nuclear reprogramming. Cell 132, 567-582. 
Jenuwein, T., and Allis, C.D. (2001). Translating the histone code. Science 293, 1074-
1080. 
Jin, S.-G., Guo, C., and Pfeifer, G.P. (2008). GADD45A does not promote DNA 
demethylation. PLoS Genet 4, e1000013. 
Jin, S.-G., Kadam, S., and Pfeifer, G.P. (2010). Examination of the specificity of DNA 
methylation profiling techniques towards 5-methylcytosine and 5-
hydroxymethylcytosine. Nucleic Acids Res 38, e125. 
John, R.M., and Lefebvre, L. (2011). Developmental regulation of somatic imprints. 
Differentiation 81, 270-280. 
Jørgensen, H.F., Azuara, V., Amoils, S., Spivakov, M., Terry, A., Nesterova, T., Cobb, 
B.S., Ramsahoye, B., Merkenschlager, M., and Fisher, A.G. (2007). The impact of 
chromatin modifiers on the timing of locus replication in mouse embryonic stem cells. 
Genome Biol 8, R169. 
Junker, S., and Pedersen, S. (1985). Time course of arrest of immunoglobulin  
expression in heterokaryons and early hybrids of human lymphoma cells and  
mouse fibroblasts. A study of transcriptional and translational events. Exp Cell Res. 
158(2), 349-359. 
Kang, Y.K., Koo, D.B., Park, J.S., Choi, Y.H., Chung, A.S., Lee, K.K., and Han, Y.M. 
(2001). Aberrant methylation of donor genome in cloned bovine embryos. Nat Genet 
28, 173-177. 
Kangaspeska, S., Stride, B., Métivier, R., Polycarpou-Schwarz, M., Ibberson, D., 
Carmouche, R.P., Benes, V., Gannon, F., and Reid, G. (2008). Transient cyclical 
methylation of promoter DNA. Nature 452, 112-115. 
Keen, N., and Taylor, S. (2009). Mitotic drivers--inhibitors of the Aurora B Kinase. 
Cancer Metastasis Rev 28, 185-195. 
Kim, M.-S., Kondo, T., Takada, I., Youn, M.-Y., Yamamoto, Y., Takahashi, S., 
Matsumoto, T., Fujiyama, S., Shirode, Y., Yamaoka, I., et al. (2009). DNA 
demethylation in hormone-induced transcriptional derepression. Nature 461, 1007-
1012. 
Klose, R.J., and Bird, A.P. (2006). Genomic DNA methylation: the mark and its 
mediators. Trends Biochem Sci 31, 89-97. 
Klose, R.J., and Zhang, Y. (2007). Regulation of histone methylation by 
demethylimination and demethylation. Nat Rev Mol Cell Biol 8, 307-318. 
Knezetic, J.A., and Luse, D.S. (1986). The presence of nucleosomes on a DNA 
template prevents initiation by RNA polymerase II in vitro. Cell 45, 95-104. 
Koch, C.M., Andrews, R.M., Flicek, P., Dillon, S.C., Karaöz, U., Clelland, G.K., 
Wilcox, S., Beare, D.M., Fowler, J.C., Couttet, P., et al. (2007). The landscape of 
histone modifications across 1% of the human genome in five human cell lines. 
Genome Res 17, 691-707. 
Koerner, M.V., and Barlow, D.P. (2010). Genomic imprinting-an epigenetic gene-
regulatory model. Curr Opin Genet Dev 20, 164-170. 
 151 
Koh, K.P., Yabuuchi, A., Rao, S., Huang, Y., Cunniff, K., Nardone, J., Laiho, A., 
Tahiliani, M., Sommer, C.A., Mostoslavsky, G., et al. (2011). Tet1 and tet2 regulate 5-
hydroxymethylcytosine production and cell lineage specification in mouse embryonic 
stem cells. Cell stem cell 8, 200-213. 
Köhler G, and C., M. (1975). Continuous cultures of fused cells secreting antibody of 
predefined specificity. Nature. 
Kopp, J.L., Ormsbee, B.D., Desler, M., and Rizzino, A. (2008). Small increases in the 
level of Sox2 trigger the differentiation of mouse embryonic stem cells. Stem Cells 26, 
903-911. 
Kosak, S.T., Skok, J.A., Medina, K.L., Riblet, R., Le Beau, M.M., Fisher, A.G., and 
Singh, H. (2002). Subnuclear compartmentalization of immunoglobulin loci during 
lymphocyte development. Science 296, 158-162. 
Kouzarides, T. (2007). Chromatin modifications and their function. Cell 128, 693-705. 
Koziol, M.J., Garrett, N., and Gurdon, J.B. (2007). Tpt1 activates transcription of oct4 
and nanog in transplanted somatic nuclei. Curr Biol 17, 801-807. 
Kriaucionis, S., and Heintz, N. (2009). The nuclear DNA base 5-
hydroxymethylcytosine is present in Purkinje neurons and the brain. Science 324, 929-
930. 
Ku, M., Koche, R.P., Rheinbay, E., Mendenhall, E.M., Endoh, M., Mikkelsen, T.S., 
Presser, A., Nusbaum, C., Xie, X., Chi, A.S., et al. (2008). Genomewide analysis of 
PRC1 and PRC2 occupancy identifies two classes of bivalent domains. PLoS Genet 4, 
e1000242. 
Kurisaki, A., Hamazaki, T.S., Okabayashi, K., Iida, T., Nishine, T., Chonan, R., Kido, 
H., Tsunasawa, S., Nishimura, O., Asashima, M., and Sugino, H. (2005). Chromatin-
related proteins in pluripotent mouse embryonic stem cells are downregulated after 
removal of leukemia inhibitory factor. Biochem Biophys Res Commun 335, 667-675. 
Kuzmichev, A., Nishioka, K., Erdjument-Bromage, H., Tempst, P., and Reinberg, D. 
(2002). Histone methyltransferase activity associated with a human multiprotein 
complex containing the Enhancer of Zeste protein. Genes & Development 16, 2893-
2905. 
Labosky, P.A., Barlow, D.P., and Hogan, B.L. (1994). Mouse embryonic germ (EG) 
cell lines: transmission through the germline and differences in the methylation 
imprint of insulin-like growth factor 2 receptor (Igf2r) gene compared with embryonic 
stem (ES) cell lines. Development 120, 3197-3204. 
Lachner, M., O'Carroll, D., Rea, S., Mechtler, K., and Jenuwein, T. (2001). 
Methylation of histone H3 lysine 9 creates a binding site for HP1 proteins. Nature 410, 
116-120. 
Lal, G., Zhang, N., van der Touw, W., Ding, Y., Ju, W., Bottinger, E.P., Reid, S.P., 
Levy, D.E., and Bromberg, J.S. (2009). Epigenetic regulation of Foxp3 expression in 
regulatory T cells by DNA methylation. J Immunol 182, 259-273. 
Landeira, D., Sauer, S., Poot, R., Dvorkina, M., Mazzarella, L., Jørgensen, H.F., 
Pereira, C.F., Leleu, M., Piccolo, F.M., Spivakov, M., et al. (2010). Jarid2 is a PRC2 
component in embryonic stem cells required for multi-lineage differentiation and 
recruitment of PRC1 and RNA Polymerase II to developmental regulators. Nat Cell 
Biol. 
Landeira, D., and Fisher, A.G. (2011). Inactive yet indispensable: the tale of Jarid2. 
Trends Cell Biol 21, 74-80. 
Lefebvre, L., Viville, S., Barton, S.C., Ishino, F., Keverne, E.B., and Surani, M.A. 
(1998). Abnormal maternal behaviour and growth retardation associated with loss of 
the imprinted gene Mest. Nat Genet 20, 163-169. 
 152 
Lehnertz, B., Ueda, Y., Derijck, A.A.H.A., Braunschweig, U., Perez-Burgos, L., 
Kubicek, S., Chen, T., Li, E., Jenuwein, T., and Peters, A.H.F.M. (2003). Suv39h-
mediated histone H3 lysine 9 methylation directs DNA methylation to major satellite 
repeats at pericentric heterochromatin. Curr Biol 13, 1192-1200. 
Leitch, H.G., Blair, K., Mansfield, W., Ayetey, H., Humphreys, P., Nichols, J., Surani, 
M.A., and Smith, A. (2010). Embryonic germ cells from mice and rats exhibit 
properties consistent with a generic pluripotent ground state. Development. 
Lemaitre, J.-M., Danis, E., Pasero, P., Vassetzky, Y., and Méchali, M. (2005). Mitotic 
remodeling of the replicon and chromosome structure. Cell 123, 787-801. 
Leonhardt, H., Page, A.W., Weier, H.U., and Bestor, T.H. (1992). A targeting 
sequence directs DNA methyltransferase to sites of DNA replication in mammalian 
nuclei. Cell 71, 865-873. 
Levine, S.S., King, I.F.G., and Kingston, R.E. (2004). Division of labor in polycomb 
group repression. Trends Biochem Sci 29, 478-485. 
Li, B., Carey, M., and Workman, J.L. (2007a). The role of chromatin during 
transcription. Cell 128, 707-719. 
Li, E., Bestor, T.H., and Jaenisch, R. (1992). Targeted mutation of the DNA 
methyltransferase gene results in embryonic lethality. Cell 69, 915-926. 
Li, J.-Y., Pu, M.-T., Hirasawa, R., Li, B.-Z., Huang, Y.-N., Zeng, R., Jing, N.-H., 
Chen, T., Li, E., Sasaki, H., and Xu, G.-L. (2007b). Synergistic function of DNA 
methyltransferases Dnmt3a and Dnmt3b in the methylation of Oct4 and Nanog. Mol 
Cell Biol 27, 8748-8759. 
Li, X., Ito, M., Zhou, F., Youngson, N., Zuo, X., Leder, P., and Ferguson-Smith, A.C. 
(2008). A maternal-zygotic effect gene, Zfp57, maintains both maternal and paternal 
imprints. Dev Cell 15, 547-557. 
Li, Z., Cai, X., Cai, C.-L., Wang, J., Zhang, W., Petersen, B.E., Yang, F.-C., and Xu, 
M. (2011). Deletion of Tet2 in mice leads to dysregulated hematopoietic stem cells 
and subsequent development of myeloid malignancies. Blood 118, 4509-4518. 
Liang, G., Chan, M.F., Tomigahara, Y., Tsai, Y.C., Gonzales, F.A., Li, E., Laird, 
P.W., and Jones, P.A. (2002). Cooperativity between DNA methyltransferases in the 
maintenance methylation of repetitive elements. Mol Cell Biol 22, 480-491. 
Liutkeviciute, Z., Lukinavicius, G., Masevicius, V., Daujotyte, D., and Klimasauskas, 
S. (2009). Cytosine-5-methyltransferases add aldehydes to DNA. Nat Chem Biol 5, 
400-402. 
Lodén, M., and van Steensel, B. (2005). Whole-genome views of chromatin structure. 
Chromosome Res 13, 289-298. 
Loh, Y.-H., Wu, Q., Chew, J.-L., Vega, V.B., Zhang, W., Chen, X., Bourque, G., 
George, J., Leong, B., Liu, J., et al. (2006). The Oct4 and Nanog transcription network 
regulates pluripotency in mouse embryonic stem cells. Nat Genet 38, 431-440. 
Lomvardas, S., Barnea, G., Pisapia, D.J., Mendelsohn, M., Kirkland, J., and Axel, R. 
(2006). Interchromosomal interactions and olfactory receptor choice. Cell 126, 403-
413. 
Lorsbach, R.B., Moore, J., Mathew, S., Raimondi, S.C., Mukatira, S.T., and Downing, 
J.R. (2003). TET1, a member of a novel protein family, is fused to MLL in acute 
myeloid leukemia containing the t(10;11)(q22;q23). Leukemia 17, 637-641. 
Luger, K., Mäder, A.W., Richmond, R.K., Sargent, D.F., and Richmond, T.J. (1997). 
Crystal structure of the nucleosome core particle at 2.8 A resolution. Nature 389, 251-
260. 
Ma, D.K., Jang, M.-H., Guo, J.U., Kitabatake, Y., Chang, M.-L., Pow-Anpongkul, N., 
Flavell, R.A., Lu, B., Ming, G.-L., and Song, H. (2009). Neuronal activity-induced 
 153 
Gadd45b promotes epigenetic DNA demethylation and adult neurogenesis. Science 
323, 1074-1077. 
Maiti, A., and Drohat, A.C. (2011). Thymine DNA glycosylase can rapidly excise 5-
formylcytosine and 5-carboxylcytosine: potential implications for active 
demethylation of CpG sites. J Biol Chem 286, 35334-35338. 
Maresca, T.J., and Heald, R. (2006). The long and the short of it: linker histone H1 is 
required for metaphase chromosome compaction. Cell Cycle 5, 589-591. 
Margueron, R., Li, G., Sarma, K., Blais, A., Zavadil, J., Woodcock, C.L., Dynlacht, 
B.D., and Reinberg, D. (2008). Ezh1 and Ezh2 maintain repressive chromatin through 
different mechanisms. Mol Cell 32, 503-518. 
Margueron, R., and Reinberg, D. (2011). The Polycomb complex PRC2 and its mark 
in life. Nature 469, 343-349. 
Martin, C., and Zhang, Y. (2005). The diverse functions of histone lysine methylation. 
Nat Rev Mol Cell Biol 6, 838-849. 
Martin, S., and Pombo, A. (2003). Transcription factories: quantitative studies of 
nanostructures in the mammalian nucleus. Chromosome Res 11, 461-470. 
Massa, S., Junker, S., and Matthias, P. (2000). Molecular mechanisms of extinction: 
old findings and new ideas. Int J Biochem Cell Biol 32, 23-40. 
Masui, S., Nakatake, Y., Toyooka, Y., Shimosato, D., Yagi, R., Takahashi, K., 
Okochi, H., Okuda, A., Matoba, R., Sharov, A.A., et al. (2007). Pluripotency governed 
by Sox2 via regulation of Oct3/4 expression in mouse embryonic stem cells. Nat Cell 
Biol 9, 625-635. 
Mayer, W., Niveleau, A., Walter, J., Fundele, R., and Haaf, T. (2000). Demethylation 
of the zygotic paternal genome. Nature 403, 501-502. 
Mazzarella, L., Jørgensen, H.F., Soza-Ried, J., Terry, A.V., Pearson, S., Lacaud, G., 
Kouskoff, V., Merkenschlager, M., and Fisher, A.G. (2011). Embryonic stem cell-
derived hemangioblasts remain epigenetically plastic and require PRC1 to prevent 
neural gene expression. Blood 117, 83-87. 
McGrath J, and D., S. (1983). Nuclear transplantation in mouse embryos. J Exp Zool. 
228(2), 355-362. 
Meissner, A., and Jaenisch, R. (2006). Mammalian nuclear transfer. Dev Dyn 235, 
2460-2469. 
Mertineit, C., Yoder, J.A., Taketo, T., Laird, D.W., Trasler, J.M., and Bestor, T.H. 
(1998). Sex-specific exons control DNA methyltransferase in mammalian germ cells. 
Development 125, 889-897. 
Meshorer, E., and Misteli, T. (2006). Chromatin in pluripotent embryonic stem cells 
and differentiation. Nat Rev Mol Cell Biol 7, 540-546. 
Meshorer, E., Yellajoshula, D., George, E., Scambler, P.J., Brown, D.T., and Misteli, 
T. (2006). Hyperdynamic plasticity of chromatin proteins in pluripotent embryonic 
stem cells. Dev Cell 10, 105-116. 
Metcalf, D. (2003). The unsolved enigmas of leukemia inhibitory factor. Stem Cells 
21, 5-14. 
Métivier, R., Gallais, R., Tiffoche, C., Le Péron, C., Jurkowska, R.Z., Carmouche, 
R.P., Ibberson, D., Barath, P., Demay, F., Reid, G., et al. (2008). Cyclical DNA 
methylation of a transcriptionally active promoter. Nature 452, 45-50. 
Mével-Ninio M, and MC., W. (1981). Immunofluorescence analysis of the time-
course of extinction, reexpression, and activation of albumin production in rat 
hepatoma-mouse fibroblast heterokaryons and hybrids. J Cell Biol. . 
Mikkelsen, T.S., Ku, M., Jaffe, D.B., Issac, B., Lieberman, E., Giannoukos, G., 
Alvarez, P., Brockman, W., Kim, T.-K., Koche, R.P., et al. (2007). Genome-wide 
 154 
maps of chromatin state in pluripotent and lineage-committed cells. Nature 448, 553-
560. 
Mikkelsen, T.S., Hanna, J., Zhang, X., Ku, M., Wernig, M., Schorderet, P., Bernstein, 
B.E., Jaenisch, R., Lander, E.S., and Meissner, A. (2008). Dissecting direct 
reprogramming through integrative genomic analysis. Nature 454, 49-55. 
Misteli, T. (2007). Beyond the sequence: cellular organization of genome function. 
Cell 128, 787-800. 
Mitsui, K., Tokuzawa, Y., Itoh, H., Segawa, K., Murakami, M., Takahashi, K., 
Maruyama, M., Maeda, M., and Yamanaka, S. (2003). The homeoprotein Nanog is 
required for maintenance of pluripotency in mouse epiblast and ES cells. Cell 113, 
631-642. 
Morgan, H.D., Santos, F., Green, K., Dean, W., and Reik, W. (2005). Epigenetic 
reprogramming in mammals. Hum Mol Genet 14 Spec No 1, R47-58. 
Morin-Kensicki, E.M., Faust, C., LaMantia, C., and Magnuson, T. (2001). Cell and 
tissue requirements for the gene eed during mouse gastrulation and organogenesis. 
Genesis 31, 142-146. 
Muller, H.J., and Altenburg, E. (1930). The Frequency of Translocations Produced by 
X-Rays in Drosophila. Genetics 15, 283-311. 
Münzel, M., Globisch, D., and Carell, T. (2011). 5-hydroxymethylcytosine, the sixth 
base of the genome. Angew Chem Int Ed Engl 50, 6460-6468. 
Muramatsu, M., Kinoshita, K., Fagarasan, S., Yamada, S., Shinkai, Y., and Honjo, T. 
(2000). Class switch recombination and hypermutation require activation-induced 
cytidine deaminase (AID), a potential RNA editing enzyme. Cell 102, 553-563. 
Murata, K., Kouzarides, T., Bannister, A.J., and Gurdon, J.B. (2010). Histone H3 
lysine 4 methylation is associated with the transcriptional reprogramming efficiency of 
somatic nuclei by oocytes. Epigenetics Chromatin 3, 4. 
Murrell, A., Heeson, S., and Reik, W. (2004). Interaction between differentially 
methylated regions partitions the imprinted genes Igf2 and H19 into parent-specific 
chromatin loops. Nat Genet 36, 889-893. 
Nakamura, T., Arai, Y., Umehara, H., Masuhara, M., Kimura, T., Taniguchi, H., 
Sekimoto, T., Ikawa, M., Yoneda, Y., Okabe, M., et al. (2007). PGC7/Stella protects 
against DNA demethylation in early embryogenesis. Nat Cell Biol 9, 64-71. 
Nakamura, T., Liu, Y.-J., Nakashima, H., Umehara, H., Inoue, K., Matoba, S., 
Tachibana, M., Ogura, A., Shinkai, Y., and Nakano, T. (2012). PGC7 binds histone 
H3K9me2 to protect against conversion of 5mC to 5hmC in early embryos. Nature 
486, 415-419. 
Nichols, J., Chambers, I., Taga, T., and Smith, A. (2001). Physiological rationale for 
responsiveness of mouse embryonic stem cells to gp130 cytokines. Development 128, 
2333-2339. 
Niwa, H., Burdon, T., Chambers, I., and Smith, A. (1998). Self-renewal of pluripotent 
embryonic stem cells is mediated via activation of STAT3. Genes & Development 12, 
2048-2060. 
Niwa, H., Miyazaki, J., and Smith, A.G. (2000). Quantitative expression of Oct-3/4 
defines differentiation, dedifferentiation or self-renewal of ES cells. Nat Genet 24, 
372-376. 
Niwa, H., Toyooka, Y., Shimosato, D., Strumpf, D., Takahashi, K., Yagi, R., and 
Rossant, J. (2005). Interaction between Oct3/4 and Cdx2 determines trophectoderm 
differentiation. Cell 123, 917-929. 
Nutt, S.L., Heavey, B., Rolink, A.G., and Busslinger, M. (1999). Commitment to the 
B-lymphoid lineage depends on the transcription factor Pax5. Nature 401, 556-562. 
 155 
O'Carroll, D., Erhardt, S., Pagani, M., Barton, S.C., Surani, M.A., and Jenuwein, T. 
(2001). The polycomb-group gene Ezh2 is required for early mouse development. Mol 
Cell Biol 21, 4330-4336. 
Ohinata, Y., Payer, B., O'Carroll, D., Ancelin, K., Ono, Y., Sano, M., Barton, S.C., 
Obukhanych, T., Nussenzweig, M., Tarakhovsky, A., et al. (2005). Blimp1 is a critical 
determinant of the germ cell lineage in mice. Nature 436, 207-213. 
Ohinata, Y., Ohta, H., Shigeta, M., Yamanaka, K., Wakayama, T., and Saitou, M. 
(2009). A signaling principle for the specification of the germ cell lineage in mice. 
Cell 137, 571-584. 
Okada, Y., Yamagata, K., Hong, K., Wakayama, T., and Zhang, Y. (2010). A role for 
the elongator complex in zygotic paternal genome demethylation. Nature 463, 554-
558. 
Okano, M., Bell, D.W., Haber, D.A., and Li, E. (1999). DNA methyltransferases 
Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian 
development. Cell 99, 247-257. 
Ooi, S.K.T., and Bestor, T.H. (2008). The colorful history of active DNA 
demethylation. Cell 133, 1145-1148. 
Orlando, V., and Paro, R. (1995). Chromatin multiprotein complexes involved in the 
maintenance of transcription patterns. Curr Opin Genet Dev 5, 174-179. 
Oswald, J., Engemann, S., Lane, N., Mayer, W., Olek, A., Fundele, R., Dean, W., 
Reik, W., and Walter, J. (2000). Active demethylation of the paternal genome in the 
mouse zygote. Curr Biol 10, 475-478. 
Pandey, R.R., Mondal, T., Mohammad, F., Enroth, S., Redrup, L., Komorowski, J., 
Nagano, T., Mancini-Dinardo, D., and Kanduri, C. (2008). Kcnq1ot1 antisense 
noncoding RNA mediates lineage-specific transcriptional silencing through 
chromatin-level regulation. Mol Cell 32, 232-246. 
Pasini, D., Bracken, A.P., Jensen, M.R., Lazzerini Denchi, E., and Helin, K. (2004). 
Suz12 is essential for mouse development and for EZH2 histone methyltransferase 
activity. EMBO J 23, 4061-4071. 
Pasque, V., Jullien, J., Miyamoto, K., Halley-Stott, R.P., and Gurdon, J.B. (2011). 
Epigenetic factors influencing resistance to nuclear reprogramming. Trends Genet. 
Patterton, D., and Wolffe, A.P. (1996). Developmental roles for chromatin and 
chromosomal structure. Dev Biol 173, 2-13. 
Pavri, R., Zhu, B., Li, G., Trojer, P., Mandal, S., Shilatifard, A., and Reinberg, D. 
(2006a). Histone H2B Monoubiquitination Functions Cooperatively with FACT to 
Regulate Elongation by RNA Polymerase II. Cell 125, 703-717. 
Pavri, R., Zhu, B., Li, G., Trojer, P., Mandal, S., Shilatifard, A., and Reinberg, D. 
(2006b). Histone H2B monoubiquitination functions cooperatively with FACT to 
regulate elongation by RNA polymerase II. Cell 125, 703-717. 
Pazin, M.J., and Kadonaga, J.T. (1997). What's up and down with histone 
deacetylation and transcription? Cell 89, 325-328. 
Penn NW, Suwalski R, O'Riley C, Bojanowski K, and R, Y. (1972). The presence of 
5-hydroxymethylcytosine in animal deoxyribonucleic acid. Biochem J 26(4), 781-790. 
Pereira, C.F., Terranova, R., Ryan, N.K., Santos, J., Morris, K.J., Cui, W., 
Merkenschlager, M., and Fisher, A.G. (2008). Heterokaryon-based reprogramming of 
human B lymphocytes for pluripotency requires Oct4 but not Sox2. PLoS Genet 4, 
e1000170. 
Pereira, C.F., and Fisher, A.G. (2009). Current Protocols in Stem Cell Biology. 1-14. 
Pereira, C.F., Piccolo, F.M., Tsubouchi, T., Sauer, S., Ryan, N.K., Bruno, L., 
Landeira, D., Santos, J., Banito, A., Gil, J., et al. (2010). ESCs require PRC2 to direct 
 156 
the successful reprogramming of differentiated cells toward pluripotency. Cell stem 
cell 6, 547-556. 
Peric-Hupkes, D., Meuleman, W., Pagie, L., Bruggeman, S.W.M., Solovei, I., 
Brugman, W., Gräf, S., Flicek, P., Kerkhoven, R.M., van Lohuizen, M., et al. (2010). 
Molecular maps of the reorganization of genome-nuclear lamina interactions during 
differentiation. Mol Cell 38, 603-613. 
Peters, A.H.F.M., and Schübeler, D. (2005). Methylation of histones: playing memory 
with DNA. Curr Opin Cell Biol 17, 230-238. 
Peterson, C.L., and Laniel, M.-A. (2004). Histones and histone modifications. Curr 
Biol 14, R546-551. 
Piccolo, F.M., Pereira, C.F., Cantone, I., Brown, K., Tsubouchi, T., Soza-Ried, J., 
Merkenschlager, M., and Fisher, A.G. (2011). Using heterokaryons to understand 
pluripotency and reprogramming. Philos Trans R Soc Lond, B, Biol Sci 366, 2260-
2265. 
Popp, C., Dean, W., Feng, S., Cokus, S.J., Andrews, S., Pellegrini, M., Jacobsen, S.E., 
and Reik, W. (2010). Genome-wide erasure of DNA methylation in mouse primordial 
germ cells is affected by AID deficiency. Nature. 
Portela, A., and Esteller, M. (2010). Epigenetic modifications and human disease. Nat 
Biotechnol 28, 1057-1068. 
Pownall, M.E., Gustafsson, M.K., and Emerson, C.P. (2002). Myogenic regulatory 
factors and the specification of muscle progenitors in vertebrate embryos. Annu Rev 
Cell Dev Biol 18, 747-783. 
Pray-Grant, M.G., Daniel, J.A., Schieltz, D., Yates, J.R., and Grant, P.A. (2005). Chd1 
chromodomain links histone H3 methylation with SAGA- and SLIK-dependent 
acetylation. Nature 433, 434-438. 
Rai, K., Huggins, I.J., James, S.R., Karpf, A.R., Jones, D.A., and Cairns, B.R. (2008). 
DNA demethylation in zebrafish involves the coupling of a deaminase, a glycosylase, 
and gadd45. Cell 135, 1201-1212. 
Ramchandani, S., Bhattacharya, S.K., Cervoni, N., and Szyf, M. (1999). DNA 
methylation is a reversible biological signal. Proc Natl Acad Sci USA 96, 6107-6112. 
Rao, P., and Johnson, R. (1970). Mammalian cell fusion: studies on the regulation of 
DNA synthesis and mitosis. Nature 10;225(5228), 159-164. 
Ratnam, S., Mertineit, C., Ding, F., Howell, C.Y., Clarke, H.J., Bestor, T.H., Chaillet, 
J.R., and Trasler, J.M. (2002). Dynamics of Dnmt1 methyltransferase expression and 
intracellular localization during oogenesis and preimplantation development. Dev Biol 
245, 304-314. 
Rea, S., Eisenhaber, F., O'Carroll, D., Strahl, B.D., Sun, Z.W., Schmid, M., Opravil, 
S., Mechtler, K., Ponting, C.P., Allis, C.D., and Jenuwein, T. (2000). Regulation of 
chromatin structure by site-specific histone H3 methyltransferases. Nature 406, 593-
599. 
Reik, W., and Dean, W. (2001). DNA methylation and mammalian epigenetics. 
Electrophoresis 22, 2838-2843. 
Ringrose, L., and Paro, R. (2004). Epigenetic regulation of cellular memory by the 
Polycomb and Trithorax group proteins. Annual review of genetics 38, 413-443. 
Rossant, J. (2001). Stem cells from the Mammalian blastocyst. Stem Cells 19, 477-
482. 
Rottach, A., Frauer, C., Pichler, G., Bonapace, I.M., Spada, F., and Leonhardt, H. 
(2010). The multi-domain protein Np95 connects DNA methylation and histone 
modification. Nucleic Acids Res 38, 1796-1804. 
 157 
Sabbattini, P., Canzonetta, C., Sjoberg, M., Nikic, S., Georgiou, A., Kemball-Cook, 
G., Auner, H.W., and Dillon, N. (2007). A novel role for the Aurora B kinase in 
epigenetic marking of silent chromatin in differentiated postmitotic cells. EMBO J 26, 
4657-4669. 
Sabo, P.J., Humbert, R., Hawrylycz, M., Wallace, J.C., Dorschner, M.O., McArthur, 
M., and Stamatoyannopoulos, J.A. (2004). Genome-wide identification of DNaseI 
hypersensitive sites using active chromatin sequence libraries. Proc Natl Acad Sci 
USA 101, 4537-4542. 
Saha, A., Wittmeyer, J., and Cairns, B.R. (2006). Chromatin remodelling: the 
industrial revolution of DNA around histones. Nat Rev Mol Cell Biol 7, 437-447. 
Santos, F., Hendrich, B., Reik, W., and Dean, W. (2002). Dynamic reprogramming of 
DNA methylation in the early mouse embryo. Dev Biol 241, 172-182. 
Schoeftner, S., Sengupta, A.K., Kubicek, S., Mechtler, K., Spahn, L., Koseki, H., 
Jenuwein, T., and Wutz, A. (2006). Recruitment of PRC1 function at the initiation of 
X inactivation independent of PRC2 and silencing. EMBO J 25, 3110-3122. 
Schones, D.E., Cui, K., Cuddapah, S., Roh, T.-Y., Barski, A., Wang, Z., Wei, G., and 
Zhao, K. (2008). Dynamic regulation of nucleosome positioning in the human 
genome. Cell 132, 887-898. 
Schuettengruber, B., and Cavalli, G. (2009). Recruitment of polycomb group 
complexes and their role in the dynamic regulation of cell fate choice. Development 
136, 3531-3542. 
Scott, J. (1995). A place in the world for RNA editing. Cell 81, 833-836. 
Seki, Y., Hayashi, K., Itoh, K., Mizugaki, M., Saitou, M., and Matsui, Y. (2005). 
Extensive and orderly reprogramming of genome-wide chromatin modifications 
associated with specification and early development of germ cells in mice. Dev Biol 
278, 440-458. 
Seki, Y., Yamaji, M., Yabuta, Y., Sano, M., Shigeta, M., Matsui, Y., Saga, Y., 
Tachibana, M., Shinkai, Y., and Saitou, M. (2007). Cellular dynamics associated with 
the genome-wide epigenetic reprogramming in migrating primordial germ cells in 
mice. Development 134, 2627-2638. 
Shovlin, T.C., Durcova-Hills, G., Surani, A., and McLaren, A. (2008). Heterogeneity 
in imprinted methylation patterns of pluripotent embryonic germ cells derived from 
pre-migratory mouse germ cells. Dev Biol 313, 674-681. 
Silva, J., Chambers, I., Pollard, S., and Smith, A. (2006). Nanog promotes transfer of 
pluripotency after cell fusion. Nature 441, 997-1001. 
Silva, J., and Smith, A. (2008). Capturing pluripotency. Cell 132, 532-536. 
Simonis, M., Klous, P., Splinter, E., Moshkin, Y., Willemsen, R., de Wit, E., van 
Steensel, B., and de Laat, W. (2006). Nuclear organization of active and inactive 
chromatin domains uncovered by chromosome conformation capture-on-chip (4C). 
Nat Genet 38, 1348-1354. 
Simonsson, S., and Gurdon, J. (2004). DNA demethylation is necessary for the 
epigenetic reprogramming of somatic cell nuclei. Nat Cell Biol 6, 984-990. 
Sims, R.J., Chen, C.-F., Santos-Rosa, H., Kouzarides, T., Patel, S.S., and Reinberg, D. 
(2005). Human but not yeast CHD1 binds directly and selectively to histone H3 
methylated at lysine 4 via its tandem chromodomains. J Biol Chem 280, 41789-41792. 
Spivakov, M., and Fisher, A.G. (2007). Epigenetic signatures of stem-cell identity. Nat 
Rev Genet 8, 263-271. 
Spotswood, H.T., and Turner, B.M. (2002). An increasingly complex code. J Clin 
Invest 110, 577-582. 
 158 
Stock, J.K., Giadrossi, S., Casanova, M., Brookes, E., Vidal, M., Koseki, H., 
Brockdorff, N., Fisher, A.G., and Pombo, A. (2007). Ring1-mediated ubiquitination of 
H2A restrains poised RNA polymerase II at bivalent genes in mouse ES cells. Nat Cell 
Biol 9, 1428-1435. 
Suetake, I., Shinozaki, F., Miyagawa, J., Takeshima, H., and Tajima, S. (2004). 
DNMT3L stimulates the DNA methylation activity of Dnmt3a and Dnmt3b through a 
direct interaction. J Biol Chem 279, 27816-27823. 
Sugimoto, M., and Abe, K. (2007). X chromosome reactivation initiates in nascent 
primordial germ cells in mice. PLoS Genet 3, e116. 
Surani, M.A. (2001). Reprogramming of genome function through epigenetic 
inheritance. Nature 414, 122-128. 
Surani, M.A., Hayashi, K., and Hajkova, P. (2007). Genetic and epigenetic regulators 
of pluripotency. Cell 128, 747-762. 
Surani, M.A., and Hajkova, P. (2010). Epigenetic Reprogramming of Mouse Germ 
Cells toward Totipotency. Cold Spring Harb Symp Quant Biol. 
Surani MA, and SC., B. (1983). Development of gynogenetic eggs in the mouse: 
implications for parthenogenetic embryos. Science 2, 1034-1036. 
Surani MA, Barton SC, and ML., N. (1984). Development of reconstituted mouse eggs 
suggests imprinting of the genome during gametogenesis. Nature 308(5959), 548-550. 
Suzuki, M.M., and Bird, A. (2008). DNA methylation landscapes: provocative insights 
from epigenomics. Nat Rev Genet 9, 465-476. 
Szulwach, K.E., Li, X., Li, Y., Song, C.-X., Wu, H., Dai, Q., Irier, H., Upadhyay, 
A.K., Gearing, M., Levey, A.I., et al. (2011). 5-hmC-mediated epigenetic dynamics 
during postnatal neurodevelopment and aging. Nat Neurosci. 
Szutorisz, H., Canzonetta, C., Georgiou, A., Chow, C.-M., Tora, L., and Dillon, N. 
(2005). Formation of an active tissue-specific chromatin domain initiated by 
epigenetic marking at the embryonic stem cell stage. Mol Cell Biol 25, 1804-1820. 
Tada, M., Tada, T., Lefebvre, L., Barton, S.C., and Surani, M.A. (1997). Embryonic 
germ cells induce epigenetic reprogramming of somatic nucleus in hybrid cells. 
EMBO J 16, 6510-6520. 
Tada, M., Takahama, Y., Abe, K., Nakatsuji, N., and Tada, T. (2001). Nuclear 
reprogramming of somatic cells by in vitro hybridization with ES cells. Curr Biol 11, 
1553-1558. 
Tada, T., Tada, M., Hilton, K., Barton, S.C., Sado, T., Takagi, N., and Surani, M.A. 
(1998). Epigenotype switching of imprintable loci in embryonic germ cells. Dev 
Genes Evol 207, 551-561. 
Tahiliani, M., Koh, K.P., Shen, Y., Pastor, W.A., Bandukwala, H., Brudno, Y., 
Agarwal, S., Iyer, L.M., Liu, D.R., Aravind, L., and Rao, A. (2009). Conversion of 5-
methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner 
TET1. Science 324, 930-935. 
Tavares, L., Dimitrova, E., Oxley, D., Webster, J., Poot, R., Demmers, J., Bezstarosti, 
K., Taylor, S., Ura, H., Koide, H., et al. (2012). RYBP-PRC1 complexes mediate H2A 
ubiquitylation at polycomb target sites independently of PRC2 and H3K27me3. Cell 
148, 664-678. 
Teperek-Tkacz, M., Pasque, V., Gentsch, G., and Ferguson-Smith, A.C. (2011). 
Epigenetic reprogramming: is deamination key to active DNA demethylation? 
Reproduction 142, 621-632. 
Terranova, R., Pereira, C.F., Du Roure, C., Merkenschlager, M., and Fisher, A.G. 
(2006). Acquisition and extinction of gene expression programs are separable events 
in heterokaryon reprogramming. J Cell Sci 119, 2065-2072. 
 159 
Thiagalingam, S., Cheng, K.-H., Lee, H.J., Mineva, N., Thiagalingam, A., and Ponte, 
J.F. (2003). Histone deacetylases: unique players in shaping the epigenetic histone 
code. Ann N Y Acad Sci 983, 84-100. 
Torres-Padilla, M.-E., Bannister, A.J., Hurd, P.J., Kouzarides, T., and Zernicka-Goetz, 
M. (2006). Dynamic distribution of the replacement histone variant H3.3 in the mouse 
oocyte and preimplantation embryos. Int J Dev Biol 50, 455-461. 
Tsuji-Takayama, K., Inoue, T., Ijiri, Y., Otani, T., Motoda, R., Nakamura, S., and 
Orita, K. (2004). Demethylating agent, 5-azacytidine, reverses differentiation of 
embryonic stem cells. Biochem Biophys Res Commun 323, 86-90. 
Tsukiyama, T. (2002). The in vivo functions of ATP-dependent chromatin-
remodelling factors. Nat Rev Mol Cell Biol 3, 422-429. 
Valinluck, V., Tsai, H.-H., Rogstad, D.K., Burdzy, A., Bird, A., and Sowers, L.C. 
(2004). Oxidative damage to methyl-CpG sequences inhibits the binding of the 
methyl-CpG binding domain (MBD) of methyl-CpG binding protein 2 (MeCP2). 
Nucleic Acids Res 32, 4100-4108. 
Vermeulen, M., Mulder, K.W., Denissov, S., Pijnappel, W.W.M.P., van Schaik, 
F.M.A., Varier, R.A., Baltissen, M.P.A., Stunnenberg, H.G., Mann, M., and Timmers, 
H.T.M. (2007). Selective anchoring of TFIID to nucleosomes by trimethylation of 
histone H3 lysine 4. Cell 131, 58-69. 
Wade, P.A., Pruss, D., and Wolffe, A.P. (1997). Histone acetylation: chromatin in 
action. Trends Biochem Sci 22, 128-132. 
Wakayama, T., Perry, A.C., Zuccotti, M., Johnson, K.R., and Yanagimachi, R. (1998). 
Full-term development of mice from enucleated oocytes injected with cumulus cell 
nuclei. Nature 394, 369-374. 
Walsh, C.P., and Bestor, T.H. (1999). Cytosine methylation and mammalian 
development. Genes & Development 13, 26-34. 
Watanabe, D., Suetake, I., Tada, T., and Tajima, S. (2002). Stage- and cell-specific 
expression of Dnmt3a and Dnmt3b during embryogenesis. Mechanisms of 
Development 118, 187-190. 
Watanabe, D., Uchiyama, K., and Hanaoka, K. (2006). Transition of mouse de novo 
methyltransferases expression from Dnmt3b to Dnmt3a during neural progenitor cell 
development. Neuroscience 142, 727-737. 
Weil, M.R., Widlak, P., Minna, J.D., and Garner, H.R. (2004). Global survey of 
chromatin accessibility using DNA microarrays. Genome Res 14, 1374-1381. 
Weismann, A. (1892). Das Keimplasma. Eine Theorie der Vererbung. 
Wieser, and Harris (1971). Genetic Determinants of Morfological Differtiation in 
Hybrids Tumors. 1-16. 
Wilkinson, F.H., Park, K., and Atchison, M.L. (2006). Polycomb recruitment to DNA 
in vivo by the YY1 REPO domain. Proc Natl Acad Sci USA 103, 19296-19301. 
Williams, K., Christensen, J., and Helin, K. (2011a). DNA methylation: TET proteins-
guardians of CpG islands? EMBO reports. 
Williams, K., Christensen, J., Pedersen, M.T., Johansen, J.V., Cloos, P.A.C., 
Rappsilber, J., and Helin, K. (2011b). TET1 and hydroxymethylcytosine in 
transcription and DNA methylation fidelity. Nature. 
Wilmut, I., Schnieke, A.E., McWhir, J., Kind, A.J., and Campbell, K.H. (1997). 
Viable offspring derived from fetal and adult mammalian cells. Nature 385, 810-813. 
Wong, C.C., Gaspar-Maia, A., Ramalho-Santos, M., and Reijo Pera, R.A. (2008). 
High-efficiency stem cell fusion-mediated assay reveals Sall4 as an enhancer of 
reprogramming. PLoS ONE 3, e1955. 
 160 
Woo, C.J., Kharchenko, P.V., Daheron, L., Park, P.J., and Kingston, R.E. (2010). A 
region of the human HOXD cluster that confers polycomb-group responsiveness. Cell 
140, 99-110. 
Wossidlo, M., Arand, J., Sebastiano, V., Lepikhov, K., Boiani, M., Reinhardt, R., 
Schöler, H., and Walter, J. (2010). Dynamic link of DNA demethylation, DNA strand 
breaks and repair in mouse zygotes. EMBO J 29, 1877-1888. 
Wossidlo, M., Nakamura, T., Lepikhov, K., Marques, C.J., Zakhartchenko, V., Boiani, 
M., Arand, J., Nakano, T., Reik, W., and Walter, J. (2011). 5-Hydroxymethylcytosine 
in the mammalian zygote is linked with epigenetic reprogramming. Nat Commun 2, 
241. 
Wu, H., D'Alessio, A.C., Ito, S., Xia, K., Wang, Z., Cui, K., Zhao, K., Eve Sun, Y., 
and Zhang, Y. (2011). Dual functions of Tet1 in transcriptional regulation in mouse 
embryonic stem cells. Nature. 
Wu, S.C., and Zhang, Y. (2010). Active DNA demethylation: many roads lead to 
Rome. Nat Rev Mol Cell Biol. 
Wysocka, J., Swigut, T., Xiao, H., Milne, T.A., Kwon, S.Y., Landry, J., Kauer, M., 
Tackett, A.J., Chait, B.T., Badenhorst, P., et al. (2006). A PHD finger of NURF 
couples histone H3 lysine 4 trimethylation with chromatin remodelling. Nature 442, 
86-90. 
Xie, H., Ye, M., Feng, R., and Graf, T. (2004). Stepwise reprogramming of B cells 
into macrophages. Cell 117, 663-676. 
Xu, Y., Wu, F., Tan, L., Kong, L., Xiong, L., Deng, J., Barbera, A.J., Zheng, L., 
Zhang, H., Huang, S., et al. (2011). Genome-wide Regulation of 5hmC, 5mC, and 
Gene Expression by Tet1 Hydroxylase in Mouse Embryonic Stem Cells. Mol Cell. 
Yamanaka, S., and Blau, H.M. (2010). Nuclear reprogramming to a pluripotent state 
by three approaches. Nature 465, 704-712. 
Yamanaka, Y., Ralston, A., Stephenson, R.O., and Rossant, J. (2006). Cell and 
molecular regulation of the mouse blastocyst. Dev Dyn 235, 2301-2314. 
Yeom, Y.I., Fuhrmann, G., Ovitt, C.E., Brehm, A., Ohbo, K., Gross, M., Hübner, K., 
and Schöler, H.R. (1996). Germline regulatory element of Oct-4 specific for the 
totipotent cycle of embryonal cells. Development 122, 881-894. 
Yildirim, O., Li, R., Hung, J.-H., Chen, P.B., Dong, X., Ee, L.-S., Weng, Z., Rando, 
O.J., and Fazzio, T.G. (2011). Mbd3/NURD Complex Regulates Expression of 5-
Hydroxymethylcytosine Marked Genes in Embryonic Stem Cells. Cell 147, 1498-
1510. 
Ying, Q.-L., Wray, J., Nichols, J., Batlle-Morera, L., Doble, B., Woodgett, J., Cohen, 
P., and Smith, A. (2008). The ground state of embryonic stem cell self-renewal. 
Nature 453, 519-523. 
Ying, Q.L., Nichols, J., Chambers, I., and Smith, A. (2003). BMP induction of Id 
proteins suppresses differentiation and sustains embryonic stem cell self-renewal in 
collaboration with STAT3. Cell 115, 281-292. 
Yoder, J.A., Walsh, C.P., and Bestor, T.H. (1997). Cytosine methylation and the 
ecology of intragenomic parasites. Trends Genet 13, 335-340. 
Zernicka-Goetz, M. (2005). Cleavage pattern and emerging asymmetry of the mouse 
embryo. Nat Rev Mol Cell Biol 6, 919-928. 
Zhang, L., Lu, X., Lu, J., Liang, H., Dai, Q., Xu, G.-L., Luo, C., Jiang, H., and He, C. 
(2012). Thymine DNA glycosylase specifically recognizes 5-carboxylcytosine-
modified DNA. Nat Chem Biol 8, 328-330. 
Zhao, J., Sun, B.K., Erwin, J.A., Song, J.-J., and Lee, J.T. (2008). Polycomb proteins 
targeted by a short repeat RNA to the mouse X chromosome. Science 322, 750-756. 
 161 
Zhao, S., Nichols, J., Smith, A.G., and Li, M. (2004). SoxB transcription factors 
specify neuroectodermal lineage choice in ES cells. Mol Cell Neurosci 27, 332-342. 
Zhu, J.-K. (2009). Active DNA demethylation mediated by DNA glycosylases. 
Annual review of genetics 43, 143-166. 
Zvetkova, I., Apedaile, A., Ramsahoye, B., Mermoud, J.E., Crompton, L.A., John, R., 
Feil, R., and Brockdorff, N. (2005). Global hypomethylation of the genome in XX 
embryonic stem cells. Nat Genet 37, 1274-1279. 
 
 
